var title_f1_20_1344="RUL SPN PET";
var content_f1_20_1344=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PULM%2F55811&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PULM%2F55811&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 581px\">",
"   <div class=\"ttl\">",
"    Malignant solitary pulmonary nodule",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 561px; height: 241px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Coronal (left) and axial (right) PET scan demonstrate a glucose avid nodule in the right upper lobe without evidence for mediastinal lymph node involvement.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Paul Stark, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f1_20_1344=[""].join("\n");
var outline_f1_20_1344=null;
var title_f1_20_1345="PUPPP striae plaques";
var content_f1_20_1345=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=DERM%2F81605&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=DERM%2F81605&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    PUPPP",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 432px; height: 321px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Erythematous plaques in the distribution of striae are present. Note the sparing of the periumbilical skin.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from www.visualdx.com. Copyright Logical Images, Inc.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f1_20_1345=[""].join("\n");
var outline_f1_20_1345=null;
var title_f1_20_1346="Resisted wrist extension";
var content_f1_20_1346=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=EM%2F63769&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=EM%2F63769&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Resisted wrist extension",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 429px; height: 315px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    With the elbow flexed at 90 degrees, the forearm is firmly grasped. The patient is asked to make a \"light\" fist and then to extend the wrist against the resistance of the examiner's second hand. As this maneuver is performed, the examiner should emphasize the relationship of the wrist motion to the aggravation of elbow pain. The diagnosis of lateral epicondylitis is highly suggested by lateral epicondylar tenderness to palpation plus elbow pain aggravated by resisted wrist extension.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Bruce C Anderson, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f1_20_1346=[""].join("\n");
var outline_f1_20_1346=null;
var title_f1_20_1347="MIBI SPECT images of parathyroid adenoma";
var content_f1_20_1347=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=SURG%2F50315&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=SURG%2F50315&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 483px\">",
"   <div class=\"ttl\">",
"    MIBI SPECT images of parathyroid adenoma",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 463px; height: 458px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    (A) Anterior 10 min.",
"    <br>",
"     (B) Anterior delayed.",
"     <br>",
"      (C) SPECT.",
"      <div class=\"footnotes\">",
"      </div>",
"      <div class=\"reference\">",
"       Courtesy of Pierre J Sasson, MD.",
"      </div>",
"     </br>",
"    </br>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f1_20_1347=[""].join("\n");
var outline_f1_20_1347=null;
var title_f1_20_1348="Perioral dermatitis papulopustular";
var content_f1_20_1348=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=DERM%2F62705&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=DERM%2F62705&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 524px\">",
"   <div class=\"ttl\">",
"    Perioral dermatitis",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 504px; height: 378px; background-image: url(data:image/jpeg;base64,/9j/4AAQSkZJRgABAQAAAQABAAD/2wBDAAYEBQYFBAYGBQYHBwYIChAKCgkJChQODwwQFxQYGBcUFhYaHSUfGhsjHBYWICwgIyYnKSopGR8tMC0oMCUoKSj/2wBDAQcHBwoIChMKChMoGhYaKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCj/wAARCAF6AfgDASIAAhEBAxEB/8QAHwAAAQUBAQEBAQEAAAAAAAAAAAECAwQFBgcICQoL/8QAtRAAAgEDAwIEAwUFBAQAAAF9AQIDAAQRBRIhMUEGE1FhByJxFDKBkaEII0KxwRVS0fAkM2JyggkKFhcYGRolJicoKSo0NTY3ODk6Q0RFRkdISUpTVFVWV1hZWmNkZWZnaGlqc3R1dnd4eXqDhIWGh4iJipKTlJWWl5iZmqKjpKWmp6ipqrKztLW2t7i5usLDxMXGx8jJytLT1NXW19jZ2uHi4+Tl5ufo6erx8vP09fb3+Pn6/8QAHwEAAwEBAQEBAQEBAQAAAAAAAAECAwQFBgcICQoL/8QAtREAAgECBAQDBAcFBAQAAQJ3AAECAxEEBSExBhJBUQdhcRMiMoEIFEKRobHBCSMzUvAVYnLRChYkNOEl8RcYGRomJygpKjU2Nzg5OkNERUZHSElKU1RVVldYWVpjZGVmZ2hpanN0dXZ3eHl6goOEhYaHiImKkpOUlZaXmJmaoqOkpaanqKmqsrO0tba3uLm6wsPExcbHyMnK0tPU1dbX2Nna4uPk5ebn6Onq8vP09fb3+Pn6/9oADAMBAAIRAxEAPwDfs4pJm3ANtTjjvU/zyMARnaOvpRaTNAinLBWG4qeOlLDuGCTt65Xuc15LWh9QtywsZlG9yABwCe1TxQCQ7QHZc/Ln+I1Eu/yVduAG5ParMckhCoSQxORjpTS0Je5LHanzdlwwJzj1zWg+0KIreMAdTuHA981QEUarneWKnhFNXlYyRKH/ANUp4Uf56VUSWOk2IV58xmGd3rUpmZlVCoyfmJC/d9qY7KoE7jaQflwOp9aSaeVsOOFAyQT+tNCBi3lASti3jPycct71CZX8oiEE7vXtQsm05IeVjyG7flU0agcbSc8knue1AhsUwJARW92f+lTM6YZli+bpyenvTRCrMWlcKw/h7Gml42ZnRkGGwBjk1cSWriySIoTYmSepf1qn864wQcnv2p005YZI3Nn061WJwR5hOGPQ9qpsaVh75G7H3c/ixo3NGgaVvnYdAaZG8edygs4zzn9KgaRZS+Rz+WKhsRIX3M3LFl5we1VXd5QxU5XOCSOT7U2Y8HLHBbgZpySMjgDAFJO7JsyOeD7QvlFcE8Z9K56/0fD54baSMiuha5Qzv/FnqegFNZ18oK4G3JJb1q3aSJs0cmtubeTb17j6VfixIRsyD6VobI5XYEfd/iHpUa2m1i6kAZ+XJ61lKnc2VQS3lKDk9qv216yuD2xioJrfyVZZAFbsKqo2wrjof51lyNPQvnN37WXj2q2D3z3pj3WQydCP4gelZD3GyXg8jrTWvQhLAgmtU31M2aN1eYUgjIAwOevvWYLs58wjkA8VRvLjzCrA4bBpluS0gGRtFNvUEjfsp2Zl3k4PPWuhtZMjoNx9a5vT2XqnOO5rYiEkh+dvlxkAcAUKbQNHQxOVjXHv1rM1SYrGCH2jucVLCSV5bJ746VHNALhVVk3An7vrW8Z3QQVmQyyrNapFLGQX/wBTKe/uRWXFE2oXHmXLoHQ7CR7Vr38KGJALfyFUYyOfyqjLG1pcgCPbGR8oI6/Wraa+I2TVtCHVIvOZUlA2r0Hasy4VFUqo2j0rXlYAkE7gRnB6isW8cuWIwPTNYVJ31Je1iBpztAHDKMClt71wME/M3BJrPkmYKehYdRVF5fm3bjkdqzUmQdfb3m1zjqB1FMluyrER5x9a5hLs+VjcVHbNTC6wy78biOcdqJXKSN+S7LR+/tVSW43L8vPbJqjFKu8gvkFePapjIhPQOp+7zWXKVzWEliMgBB/DPNItmwzvGCauQmEswAK7lyAfWp4ZF2jcRuHAzWkYpGcpNjrOFIgvyqRjGRWgjeUqgnOc4zVAS7SCuAAelTJcFtpkweeCetacxDjc01nbYAnHHOeRU0FxjkgHPGayTOU2lD9RViGTIIHU8kf1qOZtjUbG0LoqFyuUPBFQ+fF5oUE4PAJHaqQG9flc7c9asHa6q2R6MPQ0JtjLIJDhHOFJyDVtZc7tpQ/Ws/k4Ujj1oRxnIBYD0rToNF7PzMGbbxwO1Sja1uUdfm7Y7mmAh9pGRkcBqPmkQsoHPQg8VF2hjGBEXyrz1I9KZNtjBKuEaTnHv/Sp5o1KgoWDgDOD1prR75I0mjBQ+vBo2AikQuEKEuR95cdPU08oIYmZNzI3J7mptqoAwfYM4UjqKUorEOsmxlOflPB+tHqPYqeUJER1CmMc5Bw341Wu4XkiBjVXTnDZ6/WrsuGLmPbtPUdMmolUohMY24PHPB9anbQadiC0kdlZi+0L95SP5VXdY92CrMpGeRip72AukksRJzzt701ZDc2kbMGWROHH94etNu+g9GQKSsxAVeVoqWaNIiJEzI3oDj86KLEnNJjein5s8cnpWiQqfu2yXUBmJPU1HEu07W2YPQ1JJAQ2V+ZwOWHINQNSJYo2kAb14C54+tW7OGTzim4sAeMVBCCEJZtmRyx7U5MxsWRmRs9+9XET1LcKIrSqvyj+Ig9D6U5YZGzLkbM/Kq8BfeoSnkqxI4OMButTjJ2wuW2kE4U9aFqBajUNGvmyEtnqOp+lRMVC4bLID931NPEZMSlnIC/dUDrTBtWQrkmTv6UyS1axMmCMdy/HWh+MHdwRnHvUCyM77XYCNfvEd6VSjylg2Sp6Cqt0FqKu5nK4A/vE9qZnLOoChhxn0FOklMZJVW+fj6VXdkyew7kHrVW0C4yZUCHLZJ649KpufMbCIGHQA1K/AJZiF9KiY9wAi44Ud/ekBHIdpKqdqjqRxuqnJKXB2/d6Z7U6UtK3PDHvntSSFEURAEbfXuancSZVmf5hzytAuNibixOajlwSeBgcnFQSMJHyOQBUDATM0j7VylI1wx6ggCgOVIC9TThCxUs+STRsLQGkZW37sepHQ0GYl1JO4Dp6CoSSjAsMKOAKgJLnPIGad3awWRdubgvgueQMA1SNySxVv9X0GKgm3bsHp2qPcz8KRhRxTW4+hLJcKm4DJOep7UwFcnJ56g1CsIByWLDFBQqduMgiiRJN5Zmk6DpVqyUqhP6VH5fAA4PFX4I8N935AByTU3KRdsUOzcVwfc1pxuTwjHHpVCABmLvyqjIFXI5Bs2QD94ecnoKRRpK20LGQcY5xUsUzxSLk/KKp2zGNgJTtduM1MvUIzDYT1rRSsPQtm5NwwVTtG3cGbtVOVjOXnlYll65p8swiY8L7Y5qozs7N5nO49BTc29xpEFw5YJLwpHBz6VlXY8zkE4PoOlbE6hoyF4Hcd6z2jVEJQb/Y1k7hc5i4UCTAyCDyfWqEiMq885P5muguoxu3YwSeQaz7qD92cgA5zxQmS2ZoYJ97OcfdpWDsyuh9sVP5B8sehPBpGVk5A4qri5hUYoAQe/fvVqJmkAJAXb2qnLu43EAdafuO7cx+6Mcd6A5kaMch2LgEt7VYMhY5BGRVCGRkAPX0qaF/mG7rnIqbE7l/zA+CGPFSM6sg9RVWJ2YEkYA65qQgZDYyD09qV2hosRy44JyBUsUzBwytgYwfSqeCGx2qZTjp2P50J2K0NKGbj5XPByTVpWYsSn8RywHescSBcDBx6+lXIZdhwx29s1pBiNNXkbO1Tjvz0qWEE7mjJ8wHlSOKqwbpIj84WRevvViwkZXYEqXOM89RWlwRotIWCDpJ2B71IkZyrgBVY4bmmQkk4A2n3FOyWVQFO3PNS1cCSQpGSvLYP3hTGZSAhZnTrnH3alDnGwqSO2TTFJQZbCg9CKl6jJPLDQbyw291444qs0ghUBMvnoyjhhQ5EkTLkYP8J71LbhgqMqBU2bSg7UDsxrRRNGGZ3AJGBnp9adcQE55Urt5I71HEY0n2u2M8Anp9DVhI5CkgQYI/g9PxoEZ8cQS2+QkttIHqKgzlY2hOTtyyHoKtuyvbPvyvzc+xrO1OGSIoYgI3x1P8XrTasikh1zyMqNshOMeuf60VHHK0yIsv3c/Kx6A+tFSOyMwY3KflZT1qzG6lgyuckY+Wqcav8rZyuSAO5qxuxtZVKknGAOKzTJRJNsMiB5GJ42pVlcADaCzMwJ3HoaplVeUMWIcNwenNXLT7xkYbT0yfX1p6jaLhtsDezl5VPP0+lAjaORim3aRy/ofSh2LsVIKuQOcdB7Ub8p5XzeUvBPvVtkpkkC+W2C7EY5Pr7Ch2V+jKjscEZ6UwMwTr8o6e9NjRGmV5FBPOQOKaYWJ22rHtCkseB7n+lKyNFGuTgn+ECnSIFYFs8fdA60qsxJI4A7mrERlikfzEhj1X1qnPhfmYYA7CrE46luSTxVO4K7uQMDqPWm3oTsRH5y+Xxj0FQPI7E5UAY4x/WmTTZcsQQMbeKhmlCxj5Rz69fpSQ3oQzzbVAU/jVeNml+8Tx2pJSW356H9KYGwqkcGs5KwCTSfMeAMDkioYsKhZjnPTFPmHovJ655poUF1APA/nUruBKrE849qmkHlRqS/JGfpTIm8vJIBPv2qOWQMcP0JqrXJZFIwI5bdk5xVeZ2CYUjjvUjuojJA+XOOlUXkJHOSD2xTsIZJLnK9frUkODt4A+tIkAbbkYTPOauToDHiLGB3NUrIdyq6vuyPyHerEUWSrNx7U6KFyA7EBAOSakVDuJBOB0BqZdwQoAMinI4OCash8FMghR1BphVVADKN/XAqSPLTqSN59DUFpGhaqSpb+Ec81cjzGB8obPNVrd0CEEZK5J9Ks5CKjtuO7tnoKBiGQqp3KzBzg56gU5Pm3GE5QDv2qKecZj8rO0nmms6kZ8zHPIXuKCokrEZwHy5HA9KdEwwCevRs1WypuOF5P8QqdTuYyFTtxkA8ULUG7DrhuC6Db6iqs4JwRlU6EVbkaME7uhAwPeqch2llZixJwMdqBGVcRgzY5IU1XmVTkDr1rQeNhKxyOvSq1wh37lUHPf0pK4miiyZXevTuKrXC5OwAgHvWiQ2PuZ+tRyoMh84bHSqIZQMYKjBDAcmlMHykjkHpUzRlWwiryDmkz91TnGMUySEE+UuTg+hqVgFUKDkjnimBt8rK2C/UcVNAIxLvQjnqDQhkiNnJycH0qaGQLkLnafXtURUIdoHyGiHgMrdM8Uco0WVkyeehqww5OBtGKpwlfmXODUqszHYp/Gk9Crk8b9MH9KnDkHJ249+9QgdCBk44q1Fll+UDA+99KEFy7bMQuVII9ParqurklcISOTismOUJxzkHHBrStyB8gGSRkY55qgNC2DN8wYlOnXpV5SQ+wheB1HQ1lW7FjjJ3eh71bt9+GDY2jvTEX1R2XKMCwHfqDTLgqwVZQQynr6mlVmxlWAXGCe9SD5sI4Vxj7p64pXQolRl5BKhj2xUiSZK+YMIRwccrT/ACxuxyhH3SelPL/MQ8eVPceooSZdxkkcMtyhVAOoYnofSnCMsu5VIUEgAH9DTPMOZSkRI7rjvUaFuScYPDD39apWQhHVSSJFPPQ+tVbtFmwW3HBBVj/KtCQlwo4J747VDMd0YiAxg9TQO5m+VJG42gNEpzj0HtRTpgcjAKADBNFFyrmIikxnbxJ/D7ClRWJYMSxXnHvUuQH5VgeAD61MqkE/MOepHb2rNKxJGoDbuQrdfcGrKkBFAGDng1Arq8g8tST3JqeJPNKMfug4A96Ex3LC5lwZCVOOB3PvUhWPeN7EDHKjuaiMiwONwJY9alAGBtPLDP40wFXKDLLyfuj0p6qchG6k8mmMrJhh85PB9KkI+Rd3B60CJZtw3FNvHeopmwuWYU6SXYFzyOvPeq8mAQgIJc59lq1sSMkbEgZ2B3D5RVOWQFmUjcfan3DfOBjnpkdqpTSbHKKRzwT1NMCCeUsyoM4+lQPIMbmGT2zT5TlG68DAzVOX96WcsMd8ClqtgAZaQux+8cDHQU8hEfCkMAe3eo0YliB8qAYqXZhVzk5FDV0S9yF/vfLnJowDkbenpUghJ3Nxx3ppJRcfxMKlRC4xgwGSRgdKhnba6sUPPQVKxZQGI+RR1PeqcztkO3IJyAKqwiKb5lADc5+7SF2DYxyelNiRpHZ2+XvU6rmQsQTnAH0pg2PVSGUkHpnnpUn3lfOMEc/4Ukh3gKp4XkCo0bgg5Cg5x6mpJLKlSANm72qZcpG+8Zx0HvVcK+en3iCW71OMZwWJPJ5oKTFRS0iSHAI96nt1dc+bx/u96qFwGHGQfSrUcmWUqRuBqGWX7UjOCvXgDuatSwl8ncVXuKqROpcbgCRzuzjmpYZMfMdxYk4BNCGOKRqpEPzcYwar7dxPyqpA796nViQ4b5R2zUFzCV2Evlew96LaFIXc0eAoyTycdquRqWUuXXDDjI4rO3NGSBkydGx3q0h2bmk5BxtA6UkORMY0PIkHJqCURZbYcEHJPrU+zavmStlm6Iq9KrsFaIjGJOv1qmJFGTGSzVXMm9WBJAPTFSTsQDvyGXtjrVdJByRgY/h9agGhDnyn3Ek9hUR2CMCQ5461PJ90uhIJ9elQAFo8sMtTIYxyEIyOAPzpk3+tUjhcU4EOyMSAw4A9qW5Jzsz1GeO1UiSlgDLKSCOppDgE9No5yKc2c7iBk8kUjnMZ7E/rVoGOgkYgK3T1NPBO8Fm4HFNQbnwcD5aV2eNQxTKevpQ0+gJlpyTIpVQQeAfWnoxLkgBQKhgcGPdnp3NSBwzN2HfPXFS0WW1ccYODjipozlflJDDqapxsiqeNwHHXrUkbkMrKCCe/rUoRcEYc78dTV+GRljC4wQc5HWqULgBQQOTzVqJs8YACnOM84rVbCNAEkJKueF5OO9W4CAU+Ynd2qhC4V8KdyNyAauQOrBgBgUMZoK7AEMcJjPFSxgDkEbcZ461WDBQuGUY5yTTjIwO5v4u9RYC6ZdzqhwUx1NI52MFiwVPG4mow6qkgfg5BpEIjlyuGRuGBoAlkRlAbzMEHBFMlkXIClgDnP+z7/Q0TMGUjpt4GecikUliRKoPcEDr7UDRHDjf5pc7+wx96m3O51xtJOc5BqTYCCVUhv4VLZqIyEIq7wyAkZ6EZouBUuCTGqoxJPUUUqjbK7Enjnj9KKlMZziyhmVFb5V5AI5+tXGzsOwgAnPXrVNUUEMVzu6sD2qaLBVipwR0otoBNECnzNjI7VZtRKVJJAJBbHpVWNmbaXBYjipI8qeCWY/eH9KVr7DaLMiZXOd0rDp6UIduxUHOOSeaRHAU4AJ+tTZAXn5R3FULoTeYwbG0kgZx2p/mgoSUypO0VEzOFAjAG8YzUIDAEAk4/iJ6mkBLKVCMzFgAAMVRQ4ugSxPOce1WZuVbacgYJHvVFg7bpGwp7e9aWuJklw5RTjqD8uDWVdyKI8uShPO7HJqeUlxjdnbxkdKo39u0xT95kLx1rTluiY7k1t/pcYjjxuHr3ou49sCqEXeTzj0qxaosdqAi7mHcdanlZZI1O04X7xIwB7Vo4aGcnZ6HP2sMk12UYYGDnJxWvCsaw5PzEKT9arTeXDNvJ6nt6UsupW0yGMOwccYPpSilFFSblayFLeYASpUAVUm2g5XmrkagxsSTgDpmq0g2Hc2M1k1ZivcgnZpVG9ucdugqpIWKomD+VT3Jx8yjIz+dVvNLEZOG9ugpATK21WwRxyeKi3lmB7cqB70pPyMBzkYI9aiJDMTgKFI4Hrih6gSqWT7igk4BJHSpUUNIH2khe5NRRSFn2rgBu9SKxiQFvu7iD9KkCZ5hyf4dtCEnD5A/2faoLgqCpXlD/AA46fWnod7KBkGpZS0G5LKyk/MOlWbclk3Y2sOCaZgMxAbJPepYFw5BbPbApGlrlyHg4OduODUzyja2TkgfK3rUWwgcnjp1qJtw44UdQTSHYeZAoDF/qp6Gq88u/B2k4PGDUczsWySuOv1qqZcoc/dB4WldlJGlA7uVVRwTye9WVYIMBDkds9fesdL14xyM54HtUqzs4zvbPYntTvoU4s11uCQSQRjge9QSy7yd7cqeMcZqKEZxxwPepQQAdzAt0GRTQuUqXJY53P+dUnJG4DnIpdQuJWPKZI7iqIuvmJcYPQik4tMvk0NWFgYghXKDt6U+UISADuyOlVYHQqowwOcg9QanAEjgKcBRgD1qrHO9CDCRj5R7g+lMkyAHX5j3qdguVUnIIxSvHweRuAosSUnVQF2nk5BzUMjERsMfMO9XXQNbFuARxVBpQysTgEVSVmVy3FjkDENjAHFWhcLLD0+XOCo6VRQgsFxweRUkMvlPtyFHoRV6olqxPKNoYBc9uO1COx4Ay3TNCMhZtwO3HSpFQAjavJ5qWwT7i4KnI55zip42w2CM+tVv+WvBLDGeKtxjLBT1PQ1mx3LKPhQV4571aglzhsgE85NUIyVx6A1ZBGFPHPAoTGaSyI7BVPzHn0FWYn6tjr8pArIidt+04Bzw1aEbswYZyUGQfWtHqBrWskeVQLlT2ParjyL904yBkHFY8U25SwPXj8auLlQrIck9jUq49C0rZRgwwpHTvT42OQygDacYJ6ioo2Dsu5Ru+tLLhn3DqOgoaAtSOHQoqjYehzUMjyW6/LkAd25FJFIdrBVDA849DSrMJBnd93naeKNwSsWInSW3cjAyuRgc5qizq0JCrhs4NTKoUSB8N3BBwKgcAEuz7O+PWpaGkQE5jbJJI4I9aKgEilZNp5PT1oqR2MQBNoTcSBUinDJtXCtwp96YhAyQACeoqZTuDKVxjnPp9KaJLUMUiLyAQepp8TGPCBfnVs5zUMbjhS3A5O6mrMsnQc55xTuFrlw4DFyPcAU9CZNrPjBOcVDG+cxs2T6+3pTkGzLEE4qhFlIwx2s+FBJGKNgVd3XPyj6Um8FRjgeveoZp1XcynIUYxnvVWC/YbLna+w/L39TVKWRgGIUhxwPQVI05cEJxG3X1zULhy4IPQEU4iZRmDwhnZjlzjGafa2UoK/asxowyCe9TmJGdTKSW6Y9DUzzYUhGO1OGYnk1srbsnmaJIcRMzogVF6+4qveXZNudg+VjkUDHkvdIoMI+XBPJP0qo8hYg4Aj7AdqJTZmo63KOrv+4zz5pAyfSofDFjHczs8gHynJz6VblcsxUhcd80+yP2dmaMEjPQDrUqS5rs2i2o2L98IRtW3fMWM8jFZVywPBJ3Nyamu7ncAzKNxPQdqpSGRSW4LDvnjFTOXMyLaFe6mIix+FQRwmUqASuOTUs6bnAJGCNxOe9IrlVYKOvCikIkAO4CPnHBPtUSpk7egLZIHf3NThgkke8Z4/M0SJ8jOoy/8QHpU3CxWAIQ4GGQ/p61cyWU4+bI4NQINy7s8N1zUkQwNu7I7Gp1HYVwGgALBVB59TT9jBQQ3HY96asKH5iCTnPsKmMYwWc5JGaGjaKCMRqBjJYdeKsWxBbEfJPc1AUchgTg47elW7WPyoT5eGZSCfahJtl2sThVUYUfOOuTTJVkIzjIPpV4Ww3pxuaQbs5oe1+Yh5OMgYHGK1dFsm6MSRWc7doBFVJ4WDcdO9dHdWb+W+wADdjg9KiWxLLg9fX1rL2UkaJo5+OJuc8Z4q3BB8vqPetaK0CncV3J+dS3EEUVu+8KjDkD2NNUn1He+hQhixE0mD745qWSNyQUTK8cnrU1tB5kuxjt4ztFXJEMJmijAYKRzWsKXcTdtDKls8JJJKFGO2awL3SZI1ll4IABHPUV1epTJ5twhAYAdqqTwm6i2xAAhc/N6YrdxViVKSZy+mzSJletaUUi+cem4dB61RZNrfKuBk4pUlYfJtHPUiuJpplTSepefaC0gYqD0B55qV/nkGeBgcDvVJFyTg45yATVosoUspOSuMGmYtWI7mOQ23LCMlscVQvtNlW0aVHBwOTmtoOnyB8YPXPr2FaZa3bTzHNAN7Ag7e1dNKCmrBzW2PP7C5IkEcxOccZrRRFkQ55bqDWPqUH2WYSAHYTlGPf1rTtJA8AB++eQw71DTWjHUs9UWEfawZ2G0cH2PrVjzG2v8xDqcoexqqm5iyheWwD6fWrhTaxULh8DGe9ZMy2JQCGRgOSM1YVz1AwR2qsy/vEIJzwcL2pwdx82SST8w9azZaVy6RlAFwT1NIjk4BA2jrUluBIoDZw3p2+tR3EUiO24A8cEUOLtdAt7E8OHI2nHHer8IIdyvytHyPcVj2cuMRkY5zzWraz5TLgl8fLxTUhtGgiIIxtJEucgdqv28ipgP97rjtxWVDIPI3nH3sH+lW1fzCCrEjHX1HcVQGiMOiEtjBweOOelJcBkJC5D9CtNSQDaRjA43H0qxuBcHliRwTQ9UHUhiG4DPyLjtUTx7gjBTuU5/A1NlSCMY9+2aCW3bSSOMZ9KSHcdIdqbflPbmq158rBVwYiuKmd/IDhcM2AAKhuFaSNHTCjODnuKtWHDRmT9qCTlSvzj5SvYCiqN5HJHftJGcxs1Fc8rpm9kNt41eRmlLZ9R0qwpy58vlV/vd6qZcgjHU4GKkQlJDuJ9MUzmJBMoc8bufwqW34LsW2gdjxmmuiCM7T3zjvUqqruMLwBzmmh3sPR0WQBh7CrDyYjBJGW6CoF2+axAzjn1qWM+Ym51VFHANUndCZKWEYCvyx7iqd4yhjtUZIxipZd2Me3r2qNAWhLMMt2ql5CtYgVsJ82FHeopHYuFR+B7YNI82c54B6VGrBNxyWZu1DG2ErMq7WPPXiqgfpu6g8+9WrgEkZ4xyRjmq8gygKKeeuaBDY5CIXDkkNwAO1SQh5Q6LgcFjn0qM7UZBj5R1pyE42qCu7PGe1PoT1EC7zkLwT36ZqWc+QMbvunkgVDG7LH5Qzwcg96ZKxlGwcAHGKSQrkdydqKIsMTyc1VbJ4YHg/OcevSpDn7RvAAQjCj3okLfcHylxlj6YqoruBXmKrKCBnjHtU5GwkkAtjIHpVQtnKN0J6+tSvIouBu4Vhg+9NiW4+T58hDyPzp5IA2MSDnAx3FNFu3ykkbaeqM7EjDYPaoZViLyBLJgPhVPIFWHZFkWNFwO2e9CoQB/ebjip4rXawZgXI+X/AHTVatWNIxHLERGMEbzwKnW2VcDdvwCC49fSrEIjinUyL8mCp+vaia5Q2a7UKPGxYcfe+taxpJrUpXbKyFEQSTD5SNnHY0v2qIY8nEbhgeehpJL3y0KyBSpO4bR2NVI50O5Xj5P3SatRUVY1UdDYkuDL5biVf3ZOSo6UW2ojLx5Rw43CVh0NZdpJIsYeBFIXlyemabDIwumiufKxgkc4H4VSelwUDVF/JPbN5MitMjAlSOtW7PVoPLAmdWlOUKkdDXLQuYSZ4wWAba0a8n61JIpR1mUOG3BgGHJ9aLPdD5U9GdXJewQWaPHLEJQ+TGBnisbWNQXy5PMt28uTkOeTn0pbiefyX8qxf5jzIUwMemKoNJI2nPGyxSDHQnkGqmhwgkWRcLHCk6SOpXHA54oub/zbcyJJ5cbDbuzyx+lZOmTja0U8ZIGBnPanvLC8JEigRAnbjrWehXLcuBpct+7Xa5Clm6/WraTRxyMC6spBB744rJjleG4TIZ03ZBx0qS6mTObYjcchyR60JkyhcsSRB7VI1CkhWkJHpWfHGqoxbjjIqZLx4I5UGz5l2D8amskiEUolO5gABg9u9TKCk9CGmkUSAqgk5PanLOSpVxgYwD6VeubdTCAgwm7ap9aypInhZt5G4Dlc1lKNiPiNGOTyxG5VXbrkjIqxEzyOEXAK/MST1zWZBMdmDjI6D2qx5iBjj5hjBA6ilGbjsZtWHeLLGKTRbMoWNwGbcFHGKwtPhIgjGcPk9a3pmxHyzYPGM9qptCUZSoIAbgetXOXM7iWisyGAMWYtwBwauMpeESnIJOcCmyIqQnC5JOWA61ZsgwiQnkZJH09KzJeuowBQCVY/LzTGLBkIOFbpViIKZe20Z3cUwIzFzkEYyuO1S0UmWrcEqHjPKjn3qW7mUgsp5GAR61WiUxsnPBXmnohDSE8qfmUjt7VS0ElrchUkurD16GtK2cMFYHBz0x2qpDEWYkDjP5Vahysa988FazS1uyrsuIh2iNWwpJwferVtIOAU5C1mQTbZTE+Rj5hnrWhaEi5VWG4ODjPeq/IDStmD2roDz1INSSOPIRlJ+UYwOwqgx8tm8odD90mpnmVmKZwMdB/CfemwDzSec/Ke1SeYzKPmB7MaZMUXCLyevFIxRZGzx0yKh6bDsSMxKuQBtxTCCIAGYleCDTZJsZBAx2A71HG3DqXbYRnFK4r2Kl2uCGYcdNw6GinujIcNgqR8ooouzVTMRHYsy527asKFIyAQc9Sc1CixoABncevepGZi6kZAH60GRZgyxY5wQOlOhcBn4z7VFGG85XOFU8/WplG87zjPpVLcLkqMEQjuePpSY3Ict07f1pwH7v5scDnBqsGCl854Uk80xkiNvcsxJULTJZW8sqrEL0FCHdCoXhienbFRPvlIRQoBOM5p2SJGLHmRFBBA6mnqEHJB9iKjyQrIcZBxUgabzAvklGxznoBREGyO53FlyeCOD61CyliEJO0dqkmXdtkLkgHHuKrNIftLOxx0GKHuG5IFG4qvJAzk+1NjIPzbMsRknP8AKkhd9rNjhec0kOVXcWAyDxmmiWPt8ieQgBgOnsTTCgDTYXDMRg+nrUkagRmQMQ2eB6U92jK7VADDlj74prRCKMybF4GQD19KrTSKrcn5z39qsStlQQwCnORVG42bSM84ypovcBcZ3K+PvZGKjYBgVJ6fdNJGxLIrAjPGc1YijWRssce1ARFh3n73IHWriJ5aHHBQB+KchSKIt1JO1s9AKikuBCUMZDbuD7/Wq5bm0Vfcu+SkcYaVlyCGBB7GnxTlJHjA2K4yGPQ1lMRjzXbchBBA9aWW4Y+UWYFQowh7VqlZGigXTcb9xUFnjwxXtVkTTTytINsaSrtK46VUEkcV1IEACNHxxn8KjtLgPhSWk+XIGOhrZRdhum3qXYoIpoFhBJmXOBj73tVWQMJDILYiMrzxnb6mpY79WslwMSK4O8cVZjnlkul8pxtkG2RR2HrVpaDUWtypaPMFa2t4/NWXPTjAp0ltbtGy/Zd8wwf9Z0PpUFyI4JkWCWQsrk+1OS4YXCvB8j45OO9TZM0UHuirayXVvJK9rG+N3zKACAK2pZXSCGSe0dH3bgSM4/8ArVk2t4sRl8+NiXyCwFNbU51WLypZCyNwrDIAqoaLcr2d3sdFNdXeoBVknZYyDwqdfxrl3uFRpkjba/Qlj1p11q08x/dwbJB1ZScH8K50mbzG3FgSTmqlqaU6VtzVM5hhDgEknGRVlGglgRZIiGzkt6Vmx7hAoZMgc9au794URuE+Xo1YqDuacliy1yjGOOJyiDt9KqmUSBzyOcjNUxvTdIdrHOPlNS3NwixrGiYfHzEdzSauQ4W2G+YqOvmuOTnmpjmPDZIXO7n0qFhu+XYpG3vUUkhfggqANvXjFQ1YyaNS3uhuySdqZKjsDUVzMphMykNIeOaymY7WAb5CcnFPDGNo22/IecmpehlON9jQs1y4YEfLyQamkdkZnVRyw4qrZ3SvMFJGWJ5HHWtCXyyu5MsMY+hFZSjfVGDi1pIfDiT7/A64pqsryFwcqOvsagRiDtfcFp6NtBWIHHH4mpRLViYASGRR1PQ+9Oi82GOPvjJz61WLou4KSpJzx1HtUyTAxpErHIHQ0xNCysFkkJO3d8w/HtU0TYjLBgAPlHtUUozKm85V1wcdKW2UvbnaM+X8pFKQi3HHvjLddoxmiwzvKO3yMOM+ueKfa4EOFByq5x60+Uo7EouABxijYBHVluGUEAHp7mlf90wbBX1FG07gCOOCDUl2WZXjAJ56VPLpfqVHcb/rpvMztYLhTVyKRtsZKkPHznNUIflYKwwp7VaU5IX5tvelYs0I5VaZnboQcj3qTbtO4fef/Oaz5ty43dRwD7VatgSvzdhwQelGr0ZOxPnYzEdQRux6e1RGQyPnHOevpUhVdo3Eg4yG/wAahmXyyXUjBOTg9aTiNNCs5D7hjjofU0+ORR94/MDkVGJB5LoFxx196rqd/wAyjLKOQfWoKsWHnzGQ/YZzRVaJmdGwPu9aKd2KxmLhQG6sfSpUIKknj0z61XjB2AIcn1qU5ABzk9x6VRmTRtgBWOeOKmh2gcnknmmRIrAeh5zUiBUxuIBY8n2oXcRPKQqgEA7uvbFUy/yk4wijOf73tT55AwPXnj6UxVRo2HJHbBq9ykR3BYjII2nkgfypsRJlyAVVR8o9KI2+Zwc/KMk0+IhwXPTHHb8aLNg9AsyrksRkkkip3YupXJ5HPtUSqRGNn3VPUdqZFMTdFCMknr7ULR2Fa5MyYiG4YJ75zUSW6PwBkDOc/wCNTb8KAMZ9TTAcMyn7hNXuTsVVXZ8mDtI9fepNg2PkA7uAPSgthm6ZI4/z60xv3UnGWz2o2E2KqgL/ALWckH0qOd1M+5U+Rug96tbd0QZgoPQD0qjMOgII2nmhrQlFOX5o1GSpUn5faqMvzOCOSpq+xXa7E4yc49aqDActjA68elJIpIYhCsDknJqdn8t1c/d6N9aiAUKrSsQkgO1x2NVPPLt5bttU8Y961UDWMS/PeCTMKk7T27ZqtDM+XGfk/iJFVHZ7eYLKuCOjDoaijuZIpmUEFW7HvWsYM6Yw6mu0kaowjckkZ5qvc3GYYv3Y3xnl+uR71SaYibG07OlNhdhMwJwjDbWiibRiadtqGWKsQrqCM+oNWLWTahfeUb/Z5zWQ6LG/XcBxmnrcBQBEcjHOarYtq6LqyiKQhydrd6njvAJPkY4Iwfesp5WlAbHK9vas+a4eNsLnJ5qZNoGrnQtOXfh8gHt1FIs5V+Ccdue9YUFyQpbJDHsKtm6HlBgOcUo7MtR0sW7iUqw3kkU1Z2SMv6msia6LLgnjsaa144VUxTTHyms125jI3n2qoXBky2cD361W84LknknpT0kWVsDqOavmT0L2NFisirsXbzg80+5AYrh87P0qhHLtfrz704T4zu655HrTuJvqWNm2PcOoqGPcz5P1Joub9PKRQACOorP+2ru2kn86zk1cwlUNnzlb5mGccVWnnR0KbRgnOe9Vhdq5CL909Wp7QtJho8bcdaVrmXNfckhnfaMBdhOKSd1IKlsHPrwKhl2xxhQcnvUGN78n5j/Kk4oNCaJmjBc5z0GBWta3xEJj2hS+Me1Z9uGlZmkAVF4wD1qQxh3LK3zVm4icbmwpLW/mOM87Q3941PbsVMLY2sD+dZ1m5mKRg4jj+6P5mtWOEeWruW29gD096jkOaasZtxMqTbyCcfxDsKpvc41FGh5ibtmrd+uxZijAKq8g96xtJbMhDfwnIzUTXYpJNHX2p3whuMA7SD2q55IV2YE7DyVHFUNNYLv3gtG/OferaSh5IwR0+U89eakwluED5lIjbCkdu1WYSkkscf3TjmowmLpgi5B6Yp7KY5ULYznBFFgH58v5SckHA/8A101pWMhZx82MUSsGd0A4XvUSF3DbsZBBP4UtxoASg3MM5bNSxSfM5XhSCGNQZP2jbklWB2n0NOVyI8MB97moZoWvM3wAZPv6Vf08MqkNjIHHoRWZGwXO0FkYYK1dt3KxAnotCE9i7Jtd49o+XaTgnvVW7mCDyXUAnkU8OpwScLk8elU9WIdVkQ5YDpTb0HBCOWZiuTgVJA2AWJHpg1BYnzIn3ZdjwAPWrl3ax2t5HDLMWUY85kXOw+3rWSTbuU5JOxGP3THcGT2I60VLqheG8ZZpPOyFKt/eXHH6UVRCldXMWPK4wRmnZ4OWGc9O9QlSxyp24FAw7ZIBY4ximSXFmAXJbPHAFPVlZGdu9UXyZBnIYcAelJLK6yKG6dOKa2EXyMoSDx/FTZ227UQD5cCo42UEjJ2NjNR3DkqxjPNV6DESRC4Dcr/EPWpB8qlgcqOmeKpxbTJt5yBVm5IKokfQHJJovYbJ9zGF2RsAYz70igugYAh+g9qii/1PJO0tnA71fiQIwOTk8lTTtdXIbsVhuSQbiMAfnTkYuQNoIb5zzyKWKJ5LhtvAGT67RUVsDulbOQo2kjpjtTWmgmIwxIvHyL3qUKzuJCRwuMUka74SHOAOOaZIkmWCE+WBjdjrVbakXCVsMw5IGAAPWqs27cwZuG6g04sybSOMHBz61XvZRlvXqDTEyOYbo0CgBgCQtVIpV8tpCcyryq9m9VpZ5Tty2RHkfN6Gsq7nLSsFBVyckDufUVaibQEuJwQVXJh3EqP7pqJ28yLOfn9c9aASrEyKct27UkjBEBVcjPQda3Ubbm8V1HC4kaAb25XgA+lRfaRkfd/EVRuZij5U4BqB5N3I6Gi9tjRSaN5Jlk4DDcepxUMsoBwT361l205QipppNygg81Slc2ptssTz/JkHLD3qolwwf0z70xXBOSKa0JBB4INJs6EjQFzuIOfu9RUVxMjEEAZqsNo4zg1EEzkA55pXYWS3LKMuwnOcdBTY5yVOTgZoFvKYyyqSq9SKPstx5QdIywNPlkxc8SN2yuOuDTfOf5ie3FTDT7otgR4JqwuhzlN7SY47d6aptilWS2KZm4659qfDcbMtt570sunzw5MkZI9VpBCNuVyPXIo5Gh+0THSTneJDwBSQXRllJfhR+tVbpZAduwkD+HFESsqKu0jBzk1NmTzolunEjnn24qq42IRyT61PIpAJb9KgJLNnHSps73IcEyxaEjG707960GvgqhE44rG80568ipoWD8EZNXF2G6a6FtZNz4yeTyatKjtMI04GMn1xVOJGjYso4NXIZ5cll2hyep60JXZi4NGgWCJGiIcjOT6ilmlCYLAHHao4iWjwgzIffrUUkTA/O3HcVfIaRjpqWVm89g2FRV64q/bXh5YN85G1Fz+tYTPwpQ4AoimKuCDgZ5bFZuJNSMWjcuYwYGXduB5YjsazobdYcsvJ7VYjmThSCEHIVv50sjBo/wB2SWzxgYrGcTj1joy5ZyEw742JK9q0kZyY8pgoRnHcVS01I0iBlBznP1rStUjG1idoJJxnn6Vm4pGMmi/cqYIknhYbsgbfXNQSsIJlkPzLJhiD2xVsSYKnYHHAAI71lazKZZBFDGQq9T60bIcdWX/keYvBwNuWBoWP9077dnJ/EVVtJHLjABXbg5GKugmVHZyBt5x61mPYhO1bfcCMqcjPemCMmdS2CpXBx60krJvCpk5O7/61PMJW3Drt38tz1pIpsfIBFbxyY4VsGpRIgZzGxCuOM1AuZbMANnf1XFFq0fl7GG4jgfWhoIq6La4UZJzUdwpJJXBIGCKYo2y4l3JnmpHkJyBgkelTbQpaEcX7txhSoPBwa6GS2adfPuNKlkmYAllk2B/cisSLaqDJ3SAgc+taeqxRXd1I66nbIWwSpY/Lx0px0TZnU1f/AA5R1Uzm7c3UQicKAIwc7RjgUUklsEdkWVZVAGXQ5BoqLhFqxh54GST9KaAFkGw4UHNNJQbSSc1BKwJIDYGe5pl2LqEfeYHk9c0+Yb5AY8Y9+v1qFcttycACns2yUFx2yCO9UJk20bVIw3b0xioJFCoX5yTjirCuCRnO0g8+9VrjIm2pztwTnpTfkSSpGqzKxOJCOfwpsuZTsH3m5P0py4OW6LmkYbpWCjBHApsY+GUeYCE/doQMdsCryOJppSxIK8j3HpWfCG3rE5IRew/rV2LIlBUDZ/FzzRFCkOBOHZRtkfgelNgjEUDq33vT3qWDbdTSqSEVOdxpJJFH8JyDgD2q7XMWxiKuRvcEY6j1qrcO3zMpII7dsetSXbwiUmD5VPPPY1QkO8tjb8o59xVWsBHM4JyMs2M5HpVSaSJsCYnB447VDdSEjcrcEjHP6VTuJ4nZknDI+eH6Y9iK1jC4LUbc3jIzIpXA49nFVAQy4b7pPA7ioN4V/nG5c8Ypyyx4IXv/AAntWkVqdENCdnEaAbt2apzSkFWHr09akL7vuqOPeo3KkDI5z19K15bnUmrFeZfNGe/pSfZCU/pU0jCA5OCKja/U/KvJqXAu8epGItuOlKQQR6Z5pyQTy84Kr61aisP3g3MWFJQsUppbFUBWICEkH271efSJHsIplmTc7EGLncvua1LaziRMhRn0q8IgoyMA98VSSW5ScpPexh2+jKYP3rZbI5Har1ppFvEdxTf71eY/NznFSRyckZIFPnRoqV9yJbfYrBVUZ7Y7U+O32x8gVKM7TsGQOuakCSOwUL2qeYv2SRBsC8AAZpxUDOBzirHl4AyORwaZMULtjIAFNMORFJ03EL2PaoUt0zgKvvkVaiHnbevHpUe0o+ARsJ79afM7aA4EE1shlLEDJHUCoPITlSoAJ9KuS5G5lIwBVIzBiQDWcpslQTQy9sLeaMADaR/d4qg2kNt+VgBitEy7eppBOxB+lCqLqRKn2MSbRpkXchDGqhhmhBMkZAHc11kUyyRhT170ydY3QB1DL6HpWrUZLQh80WYFsSwx0Jqc/KQF596luLEKrPbkAg5xmqrStF8rrj3pKPKJ1L7lmOUQnIzn1NI07yEZqqP3oJLY9ADTFZhJ94gU7j509DRYBEUsR+FQSXGQQR06YphlUnruNOEqsxwuB+tK2hEmW7KQcecSx7LWlF86ZxwaxCwY8tjHSr9pdklVZ8Adh6+1ZSictRG5b/PtDFflPC+lX0cwkuF3kjOPU1kW0yFsBVLHjGePxrSglWNeWBcDJ9K5pROU0rcuYldz1GCBTp08zDquAPve9LaqsiYIaNgOfSrkBxut3AaPHDeme5o5b6FXKqKnyIQNuKW4XyJAvykqecdxSz7YHEKsGYAEnrxUVyMsnIBb06VLKTItxD7yOU6ipp1WWPBzvUdRUUGWeVD99l+WkWOX5Scg/dKk8VCKIUuSqRyxj/VHBrHtblxrB5byWbPB/WtKSRIrl4iu5jyeeMVSsVd7mWZ4gqscKPT3okrmlPZ3Nu4dnUHOV5wc81ALsrgjGV4zjtTPNwPJkOcHrURRo06Ahs8k0+oLU2bK9+wksIYbjeMjzBnFObVmeXI06x2/7lc7HM0s+d2QBg44xWjEQOQOnSs5yu9NiZwiXZrsyTGVUROApSMYA+lFQXqRxKDb3Bl6bhs2/lRUMhWMNkUBVLHHXrSzR7QFI9+anwAOijbTJkMgBY4U96vQ0UhjTbIkJB3ZxzVrLOnOABgk+1U/LYMWYllHTip1DsFfH7s44qlsS2TGTCnIOztSxIx+91ySfpUcsmEy+Dz931qbcUiRpQVLDoOuKUUFtBwUrbhmH3+c0qsqRSTgjIIHPUn2p/zGDnIz0B7D1qGFD5W4Esm7A46+9Xa+oifTMTSStKwViN3Pf2rQjTMaOGUgdQeKp28XlzZZcDoM9jVxAVLIcMcZFaJaWZM3YZIEDyYXg9umDVZ3X7ykbs87qJpSnDrhiTnnrWfdzb+mUI7jkUjN6D7yQbg/GT3FZrmVVDr8yZ656fWmTynaqiQYznJrEvJJFy6vuwcYzWsVYRY1C7idW3LtlHG9eh+tY008hb5zuYjqDmorm4bPz8elVRLlwd2PStUykrFtXduiketShCTllOPWorYZbJcqKknu0T5UO4961jC+rK9qloSRjaN3GB69qjmvVzhE59e1UJLhnYFjj2HSnxsG6dB0FXdLYuEpSJWheU75MgelTWNuBJ049aRHJHoKt2S7QQTk1F9TpjDUuAqifWnQON2MYqu3Wn26lnYHiplLU6YxSNKKRRx3p5mGcjpVZioUD8DUaHduA7dKhyNoltZv3nzcqe1BkO75c49KgHDA96nXGBk/N1pXNo2LiTMBkcKetOgmYk/MQtQSBlTapHQNk1ELkRjG4HPaquOyZqI5ywOcHk81BOfmkBJ4HpVaG4QNhyF+tEtwu+XDhsgYouLlvsS2zYKnJI68VIdhO4qST0H/ANasfzmLEjjjsakiLkAhuR3zSTHyXLd1LGE8vb85OKqLAPNIY9afLK21TjkNnPvST3LTEM2N2c596JWJ5bEMkZAJ98VWm3R4xxU0s21MY5zmoZ3LJyMjFRbsS1YSJiG3ZzVtWxDgjK+/aqCMQvQgVZik+UFjxWsH0M3sSEMM8DpWbcfvBnAPvWkxBHB4Pp2qrOmxm29Kud0YSSMeWNS2QSPoailSRE3D5vTvVlsb2B6H9KQsRHnOAO1SpWOeUOtzPiuHGA4xnpV2CTJ6mqNxhxkD5utNt5WXGevrniqTuZe0cdzYI3Lknn0oRtvC9aZHuZd2QfoakWIM3J5pSQ/a8+iNS2uUQoSDsxyq8tW9akzxgsQkJGQepArlraCQcA8elb1nE+3YABx0zWEkzGUGbsUsRMawg4Xq7fxVbjZ0GQ33+CAe1Y8STJCF42L1ywyKtJMJFDLGxTHqKxaaJW5oCBSWlmYKFOPrVbVZ44ZrdIpMpJ8rY/hNKDv2kZA/uk1WNk0txGQM/N+VRKVti426l6CIyzod6hgcZ9qguJP9KmijYZJ5GatKCqOV+VgcEVSWzBut6sSTwTUt2Vio2epVa3Zr5WY8LwTV6O28yNmjUnAJOO1PMJQcKSvUnPNNdp4BmJ8Erjg4yPeqVuolLUoWkqGQlwSi9fanajcCOPZtyBzj0qG2jkWZy+PmPTNLqUIMWRw3Tk0RdjaNrlGwnjMjL3Jxn613b2qWH2yaGyTEQSC0VhuErEZ3e9efWVpIlzkdCccdM12V0ltaW0qtLdyS2Esas3mYUE9Qg7fWpIxCV1YbrSpDqDIqrGWRC6D+BiOR+dFVtVt1t7plR2dWVZFZ/vbWGRn3orKS1Mo7IzvlXAPB/nTnG7BGAB2qJnAYcA5/Sp0XcMZz9Kpoq1tQhXqG79+2KsbMpgD5ahZSc7enTircGMHZyMfrT2IZlzW7POGG4BTkD1NWgG3bnz8vTPYVZkILDHBGDSOPlYn7x4NCdjRSvoZnmZkO4kBjinQapFGGiVg2D1Pao5oJDgorFicACqsGnSBztQruBzkVUW0bJRsdrZzW/wBlkdmBZxgAjPNV5JVWMxhUDn5gc81jWdu0TLvLN6NjpU9yzIWJ+9g/MBmtpT02OWcVfRhfpIkAkR8ydcY4FVB9re32sJPKABJA96c5nuY0Db2TdjgEVN9nnbbFAshQcZxjNVFIjcoTBZmK3EYIAwGC4/ya57ULVEyQ2Bniuukt5FRjIAWzyK57VQCSFTcx/KuiKXUTutjlrlFZztYk96q42NwpY+prVnUZwqhT6VQlkCsVByfT0rX3ELkkxHLnGTgY6CohHtGSevc08SN2wakkhIiyx+YnIpOaexUYW3KUjckKPxqe2B43dKmNptYbfmcjPSr8enuEAIxtGTWbOqm4oiiXceM4FWoWMX1q1DYkAFR+NSR2Ll9pUncce1Lmtqdd0V1JZDkjJNTRZTvk1aSzZSQUwuasQac8j4CnmonURpGaM8MxYbh3qVcRls857itBtOfeODxkVdstBa5nVQSATjJHSo57lqpFGJGSQWA4oikPlswTcemT2rpbvRZLceSnzgkgkDjNNTQpo4ZSYFBI4HU01qUq0e5y8twGch1O/HDZ4FR7kO12OfX3FbJ8PX7AoLIkuf8AWY5qAeG77cqNA+8DG3b2p2kV7aC6mS0v7xOCQTxzVkl2LDoQK1bbwhqc05jNtIm08kjAAqRNBnN89ttIcAYA4z+NNJ9R+3h0ZisyrCq7BknqalaTB6Lj2rqrXwirfaFkKtPEOQecD1FVYvDE88EckSsw7njFXytAsRBnPlt4yAAO4qIfeIrp5fDN1CXQISQwBIHFRDw7dEkmFsr1xWbvfYHXh3ObuE3KB0fr9aYiEoAQck8Gunm0Bo0JfAJHfnFLY6Q9ygtwoZQS+cc8UkzOdaK1OX2nb14HGKdJGRDuHSus/sNQjxMuZAMq+P0qvJozrCpOQjDge9WmYOvE5EO8bMOvelmMnGT1962bjS2UtjJbHPFV7vT3+Ty8HjnHUU+buKU0YbJg7j/FxTEUnGRwOMGtOexbychWLA4YelRx2kkr4C/MR0+lNMwlNGPcwrHJ+7I5HSmRxoxAf5WrWubRWQsM8VTa2LKOxxTuZO0hbeOPBRt2D0welOhWSF1UEOp6E1FEjoAyZJ9KtQK5ccZDetaKoramTpq+jsado0x+9HkewrasdkiYIznqPSs/TDICgfaFPrXRwWkUpV4/lYijSS0Ju4ysxi2YkQlEOPWoGspImPlsMn5tueK6CPThkoJyiLgkryOaXUdDmETG3uY5ABkkcGsp021oU3EyrHJCkxBz3G6ryKA6uCwVDyM1UhtZ7cpuhc5AKn1prXEizbMOCDj2NcK00ZO+xrXYtlVHRtzk8qTVdkOxWBXarbcA9KYtvGWQn5mJyQTmrE+GQGGMKWHK4ovfcFoSzEQ2zKxVUPIA71jswkw5IyegoFx55eJnB2cHPemxWy87TtZeRiok7vQtKyCeLAGANzc1EUDD5uCeOatOpcorkICOMd6ZIq5weo9KV7FJlOXMIKqxYE1uXgvlttt3pFtcT3BQsTchPM2/dJGeT9OtZUsZfqPl649ab4i0m012+W5Gp20MWVZVlyHhIGMKB19sVtCStYcmna/6/oLqUeq/aDd6jB5e5tpZSCq8cLwTjjtRV97i1aHVHW43CcRxKjD5mKYzK31orKS10CLutdDn2bcQBgVctmGMA4Pc1TuR+5jMQPmkndU1puKLkex+tUx2vE1oUEucYUAUifuRtI5qFZDGyKvBq0qhyX649aT1Whk1ZkUxEki4GBjmkaQBSJWB5wtRXT91O2scXDC4UqpYq3c0LexrCN9Tq7WHJBXBOeM9anmgVUZmQ7u59KoPeeekbbSG/vCp5piYyoBOevPWt20YzTTKE9xsk/dgn2BqUPIdiOMr0IPX86qpGsEjSu3TBAxVq5KyYNszMp56dKmKdrkyaZYWVoG8uNWVCeNzdKspN5iKkjjCD1x1rKdJBuJckhc4Y/pUXmuF3Ngj0/rW8Z8urM7K5JqUoljaNCMk9hj9a5y5hCkAruPTntWtcXJEHloNxyCxHcVUvIio2r0b7vOce9W5X0KTSOdvkCq20Y7VnR2EkimQjG44CjrXY/2dA8ErSSBm24VSMfjTrWzTKxqAmACrH0oDnOYtdHcuA6nI7AVoR6SQ4LrnA5B7V0sUD2hVmUEtzuI+8KcdiuCuPXnt9aTmkPnbMxNJVJBlV+YA5H8Iq8dOh4+TJbofWnxyBmYbhknqBxVqNXkTfuGRn6DFR7Rj1RX+xqrAZG3uKescUa7V4YHjAzVpYwRv3BqaI+NwGMHpWcps0i2RNErou4A59Bir1rbBcDgEHFQiNgSzeuSKv2SGRQUIO0bjuPWp5h3L9laLKNz475AWluLcRxqE3fKfmwOtTWMyw7zIjN5i9fSmNhlIdigNaNpJdyVKV7DZJvMMbFAVUHgVBJd+W24DtjFSKRGsixOQB1Paqsz70YFlBIySB1pczRopdCS01+W3kD7srGeh5OKkXxIDcq5TPyjLNWFPbbyGLgA0JBsG7cCvvR7ea6lNQep3J8R28sbtLGA2BtBGfrWBNqMZv5bpV2Bl2gYrJRtxbdIqkDIFPSTk57im8RKWhMIqOqJJdUmjuJJgqM7jqy/yqtbXkqoqpuAA5BPFW90T26Z+YnuBgCoo4A74XAHrjNZupLa5opo1dO1yW3uS7xK0Z5wc4zU99rzSwvHCiguclscisyKKZtsbbQPapTarkbSXA+8cYxWkas7WM3y3uyOa8DtlsE4GeKZZIUy6q3U4xVqCwjO2T5pRjJVe59KtwxFQin5ZCcLx92puwlU6FaZjgNg5Jx+NRNhw4cZZjnI6CrlwpR/K4Iz1B5z61UYhQ24hAeRkUc1jNeZnhNu7ABJHp70t7BGWQqoCgAMcdDVgOJAPlBI/lSXEayOEY8HmmqmgNmOLMPuCYJk7kcVAmmBDlhuOCUI7GtQEIzAfLngn1oLiSIqg2Z/ip+0IcmYU2lI6sdwBz+nes86csasq4Yoc5x1FdFDIDLKjxfLgbZAfvHvRcxqYXORu+nNUp3FdnLGw2jcg6N+GKsi2ijYoQGC4IYDrmpZpRDKisPvcY96vFIyDhBgDnnrT5httalX7NtZcfMhG4Edj6VpWrhSMkjaOM96qAqNynJUfdHcZqeF8AFADgYIzRzk81zYinZCpVwFYYIPrTpZZiNzA7eMtWWsqgdsZ4HcVeS5BBbd8owMdazc2DHTzB3IQyKqrhfrTN7I6EtuGRkHvVmKaESPJOyqoQsueBVeB4pirRNnOdzHpj2qJagn0NOCN5bQyMqctxg8iiSISfdGW6cnpUMTAYRJNy54YClMwTBR/nJPakxX1KY04+YWUKAc5pxgKLvzlF61aD+Y5LHCjggVC2CduRg+tZ8tkaOVyqFbeWfAX09KjJQzHbzirMsZRXC87utQBNr54zUFCPgnAPyk9PauiuJ3g/tCK3srf/RVR4VMQO9OhPv8AWsJk+7txgnv2rRvJbLT7va91fm5t1CboyBjjOBntVRfLqRPWxjeKAw1VyxCF40cIBjZlfu/hRVbVJIrq9klgkmdWwcynLE980Um9TVKySI9gYbV6ipkiEYC1Bb5+8e44NXQGHyEc4zxVvsK72RUlfc6hiRjofWrljIeQ5wvTHrTBB5i7mAOOKQBUzlhgc1OqG9VYmmgMqMFHAOMjvVAWAQ5cHHc9zWlZTM2Buyh5yKsSIZFkII44Ge9aqGlw5nHQrRxBUGDxjjFWUlYW3lN/q2Oc471Xt45l2pk7GPKnpViZTGQu0DjkE5oM5Ntld0MkW5cYBwc0kgEFsykvknr2pHuTgoTj2AqtcXTuyoSeBx6UcyJs2JLKI0aVDuCjnPtWJaSXWq3ExgO2OIZbceoqfV5diSKo+/z+lU9EiKJIUdjubLDPari1fUaVlc1ifs8Y3qFJUBRnnNIbgNGFKnHTkDiqpDx3ZmIU44B9BT/MXy9565q3IztckkdDFkk57CrlsjbE3heB1zzWDczBriKPO3I5PpXQ28qsqx71aMD7wHU+lEXdXKtaxYBO1iPnYdyelZmoTFLd3QAleoPrWlMcRkQYPasu4QEDP1xWUpFRWozRGE8W+ZhweFrbQKyhUyFPQY4JrEhtypJTAI6ds1qq0m+NlblT09KCi3AgVWPVl5xSD1Az6j0pkEocbB8xJ5x1NSldu1Qm4e3U0B5DWTchbkEHAx0xUtsVEgU565GOM+1MYNGjSRE7c429xSqZZCrADjoajqUn3NT7Y6MV8wMp4x/dFSTyL5G5mcgHAY965ie+mtrlkdiN3J4qyl2zP5jysVbBJrXnurMOWz0NJCJ2Ob2K2jzg78jg96oTXEEl062TyPCnHmH+I+tQ3MUcwDOd3OdvQ0sEMccgVPkA5I7GlzX0sPRFtNpUl9p/Q1WnHmnC5AHvVpZTIpbjI45oTayElkL9DnjFRpsRdlJISc4Y8dAepp6wNJIRzuHG32q60cixr5ZVcnIb6U/9+3zEMWP8S9aOUq7K8UKk7VGWPbp+FOi3IwLRkL7UXKOx3RMfMB4I4quZ54123AYKDgEetP3UtQNa327XKnn+HNWEKEAhiwPPHrVCKWGWZd7lEwBu/rU801pHKEhkdtp+8Kq3Ul7lyGSVSu0hQvUU+R037lba7fLyc496qxndIyxliX5Oewpn2hEUhjnJ4x0ob7k2JJpFYlG2u2OgPX3zUEkcjLmTCoOAD3ounDbTs2lhglaryFVXbMzHAwMdh61NygwEk3MDjgcVFcBhKSM7c9u1IZMu2zIHvUM5CqWO7C9QDnP0pWuBDIWkO7BJB6CmCb5xnKqeoHapZDsi+UMncc1T+VYJnkyZOxqXuBKpTJIPToabISqlkYE+h5piDeqngZ5+opsxUSNgkHoxqouxLMyWF7icSSZyKQ3xD7Pulvl/Go7m4JZwPu5wDVCXPnxt5nzA8Crb1BRvoXbu5+ztCQM7s7gfWnhnEhG7v271Sv5PLtWnYq21gPenLdCaOALxuGWbvTW5LjZEtzfyWzQNID5cpxuPcVsw3AdCBjC85H8VcprbTrKLaVFKKBtPUge1atnK8Ue0YIIGM0pJJ6DaVjdlm+0QhGO1FJ4UU+F3VfKDKiY+UmqFkwwyA5z1JqtLdOL+S33cI2QKStuwSvojVsL3E5hmIDjp71e2tOyHJIAJAWuTPny6ssxXCnua6u2k2r+6baSOtLdlSiki2vzYUIAD1pxjEb4YDnpSQs5TJVDjq2ear3M/lt85JY9M+lEopq5KVyWQlX2nKqRwwHBqCQqfm2jI4602SViqsCduOg6UhjO1CcEnmsLMtKw0viIbs8nke1dBqLXkUoS20mKWBVHlO8JclcdzWRBBayEi6uTABjadhbJq4fs6qSddnCgf3G/xqloRPV/8OY2pMTeObmBYJsDMapsA49KKTUvKN0ypcG4UqMStkFuOnPpRUNlx2K1oOSjnnFWIgxAPcVVtVdSQcEnvVtWAQY68itG7hcmgEfmDzWIiPLFaoX8bHJjHytn8q0EAC4yOBzTJNuwkKSc4qugRbi7lCyZ7aL72DjoRmtW3u0SBcrliec1kCcG4Me3B96lnmWFOQOO/rSUpWLnaW5qXE+Qn97v7U2SU7QZMY7Gso3W+EFiNrHr7VX025+1aiYXk/djOAe1WnchQuX7j5SC3puFU4o5fOjmJXZICQM54qtd3O69+zo6kZ2g5rSZUtIAEdWA+XNUohJWRRvFSRjg4VT0I5qGOQx5DRjaoIIAxmr80qsz8AjOAfbFUwdzBcAuTtwe9HXQz1Fl+a3LDgkZKk9KriZCFiUF3b+Fe2Kt4SQSE4/djBWsa1gE2o4jcq4PQGqaY42aJim6QvnAB4OOtadrFlVbLKM5z0qldxN5WADycDmtC0kmMCRTgYiGBipfYqTbRZaVlPlN0PQ+tVGJaTDHCjoAOakeYtGWOAVOMmnRK0iZyM4qNWxJW1FgQugOGyDxirEZaMDbgMeCT0NRWUilCmSrg84q3IHc/LHhUAPJ702nYoqxGVLlWQY285rRhmMpznJ74qgs+2VInA5arEcs1jfuY0Eu9du0DpTina5bV0X2cRwuUJZSR83oaimkVQ6Y3MMOGzyPbFVixl+8GGTnjtUrIoQuMAj73rQ99CLDWCzKC6jOSR8vFVHzIdpx14wMVfSRXBA9ahni8xgfMZHHPA+9QwT7htcIN4wuQOakgDys3l/OF5Le1VpVKoPPJOWHLHnHpV68uLcxRRaaG8z+LFC/mLsySOJd/ynKAZJPSpFg+ctJgA8jaM0+3SLycOXGW59BV1ULKFXYpYcN60dTNy5THEc6zF2KtGvIBHUVdhcclC0UpACqOlW5IpIYW8xAVPBYdqyrwSIQUYBQec+lCLT5ixcspu/IDgErneaqghywblf0Bp+pRq0g+dXXG7cDVSCSKJhFK5QMeCeeKbvexXLdaD7iFk2liAAvG05p9tFIrb0YBm6b6I/KdVMUisBwU7j3p09wYkVEfAY8MvSk4kak0dyy8OPvHrmlQtIpIAYKflUDGc1VRnUtFhSQN2T3pfOk81WjkEYHP1NIRYu1dQoYlTnJHWiJyY2ikHyk5LDvVCG4dpZ/Pl3Z5JIxn6VIsiyj5AQo4ouh2J5fJeMJGxVhyc1XOWyOCOgHrRGFyxOMKPWp5LeOO189nLsVzt9varjBy2ApSJtIQHOeRk9aqMjF3L4wei0Q3CtOhB5HQMasLGC5ZyVz6dDWVruwNW3KyoSwz6YwKr3jNaxI8h+RzgN1BqxqBFtHn7pzgZ6Gsa/kmngSEufLTnbjpzVOPLuJRuM1CRIYVBBDOehHb1qqqBtp24YYx/jRrU93efZo5VGyBAEx1H1qtqF0I0iMZPmZ5+mKfXQq2hPLCs5EbvtUnGSKZEgG6KMjMbbVx3FE92hsY5FfMqkgpjt9asW4yY5IBmVsbeOpNUtyWu5BcQPKwLt8v65qxHujgiCAkcc+9V79mtQTcfLIHwV7irtjcobK4iKF9yfKfSmld2JFuJwgGSVzxx61VaGX7Qt0cnJwD2qG6vIptJiRVxMkjb2z1HbioLG/nvNPGnoV8pZPMX1BpS00NIx0uddaspRGbHFacZwi7R3zz6Vi2b+VF8456Z9TV57kRxhGPJPHtWdrGbeprpMBGw4LdhWZqt4xt2iIDA/xHqKmilCoCMdKBEJVcunynpxTu2tCoyUXqU7Gf5P3pJHQAVpIMR4ZiSBkbarC1WNAwI5pIpju2ZwBWbTW5cmpaovWlrcXu8QRhynXLAcfjVg6LqOCPKGT0/eLj+dUmAYbSR2wa2prbSoEu98NxI1oVEjebjdnqQKFFMwlJo57Ubf7JMYrhQkpxkZBAz6UVNrUEcF68cCYh2q8QLFsgjOTnufSik3qCbM6Mo8jDPIHFSJIIwAx/CqkHyIGbJ680ST7fmI57VTRcdS2lyN/cL3zVyJ45EbPAIyMVzaXLTOyA4IGcdzWja3HkhEkPzHnFaRi2aumWZbfFwHHXtSXMIZsHB46Go5rkeUCW+ZT1NSKwlUHIwP1qWuhm7p6lG8KwRHOCMc+1UbeJUj+1q2AeBzzzV+8h3rtP3fQ1HDafJt6k9PQChJopTsrmVLEXkLnr1JHar8U5aA8kkDAxUd6yxuQccDHHemaTljJJn5Rxtqo6sJaq5PI7xxvIGwwH3fSs2KWRbhLjko3K81o6i5+VQcBh1qr5flRJEWyBk/Sh76BFaD7e5KxzBgdsingetVbHzIZWeNcnkMafcXeHYqP3YXG33o0q8ktobgCAN5vBY9vpTvqrhaydi1K5hjVwecZ5q7pX+kvsDZLjB9ap2Q+2SbGI+VSWp2nTSWd8s0Q+ZD0P8VGnNfoJRurIt3ytCdnUE9/Wn6XcW4tZI5nxNjAwe9RXU5ldzJhi5z9M1Xksv3bSR9AOTQnZ6FRjp7xdt7tRLHA2CueG7k1sOyJl1bPYiuR01XNz5cp27jkZ9PauouTDACqEM0i5xWi1Wo3Cxn3ELyagrQANjkLnirVrcvPdLvQo2dg5xVSFTLLG8Em0kYx6GtHU9KubVkaSUFmG4EUo3tdFuz0bL88csMpgUAuPmypzxVYg5BwD9e9QaVHdPK7LJg4+bNaIkiw6ELIV4BWh6q5i007FNSPMA3Rpt/vcZqyCm4hA7jOd2OlUblSoEm3GCADjNaVxB5FxFA10jmRQzMnQD0PvULUHDqRvbxXKuvvnDf40kUSQIu0hPm24Hf2qzHEFjUT5cliBgc4rMLwZnF0W8zJ2BR0NDVioJs6CNcx7ACFXqevFTDbLL5IjV1XDEjqazdKEixASkDAxuIrVT966II1UEffB4+tNtGU0r2Y+SDcpjXcjEgbSeMVSubRpYmVgoC8cn71XbqBo9xVSHIyG6ioLh3aJVSTKLySOmaQ4aPQxEtI1UqVZVU/MFNUpitpewzDJTdt2MOcetab6mIzNE7BQ2CcL3rLmlt7soJptp9R2ovZpnRFNFqa5tDcstmdjO2Q3TI70FfNT5VzFn5j/AFqBLG2xuWQMM5Ge9CvPCJPJlUj0Jq3Lm3G0iW2gijLBifLblWzyKnjRpmPlmNYkzhiev4VVtpThwwGG4Ynsai2sbQkSoYmf5kJwR9KISinYzcdRvlrI5QAvtq2DHFGroQ8WMOG7Go9MtnUSTDAC8gZ6Cnm1RtzSEjI3Eqe/pUr0Ib1sUZp1ZiYxyT371Bf30qW/llcEcADk1dFpEIyzg/3sk81C0Ec/zHavGc9aV2i00ijYws5LyZAJ4Geau3bmCIqWzzgCo5Z4TMEjbKoOuMVWcPtchsrnjNRfUH72pR17WZJbBLUjlDkEjmqGnzSNGWLbieKdcR4mEkuHOelQo0hmkYAIrMCMdhTd3qW7WsiRGYSMHO5ay5plMhBPfgVuSCKSNV3hCzYJrD1KJUumiyu4HhhV9LkIroxkvCGA2Ec1vWko8mSMnaygMpHGCKpWEANq8h2sVPHrUTzb5gigjPDGktNRSXMiWZ/tV1+8YuXGWJ7U6K5ey1KaKFgy7Rt7ihY0Rf7zHqadFEDKXKYb+dF9dBJWM+O1leWUsMBjnNXdPgEF4oJAx1HY1YgljDsJFDHp9DVa0Z3lkBGDnipmyk9LHQxP5kyBCNoOSKj8Q3jfY0hRfm3H5hTrHdGpc9ccZ7VR1B5ZmUBTle5HWm23GxMYq5p6ZcO1uqlvmxW2kpMJbJJHUVx9pMNyqCVfP6Vux3bDuemBmoSsE4a3RcmuW8sEkAA45qlDeqbpwxDHHHtUVwDKpKjH94ZqC0sSLgSyEYHFJjSVjajbIJLZPp7Vp3WoTWmqwxX0lmXmiWOcPyoHbzMd+lY0QYO5jRyg/iA4X61q3tpZahKbu6tNTiuH5kSOLcrHHUE9M0RRjKyeuxV1ZpxqM5uwnn8cJ9zbj5dvtiiq+q3Ek90WeFrcbVRIm6qgGBn8KKh7gtjPZyY85OP4ccYqC4z5Rzy3agBt2Nw6dKEG8FccDvWzHF2MkiRZsqCQfTtWpZjavmFST0yaVUVSccH3qdAfl+bk9vSnF2NpVbqwTyqE24Ge+as6ewCZx+ZrE1F5C4A6D0q3Z3ASDDIN5PU0RtfUiVnHQ1ZACPm9M+tUPtBVz1ZBx7ZqV5m8lgWwQK5u+vPJJAAKjOPb3oCEbssXGZpXdenYetXtPZ4QMKNxHORTdGWOewLswEmeQf4vpUuoMUtlKcHtjtVW5VdDfYbIFckHkg05SGjyy8is22kaOQgtuLdK1YWe3bDqrE9T6VmldXKtZFSSISRPlcMeB7U2LekCpkFh0FaTyBX/ANnvxWRIzfaSeVUdKFuKPvGhZ2zBQ5Vhu4yK0lgAYlCDjrmqkN4TBHCCSE5Ge9O81iSM8kc+1XNpaE2aFMaEB3YYzwabO/7iRIC23GRu4qJNhZFZicGrdvcx/aijjJxxThsVrcz5/MuHhkaPy9gwTVyRyY0b7xHfPapIrlZZdm3d83Ix2q29ttJXytqMaqUexTlYqxRTeYBbANjDZ/pV7dcyhftDOxH3V7D6UyOV7JZSqg5woyema1mt2ht4vnU8byc8D2pRg7A3sZtrHdJcMBkpMMHPar6DyiA6g7VwAO5qTQdSij86zuEO6VwRIewzzUl5LEt632c5jbhR7VTsle4mnewmoCO5hjjtNwQgbyR9w1QEUUDFdzMxP3uprQRMxyBSqqRnjufSsy5MqSq5AQkAZHtUyetwguhq2irtLSPkHlZD1UjqKX7LBJg4XrlnPXms23aeSNFIOFJ/XvWvBARboASqscnIo5roJxSehJM8cAEURDqfvH3qSO8WO0CCXYg6sBz9KoXcbLG/lfebhXHc1QuNsFu23czqAWDHqaht6ijC+huT6mHUrHucL0YjrUBIMYLqwLAkiuea8JRfMUrkjbWvbyLPCMShyeB7VKlbc1lS5XdGKQF1GQPuEbDHPNT6fGbCSWC4tVm81SUV/wCda17pizQBgrB0GDg4H1qjPLeXptVkQf6MdquOuM960Vo7lubnoZCreSsZI0GyNsNg/wBK07Jri0ZpprbepQou4ZA96S708xF5Fd1LDkA8Z96rzzXsi7HUldu0Y9KFZbkt83Ua7MASNh3MPnU8L74qxJZJJF5jK24puGDx9aghQKggSNt74zuNPYSrOYJDwBwQe3pSb6k2uX7dRHFhZMoy4PvThJhAIiA2cHP9KQAQmJmBNuG+YDqtU45o/wC0ZtsZaNidpPpTk9NCOW4rxTPJIoIkLDgmkuxsg8oJiUfOdvBpZpnhj+XruG0jsaz7q8k1DUd902MjDEcZpJxsCTkylCyTzZAyc4PtV54UEeGcYNZduFhu3WNiYw2Mj0rXuZIBbcHcTxg9ahWvqOaZha1HHaTxgOrbhnntVRmItg4UHHU96kvbOWWUSryq9d1VYzcZl3ZGegxxTuVZWK7OJyyJkdxzVWaFk/eOc7Tg+xq/HCRuBO1wMk1Tuoy04/ebgw6U01bUEieBT5QeI4zxn0qS2hCFmY5YnrTLSLy4grMQue1aCvGZAqqTxjiglqzGyAEc+vUVNEieXgHB9utMaLJBVsbTnB6Gqcl7LHdsygbWHK46fSmtHqJq6sQXcLLeOwlBVjwRxmr2nEPJsl4kHp0psdv9qkDkHb6Vdt7aJZd6/eHXntU8onZaGlbYUZbBI4qrcoSp28DGM0lxMigoDjFV9Ond5pEm5XsaLWYK61IIrZS6szEP6npUkl0EbczcA7frV7ewyqlMdgRWBeo8UzFh1PfpWr12NI2Z0lrKsgVgflxn61aQkZA4B7Vz2nyv5QBP3egrcgm3RjI+b2rFnPNWZZimk2tGrsFbG8A8HHT61v3MkNtP5M3iC/VxjdhCQhI6HmubZ9pA6DrntXRi3N/i8uNIkaaTB+W4WMTe+088+1CMZ2KGs6fg3MqX73U0GzzRMuG2t91ge4oqrqeqOVvYpLbyrq4ZUkJPEca9EA/DrRSaXQuF7amAJkyFb86sRMAzAHjHWs9SzuQw4qckqPk7VYbFkygqcjkd+9OVju46VDCFJOfvGpwNvzN93vikwI0VckMgZif4jgVDNHs3NjAHoeBVtwM7s5BHSqV8SisqHMZHNF+hcNyRWd4jnGTWNfWrbskZB9Kuw+aEO7Ix096vQlZSq9SKp2saN8ruZmnMIlQMxAzgcdKv3gRiyW8pdD/F6027VIsrgjd6iksmUOAFzjvU36Bv7xALNldTuxj0rRhV2dVk5NWnRAoYH5jzioFlPIPB61MtNA5uYbfOyhVKjPbFQqvm2yJKoDZ+9jrVhf3zgA5AHeh0HfIVeuKcVYLNDUjCAHI61akTYueM4ycVBaRea5ZRlRzip9UkKKFwcY4A603HqxLV2KUEO+QsCQ2RjHTFDwmPdKeSeARU+nt+7K7V2k5LHqKma0ZoYwQefuD1q+mhbfKyPTr2COAqVzIG4IrWu7oyRxmBjIVHI9RWbaWbSH/V45yua2rSJAY45AEdTklepFVC70YpW3RkQsLpnWf70jjnPQjpXTTW1rZNbQSTOVkG5/4sD0rGnslF1uicqhOfmonlCFTIxL+veqhLkVkOXv7Gjf29sZGeMk9k7U3QJYbvXYYJV2hHB5+7kdqhWTe+xQwB5GeuapWrta3gkcP5qybx8uBmhtqSYRWjR1mpbVnu1VAAXyxXgD2rF8wS3yxuVIwOoq+kr3McrsTuA3MSOpqm1qsrmZnKsAAF71FR3ldCp+6XbWDdKIwQDk7iOlX9ixxN85Zjx7Cs+1ZrU/IwLngg96vFi53SAFyCcA45qXK71Jm9TPYkbwrEopJ4rOvm8y1YKBj0A5P1rZkidpAhBwRztGOtTX8FtMypYwlGVcOWOaSjzJlKSizk5WmvLCCM7MQkjKjDVHYK9vOiq7YI6VuHTZImxECFbkcdfWpk015LhZNoVEP3abhdHQ6sVEu237+3LkEdiCay7sqrkDKY6gd62URQrgAjd8w9KpXVm7puBAx27mjyMYyVzJ+0SL5rRoZbcAByepqVp4fsglj3jI5GMkH2q7DaSFiICFbbhlI4YVRlL2ZVBAVQN/rCMgmnytIq6bKhlN2yRMnl3CfdPQn2p9rZXL3LSyvuCjAyK0LiC4u70XUgQtt42DGcd6sq6GNOTnPQUrJCnK5WuXEKSoNrhl5HY1g3Ezxw8MqtnIA9K6CRFZnzhR0FZF3pAZt8m5AenoabdwhJLcLFnulPcD2qre2AmZ2+YMDwc4FaMVkYYV8piTnkU5Ld3Rs5JBzj1z2qbdDJytLRnOTwNEiKsYHzZLjvVlLcSRqccjitCUKGKlcEcYanvH5kCleq+nepcXcqU29CjbwCdzCWGF5+orH1KP7NqBj2kDtWukmy4DL1FYOtTvc37uWJyQB/9etNOWw4Rbe4140LFFJGeMntVHVLOOyulQyh+Adwq7ICI9zccYxWbeQHcHzle+ajVKwrak8ADREOeM8VZijMTBuRUVocIqEDrmtParj92p2DGR6GpTsJy1Kqk+eGbITuPekZY2uiONpHHHSrDQqQCSQetM8pAhZeW3c571SZSkRW03lg5HGTgEdaIZ3FyzIi7T+NQazM8zW6YKIv90VYskLRqDwR+tO+ugNJC6nci5UEgBlGOBiotNk3MGJ2+nvTdReFTtUkHvn1p9gF3qV+7jPPf6USeopfCaFymRvj59aypreRpBvOV7DPSujQZB2gBT2qqUAD4BznvRzGcaljOgjCtgjH9a04igwX+Uj7voR6VGIBkEA5xyKSQ/Ko5ZMcY7VLIbuWY2VXAfLAc4PQ1tavaf2retdw6haC2fDjzJdjw8Y249vasGGGe6U+RDJLtxkxoWx+VK+n32MfYbkEDP8AqW/wpJE28yfxDdRXWrNJFIZIwiRiUj/WFVwW/GimeKwy6uIymzEEJIAxg7Bnj60US3CL0Ri8gAZyKnRQjLgknuKzRN5cw3A4NX5JfTHIrQGTHg5HFTLKDkFt2Oo9apxNjh8sW96kZtrjjA9qQyykqt/EAOg9xTJVVic9PQUZjRQRyPSokkDA54PaoYXEJ2JjIJ7UkKrHIGjJ3N1z2NPZMEFOh60JsLEdxS3K5iHU2YleQSBVS1dg5LBuOw71oMqTBVYcjvTRGiuuG+oxVXsaRmmrFpZlaNt5YsB1zVG7vFWPYgwD1Y06VMdAT/eqM2jSRqdvyk8UN3dylZF22KPDAyMV2rls8VLKfkkK9wMc1TSNsbWG3A6etPDN93BB96G7hKSuWNPmaFWAU/Nw1S7jOS+M44Ap+NwypAwuT2qe1jjO3Gc4yM+tF2S5LchELgYXITq1Wo902xHlIx/q8dagnn2L/sqTnHr6VBZs7XaSMwQA55qqbvuUotq7L0s8tpdLGYmwF59T71u6fqscl4nmQDzCoU7eMf8A16y53a4k81jksep9KesPJkVwpHf1q/aOLsmJxUug/UXDPPu+Td0Uc4rIjmZrlFkJA+7kV0NjbrdrJJuBVeDn1qhNbWv2jY7gMDg+1J3XvNmlNqLtY1kxO0ccEYRVXbu7n1NZWpzmNt5Ys5Ygeuau2KNFEQu4hu7HrVbVrdpCjKCrI3y4p1JNpExl7xYtbfUIrOC8kbdBO2wYbkn6VreUqjcNxAGcY61i6bBO0kL3MrMq8hAcgfhW/cFnDYVUAIAYdMVLkrEzdmQFckFh84PXFT2qbQ5cgnGQaSCPzJQjOQV5yelLIWKZ28A/iaS02MnqNYyDagb5345+tXY4fszuJ2BlIxkDrVaO0NwVm3jA4AzyKnIZbg7m5HQ5qo36DclsT2zQ3DBmYps46VK80T/IjJnPLev1qqrlY45NwbnkCmwv5wdI0UMDk5HJqudrchq5JNCUkVPlZCOGHNQCJFKgBjKpyWzwRTgwjlc8kMc9asReVJGNysMcnBzxSTuwu0RG2kTJKANjqpycVS1R7y606KzGwwK+4Nt5B9Ca15ZFQgwtkADrxmoEi86efYCqt83HrWl76FRlZ3ZjgMtq0iyNgDG0muYubi8SXzArImcZNdirON8RCl9p+Uiua1m5e4/cmFjMRjpx9aUopxN6L11C0vnntd5K7kbaR6+9X0bzo8ElthxtJrnbdBFG8m1xBIQik9Qwrbs9jxNu/wBYeFAOPmrLyHVSvdFstvhZoxwOc9DUMc/ljcpwev1NNjuFhjkLAqhHG7uTWULyOeXy92W5xiqu0Y+zvsS6ksrz/awMF/lGBxUFrdgSojvjcSBx3qrfXUnkbN7gLnA9/WuNsnuIdVBZ5CpJPPb6VTlHobxjeOp2WqEWs6AsDu7jvTUtoZIN52+YOee9Z92k8jrIy/j6VfhmWKFPMBY9+Ky5rSJlGy0KMy5DARsyAcnFUWgE8eVPFbmqarG8CxxKq4Xb0rF0iZUikD8Y7NW0orZEpO1yPBRegOKtafvZSCwAPUVWWZftLBiMMelX4FjVxjqelc0lYTJ5E/doCR061XRd42qMNjPtU07uEGBlRwSe30qhFK3zhWIGeD3oaaEmTCHftVmzjkZqEzpHMdueOAasbS0THjPaoVtgzdMcg5qtguhtzbRyRbyeT3qeyhVfL28r060s6owEABwP1ogKwNtU4wetJu4m29DQV+WPVRwBR95uGypHSq6uNhIPzE9D0p6FQ6lPT5smoZmShcIGzk9xVSeZVfae/erJJETMhGfSsfUJ+Fxy3fHatUlYqKuaFvfXNnuFpcSRF+vltjNTNrGqhQf7Quhn/poai8PpbPbXt7fRfaIrSNSIQSoZmbALH0FWriC21SxludJiaG5twXmtNxbKf307/UUrNGbavqjNurmW5cvPK8spxl3OScUVZ8SQw2+qeXboqReRE+1fUoCTRUNO407owlAdcscntzUgfZyVyPWqayBeMnFSozZHOc9K1JuXoySAx7VMki7vm5qnF8sbCTJ57Ub9z8DHHSkNGlvDADaAagVQGJ3Z9qFZQik96iHD84HOaloonE2xlBPU1PDtLn5Tk9MVQunzGzDhs8U60mZYxubGDSSDoWCrJK3OMHFOlUNyh+6KQP5kp3fdPemkkMQv3BxRYaYq52DAO7PPvUyZOF4zjOCaiUgJu7elA2FNzBs49aWxVyWTcXDc5AqVMScuvPbPc0xASnyckjBPpUiBCFwDgdzQBIil5EVgBnNaCrsxt7DA/wAaqACQgqTipw2Oh+Xt7e1RdiKd0jFiq9DzkVZsrZ+N3zH19KnXa/zEc57cVchKKpC7t/8ADj+taX00NVNpWJLeJNmAc9jTZ41VNqAkirCpJHFkjOT2p8a5YeaflqiU7MyYVkhVwhbB5IFVhazNcGUnIYg/jW1cRiNcqAQenvU2geUZJ5LosgVTsVedx7URjzSsaOo7XJIzIbeP7RtUDoB2pJiJGUnoO2OtJdXKLnrsX72fWqumrc3bFl+Ueg7CtLNuxMU9zShRQp8piM9cVJtAbac4PJBqW1QICrvkZPNShYyz+ZkuP0qZx1M21ciUblCsTntT7eR2/hAQcBj3pXZFiJJY7fSlhXcFjB2p1yetJCuWLQxby3QYIHfJqbys7ZcAqzbSvce9RIF8tTtycYHvVho1VR5pKk/PtB4wBVRIItVKRhBDFggElD6Vk2YuJ8yINhJPAPatm5hVxDMSWdxuA7YqjPG1tPmGMsG6AU2k5XLg9COMFNvz5Df3hVm3mkBVtq9Cu7OOKghhMlzLJKGiTGQnbpV20jEqxLOVYBeNtSlqEtB+8C3yyKYlPUdQKQTosQZVIYcAD0qW6tGhj3xKzL0OOlU5otrJiTGTznsappoha6kUyt9oWRQqu3BY81WubQ53JtLjjNaCusTut0BJGVPtk+1V4tssZy3y44BPQiqi7FptamBJpJaEiQEtuyoA4zVSyvFMzwlcOny4rdub6eBDFbkEg7g2M4rn4bN5Lt7l/wDWM2TjuaibSa5DaLbXvE+qsBbfZWCqNwJYdq5nW44bO5jNo5OW4J4x710OrhzAFXrn7tctMlxI+2RQVHAqpSWyLprqy/cT28+h+Z5jLeo3K9mWqsFvHMYpume1JHZ7oQsu4H0rQtozbxCNNvPqOlZuewN8uiLNzAixQAyEq3GT0qrPEJZQiEgBe/SkmVmXbkEdM1bv9NuINGa481AEIyCfmIPcVtb2mqM3uc9dwjaeACBkZqgkMsYbYx+bGauxTs8vzgE45z6VaEKNGWPBHIxWCbTLlJx0ZkxwYYF2yzetaa4GFA59aWVEADKcHABzUVwGjZXGDxUyMZMLmSTGxGOxh61Rt45FdjuJx2qyrZQFj39cYqWMEFueMYzRdsLpIejb1AUc96l2ncseQDnkg8UyMqrBsH0zmm3TeXlix56E0GfUeACxD4JHTmor5ggVVAUnniiA7+evHWnyKh2krkVXM1oUnYfaP+5JbBz1B70pIzuBJIPTFQqQCTk4PQY6U88ruBzntUsl6kkr8EetVGQMcMBk/rUkrKRsbhvUVBjahGdxoW4XsXtJbUobyV9Kikd1G2RVj3qQezDuKIdN1u1ukuLaxvo5VO4OsJGD/hVfTr65sb+K4tdxfO0xjJEg7qRU1zFrQkllS31OG3JJVWLttHpnvWmhk3qM1ya7udSeXUY/Kuyqh0KbDgDg47cUVlzSSPIzSu7uerOcniipKWhShYEhuCo4qZWJyVGFHas9XAA64PapojyM9OlaNIlF0MSeDx6VI2QMjmoSUUZU/hSB8nBqSi0X3BeTx0FPEgB/ecN2qkpypIBGKR2fIOOnQUikrmkH8xcPgKDk+9Ioi2NtO454ANQo7eVk4GeDTU2xnjv19qALlu3XcM49e1SyP8o296pFwS3ln61JIcxjBAPWgOpKxZGXPCn2p3YEt8pPBPeqqvuGVPIGKnkwyp8p+X0paFI0LV1RsdTj8qmXBlABGT2PrWfEQGBU5PvViOVi5Cjp3pSGXkz90Ngjqe1TxRbskZ45JqvE52AYHHP1q3FOYguQOfxqAQpUls54qeKVVMYXJwckZpjHcTyOe1SKrKVJTOO+KlN3NFsaYn8xSCvA6AUbsAADHsetVdxQ5H8PNWLaRJZN2ck1qmQwuY2lGEOR1PtUUVsY1ZyxUjmr6oCN3OD2FN8tXRl5A9T6UeaHGWlmZcqvd28uxTtHJapNN8+I5D4K8Y9afHBJAXRd3ltwee1WY1RCArggjv1zVqVkap6WNKzdViZZMGVuSR6UyR9wIVeSeo7VXspC4OMkKSKsAEMUJwAeSKer1Zi9AVC8RB4OOualtjulEjZ4IP1p3lKmTll55XFNjzlscLuH3uBUt2JJdzO/3sc/KOmTVyNQsoWQ7+NrE9jVWOPcUfcMn5tuegqbLN8q8KMnjnNMRbikTymjXAH3asCJUj2N+8KrkMhxismxAUOsrvh1OCB3rRjm2QK0brkfKc9TWsNdbCasVrmLdGqI/wA5HQHPFJZELEFiH70ZUoe4pZI41IVnIDZLbeCKhWJjGsiEqD3B5FS3rdoaLod5IgqY3pncg9KhuDGsALjnGfypU3xFnQlcgYbHDGsrXy7QqzyAIFxkdzTb0uOMU3YsP5UqbrcEgcjPvVRjvhcbcN0GOPrVTTbh3hwTvlLbdo449auXMnlrvxlwcfSs79TRw5XZlUcKNoGT1BqSKFY13HHPUUQbCrF+CckVIZFI2sQhK5XNCsyW7MzL6NWkzgFQPlrNuYUkm2xDjHXpVzxHcNbQx7GRjnnj9KpwnfCknOWPOaiejsi43tcq3EBV1zkH9KV1O1yRlscCr7puyOODx9ahB2hyQOOuam4nIo26KgYSgk+tQa5flrVrdyRx8rdRj+lTvI00hZMAEdKoXkJkODxjgitIVOXRBHe5z8bbLpDEcrnknvW9GxEJcqeenpWeLLY/yjjPFXprjZAh7L0XFNWbLqe9sUrq48klZMjPQ1FuEzoFOfQ+lUdVvftGQikE8Yz0o06Qs6q2eABxRNLoKULRuaNwoXcc5bOKdG+EHQk9vSmhTIzZ+6KFb7w+UBeM1FrGLLUcmJFGBjqaqak7yqRjv17U5Xxkryf6U2R1OUwV98dTQxLR3E09WEeN3I7VZ81I2b+L2qszquwr2HOKTfvONuQe9JuwFjeGJC9euDQGwpwApqNmw4HQjpUZYs5569aQmx8j5J6FvWoZeSdnAHJprKyZJPB6VE0u0g9hVJaktnReF5MJfJbTRw6lLEFtpJDtxz8wBPQkU+LTvFKS7/tFxER/y1e7G0e5O6qGjxWr299e38bywWqK3lRtt3szYGT2FJfWdrqGmTX2jpJGbdc3Fk77yi/30PdfX0qzJ7kfiq4gm1uaS2kjkXagkeMYV5AoDEexOaKreKobaz1U29onlxiCGTAOeWQEmihlrY5cOQ2M8kVaiOFyxwKzwVPzD8KlikJHLcVpYDREnAY84p6v5pVuBz0qpG3Tnj0pwLAHafoKiwy8ZW3H5iV6YI6U4SdRnOOhqmsvyDP3u5pyy8bTxmkxqRcSTGAW+X0p2QBkNnPWqZYDgHkUK3yjnnvzTsMuLJt+7yfpUnm7sA43GoYsDk5x/OkJyRg4HpUiLcD7BsYgAjsKsxud+OTjmqSlZEweD65qzFIwPYDGBSZSdixD88pOdvvirUKkODngiqkLfPjOPerMTsRsb6j2FKWxRdCsoGCDnsKtKhwNuDgVSjwxHBGBxVq2POzoc1k2VoWIxsGTyatYyB8xBNMUYA2nk8H6VMoK4YLgY5zRHUd7EkTKDyMcY570+CPy5A2ccdKjRgScgbexqXDdfT1q9iW7lyFtzdeOmKs7fLG0LluwI6VShlGVKjjHFTyMSBgkZ6807gSFFK88A8kiqcsLEkIAQOeKsllOxegI4APWlwgYhVIBHOaGWtCOxeW0jYbhiQZOBT4ZDK24khD6CpVhDRp0AxUECNECqnC5p3d9Q3LsUgNxsblWXhs1LIOqsRyAMe9ZTTBm2xlTtOMirYkAU72BOcZz2qpSVyLF/cH3JtVcDLHPpUsDMMoFIYHO7GOKitQ8vyQ7GC8Nu4qZZD5jLyABgg1VupLethZQm8mKTnAznpUkcEkIzGd0fB4H3TVAyygNnYoLcgdx61bt5EJCvIy8buvU1SYcos+2UpvwSxJBzj86YEVi0aSMG46cihNpkkbaCQflB5qLeI3ZsBX6cGhtDQ43MsbujEEZPDDj8KzNU/foU2HIxxVoNtc7iWJPGacdsrHePnPJ9AKzTurFxdjJs7Qwk8bTuB+ta3lOzsNgK96YUZZAxYDsN1OkdmVVVjgnn3NNIJy5ipcCNQ5kBBz1FQH94hz1UYBPce9LKWl3g5wp59veo5yAg3kkjj5anS9xbGddWyyks/JPIUc02BQqYboDxVtsj5icc7eO1V0H77GfpUtXHfQjdc8qe+6oZ2O5gR8verDuu/bgL6H1qpqDeTOVYDOOxpNdQauVXUByoBx9aiKBn645xg1KSSdw47D2p7shLr90gZB9ahO4r20K4jwp+XlT19RVO8UyAgLgHvV6eQBFDADjg96qSkkgdSf1q4vUEzm7y0ZnyGwOnSlgRosFeOelbEsaiQFuh5+lRzqCgVQuT3q73G6jasQeYxJbp6jtTEeMsSSNpqCTzOSPXAApFA5DHHpSbMmTpjAyaJX2rnPBqIElyAcU12cHnBXPNCFclX5lLA8HtTd/ocrnmoZJPfBNQvI24HPTr70NXE2X45ArkOcpTnUYJBA9DVBJuCHWpXn2oQD9R60JEpkjvu+VufTFQvxwR1piS5UkjHpVcuxLFvmHY+lWNmjp+qz6ZO0kAR1kXZJHKu5JF9GFU7TUprK8F1Yy+XOpJXb0APUY7jtirnh62W5klmmjM6RskUcBbaJpXOFUnsvBJ+lXIb17nULqycaRdQwhikKW4jWfbywjcDKnAOCTzimkQzK1fVZNXvnu7hY0kKqhCDC4UY4H4UVX1u3Szv2jgdntnRZoWb7xRgCM+46fhRRYpeRzyTJsGTgelTrIoAP8NZL9B9atL/qhW7RJfjmAc/pirCuQcn8KzbT7x+tXk+9WTGmTLIN23PSpBIpOG54qunRvrSR/60UmhothxnkdOlKsmTg5NMk+7SJ1FJDTLQmZlwDz2FSRr5jAFiCO/aqq9alh6D6UNBcuhMnAIIHcdKsQFQPmJxnpVVeCQOlSr/DWe4y+jBnVtvyn17Va/wBWhYruZjxnpiqdr978DVpvv/gKT2LTLlvlSCrckcnFXIWyw2KT2z71Ts+j/WrsXGQPSshrctKxVRnr7VYSRtnPPpVIfeFW46IMbH4HJ6ipwdyAsuW9aji6SfWpI+1aICeMs8nC8j2qTDI2V5xxk9KF60Rf8e0f++aLIB6DhRjkdqhluFR2YocdgTUi/fk+lZd+TuH0FJs0jqzorNg1szOcA8g+tV5CpmwjEq3rUWm8xAHptpsX3BWs9kydmLLFGjvsAQ98d6rs+4HaxYjtV+5A+zH6Cs+D/WJ+NZy0ZS1uXtK1NIi8dyPmDAirjXj5dkOSeVzWNIB9rXjvV5P9X/wKqjJuKuKUUiw+JIg8pKs46LzUxVZSo4Zl/WoeyUvRTj1p30E9i4pAwFiYHbwRUcqsZldVLFhzkU4E/Z4uT3p9sc4z71o0rEFUbmm27cHGcmlZ2UcgMM84Pakuun41D2P+7Wa0RbRLJcRSNmU4OOCTwB61SgvBcSlU42k8jpxUcvMT5561DpIAWTHvS5rjUVYuyMpyACCw/Oq+4JNnbu4x/wDXq2vVv89qoj/WfnR0JZA37w7Yyck81CBtlLcAgcU/+JqrknzepqWxoGbY3JJz1+lZGov5ko4IGeMVrTffWqH/AC3ahPoUh3/LMbsdAM1GGydxAJ6Usv8Aq6jb/XD6VL0M2R3fy7Rn5u3pUAHDFztyMg1Jc9qjl/1SUJXEViwaUIW4AyM1WlwCw4Oeh9KmP+rP+/UU3SqiIpmUAlcDFV5iQRswFPY1M3Q1EOX5qyWODnZ0wfWojJtGSMZ6g0896gn6fgKEieox5CW45z2FCuM5xmq/pQPufhTsBPI4ckjjPvUPnbTjrUbfeH0qF/vLQJ6Fhpjj5iefSmmcsgC9PSmj+L61TBOetUhLU3tB1GO1aaG4laCOYpIk4Xd5MqHKOR3XqCPQ1rN5UTy3WzR7HzQwa8huzNtDDDGKHqGIJxnpmuNH3ahuAAOOKolo0ta1CK9v3kgjaO3RVhhRuqxqMLn34yfrRWHIT83NFVZMaP/Z);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Tiny papules and pustules grouped on the chin.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: www.visualdx.com. Copyright Logical Images, Inc.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f1_20_1348=[""].join("\n");
var outline_f1_20_1348=null;
var title_f1_20_1349="Molding short arm cast";
var content_f1_20_1349=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=EM%2F52657&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=EM%2F52657&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Molding for a short arm cast",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 324px; height: 432px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Improper molding or any sharp indentations in the cast can cause complications such as pressure sores and skin ulcers. Clinicians with little experience casting should limit molding to gently compressing the cast into an elliptical shape at the area of the fracture. The palms and heels of the hands should be used; avoid using fingers. Practitioners with experience casting may use a three-point molding technique.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Stephen Titus, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f1_20_1349=[""].join("\n");
var outline_f1_20_1349=null;
var title_f1_20_1350="CLL and AIHA marrow";
var content_f1_20_1350=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=HEME%2F72694&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=HEME%2F72694&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Chronic lymphocytic leukemia with erythroid hyperplasia",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 426px; height: 288px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Bone marrow aspirate from a patient with chronic lymphocytic leukemia and autoimmune hemolytic anemia with bone marrow erythroid hyperplasia. The small lymphocytes (black arrows) have a dense nucleus with a thin rim of blue cytoplasm. The nucleated red cells have an irregularly clumped nucleus with a greater amount of cytoplasm, which can range from basophilic to polychromatophilic, to eosinophilic (red arrows). (Wright- Giemsa).",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of David S Rosenthal, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f1_20_1350=[""].join("\n");
var outline_f1_20_1350=null;
var title_f1_20_1351="Inherited syndromes associated with cardiac disease";
var content_f1_20_1351=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/wk_utd-rgb.myextg\" width=\"220px\">",
"   </img>",
"  </div>",
"  <div id=\"printHeaderText\">",
"   Official reprint from  UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"   <a href=\"file://www.uptodate.com\">",
"    www.uptodate.com",
"   </a>",
"   <br>",
"    &copy;2013 UpToDate",
"    <sup>",
"     &reg;",
"    </sup>",
"   </br>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"1\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Inherited syndromes associated with cardiac disease",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?1/20/1351/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?1/20/1351/contributors\">",
"     William J McKenna, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?1/20/1351/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?1/20/1351/contributors\">",
"     Bernard J Gersh, MB, ChB, DPhil, FRCP, MACC",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?1/20/1351/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?1/20/1351/contributors\">",
"     Susan B Yeon, MD, JD, FACC",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?1/20/1351/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Feb 3, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Hypertrophic cardiomyopathy, dilated cardiomyopathy, and arrhythmogenic right ventricular cardiomyopathy are commonly inherited (",
"    <a class=\"graphic graphic_table graphicRef64479 \" href=\"UTD.htm?17/63/18429\">",
"     table 1",
"    </a>",
"    ). (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?28/44/29386?source=see_link\">",
"     \"Genetics of hypertrophic cardiomyopathy\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?38/41/39576?source=see_link\">",
"     \"Genetics of dilated cardiomyopathy\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?22/62/23528?source=see_link\">",
"     \"Genetics and pathogenesis of arrhythmogenic right ventricular cardiomyopathy\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?30/3/30777?source=see_link\">",
"     \"Definition and classification of the cardiomyopathies\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    In addition, a number of inherited syndromes consist of defects that produce systemic as well as cardiac manifestations, most of which affect skeletal muscle. These disorders will be briefly reviewed here and are discussed in detail on the appropriate topic reviews. Amyloid cardiomyopathy and cardiac manifestations of Fabry disease are discussed in detail separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?23/10/23722?source=see_link\">",
"     \"Clinical manifestations and diagnosis of amyloid cardiomyopathy\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?16/45/17111?source=see_link\">",
"     \"Cardiac manifestations of Fabry disease and screening in patients with left ventricular hypertrophy\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     NEUROMUSCULAR DISORDERS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Cardiomyopathy occurs in a variety of inherited neuromuscular disorders. The underlying neuromuscular disease is usually apparent at the onset of cardiac disease but some patients have no or only mild neurologic manifestations.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h2\">",
"     Dystrophin disorders",
"    </span>",
"    &nbsp;&mdash;&nbsp;Mutations in the dystrophin gene on the X chromosome produce both Duchenne and Becker muscular dystrophy. In addition, deletions in the 5' muscle promoter of the dystrophin gene can cause a predominant cardiac phenotype that presents as a dilated cardiomyopathy. Skeletal muscle biopsies of individuals with X-linked dilated cardiomyopathy due to dystrophin deletions demonstrate the classic pathologic changes of Duchenne or Becker dystrophies, but the muscle manifestations may be subclinical. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?38/41/39576?source=see_link&amp;anchor=H5900707#H5900707\">",
"     \"Genetics of dilated cardiomyopathy\", section on 'Dystrophin gene mutations'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h3\">",
"     Duchenne muscular dystrophy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Duchenne muscular dystrophy (DMD) is caused by a defective gene located on the X chromosome that is responsible for the production of dystrophin, a high molecular weight protein that is localized to the sarcolemmal membrane of normal skeletal muscle. Patients with DMD have complete or almost complete absence of dystrophin in skeletal muscle. The clinical onset of weakness usually occurs between two and three years of age. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?1/16/1290?source=see_link\">",
"     \"Clinical features and diagnosis of Duchenne and Becker muscular dystrophy\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    DMD causes a primary cardiomyopathy with extensive fibrosis of the posterobasal left ventricular wall, resulting in the characteristic electrocardiographic changes of tall right precordial R waves with an increased",
"    <span class=\"nowrap\">",
"     R/S",
"    </span>",
"    ratio and deep Q waves in leads I, aVL, and V5-6 (",
"    <a class=\"graphic graphic_waveform graphicRef53681 \" href=\"UTD.htm?42/56/43914\">",
"     waveform 1",
"    </a>",
"    )&nbsp;[",
"    <a class=\"abstract\" href=\"UTD.htm?1/20/1351/abstract/1\">",
"     1",
"    </a>",
"    ]. As the cardiac disease progresses, fibrosis can spread to the lateral free wall of the left ventricle. Significant mitral regurgitation is often present due to involvement of the posterior papillary muscle [",
"    <a class=\"abstract\" href=\"UTD.htm?1/20/1351/abstract/2\">",
"     2",
"    </a>",
"    ]. Cardiac involvement is also associated with conduction abnormalities, especially intraatrial and interatrial but also involving the AV node, and a variety of arrhythmias, primarily supraventricular [",
"    <a class=\"abstract\" href=\"UTD.htm?1/20/1351/abstract/3\">",
"     3",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?1/16/1290?source=see_link&amp;anchor=H8#H8\">",
"     \"Clinical features and diagnosis of Duchenne and Becker muscular dystrophy\", section on 'Cardiomyopathy'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h3\">",
"     Becker muscular dystrophy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Like DMD, Becker muscular dystrophy (BMD) is an X-linked disorder involving the dystrophin gene [",
"    <a class=\"abstract\" href=\"UTD.htm?1/20/1351/abstract/4,5\">",
"     4,5",
"    </a>",
"    ]. However, in contrast to the absence of dystrophin in skeletal muscle in DMD, most patients with BMD have an abnormal dystrophin protein. BMD is later in onset and slower in progression than DMD. The clinical manifestations are also less severe as affected patients typically remain ambulatory until at least age 15 and often into adult life. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?1/16/1290?source=see_link\">",
"     \"Clinical features and diagnosis of Duchenne and Becker muscular dystrophy\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Although muscle involvement is less severe than in DMD, cardiac involvement in BMD can be more severe [",
"    <a class=\"abstract\" href=\"UTD.htm?1/20/1351/abstract/6\">",
"     6",
"    </a>",
"    ]. It has been suggested that, because patients with mild BMD are still able to perform strenuous exercise, the associated mechanical stress on the heart may be harmful for myocardial cells with abnormal dystrophin.",
"   </p>",
"   <p>",
"    Echocardiography reveals early right ventricular involvement with the later development of left ventricular dysfunction and heart failure that can be rapidly progressive and is usually the ultimate cause of death [",
"    <a class=\"abstract\" href=\"UTD.htm?1/20/1351/abstract/6\">",
"     6",
"    </a>",
"    ]. In addition, abnormalities of the AV node and infranodal conduction system can result in fascicular and bundle branch block and can progress to complete heart block. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?1/16/1290?source=see_link\">",
"     \"Clinical features and diagnosis of Duchenne and Becker muscular dystrophy\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     Emery-Dreifuss muscular dystrophy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Emery-Dreifuss muscular dystrophy (EDMD), also known as humeroperoneal muscular dystrophy, can be inherited as an X-linked recessive, autosomal dominant, or autosomal recessive disorder involving the emerin or lamin",
"    <span class=\"nowrap\">",
"     A/C",
"    </span>",
"    genes. The different forms of Emery-Dreifuss muscular dystrophy have identical symptoms, which usually begin in the first or second decade of life. Muscle weakness and wasting has a humeroperoneal distribution and tend to be slowly progressive. Contractures are often the first manifestations of the disease. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?20/58/21415?source=see_link\">",
"     \"Emery-Dreifuss muscular dystrophy\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    A cardiomyopathy may be seen in EDMD. It is typically associated with AV conduction abnormalities; other common findings include atrial paralysis, atrial fibrillation, atrial flutter, and infranodal or AV conduction block with the development of slow junctional rhythms that often require pacemaker insertion. Sudden death can occur.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h2\">",
"     Facioscapulohumeral muscular dystrophy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Facioscapulohumeral dystrophy (FSHD) is the third most common hereditary muscle disorder after Duchenne muscular dystrophy and myotonic dystrophy. The classic form is inherited in an autosomal dominant fashion and the affected gene has been mapped to chromosome 4q35.",
"   </p>",
"   <p>",
"    FSHD is usually slowly progressive but there is variability in both age of onset and severity. The onset in the classic form is usually between the ages of 10 and 30 and progression is slow with an almost normal life span; however, the infantile form is rapidly progressive. The disease initially involves the face and the scapulae followed by the foot dorsiflexors and the hip girdles. Asymmetry of muscle involvement and sparing of bulbar, extraocular, and respiratory muscles are other typical features.",
"   </p>",
"   <p>",
"    Cardiac involvement can occur. The manifestations include P wave abnormalities, intraventricular conduction delay, and supraventricular arrhythmias. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?25/34/26153?source=see_link\">",
"     \"Facioscapulohumeral muscular dystrophy\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h2\">",
"     Myotonic dystrophy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Myotonic dystrophy (also called dystrophia myotonica [DM]) is a multisystem disease with autosomal dominant inheritance and variable penetrance and clinical anticipation, eg, increasingly severe disease with each successive generation. Two main forms have been identified: DM1, in which the genetic defect is a trinucleotide repeat in a gene encoding a protein kinase called myotonin; and, less commonly, DM2 (also known as proximal myotonic myopathy or PROMM), in which the disease locus is on chromosome 3q21. Clinical features include myotonia (delayed muscle relaxation after contraction), weakness and wasting affecting facial muscles and distal limb muscles, frontal balding in males, cataracts, multiple endocrinopathies, and low intelligence or dementia. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?19/26/19882?source=see_link\">",
"     \"Myotonic dystrophy: Etiology, clinical features, and diagnosis\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    In the classic form, DM has its onset in adolescence or adulthood and disease severity may be mild (eg, isolated cataracts) to severe with marked skeletal muscle and cardiac",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    endocrine dysfunction. The congenital form occurs in children born to affected mothers with myotonic dystrophy.",
"   </p>",
"   <p>",
"    Cardiac manifestations include atrioventricular block and intraventricular conduction delay, with occasional progression to complete heart block, atrial fibrillation, ventricular tachyarrhythmias, and a cardiomyopathy characterized by a reduced left ventricular ejection fraction, wall motion abnormalities on echocardiography, and in less than 10 percent of patients, heart failure. Sudden death can result from conduction system disease or ventricular tachycardia, and cardiovascular causes are responsible for about 30 percent of deaths. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?19/26/19882?source=see_link&amp;anchor=H9#H9\">",
"     \"Myotonic dystrophy: Etiology, clinical features, and diagnosis\", section on 'Cardiac abnormalities'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h2\">",
"     Friedreich ataxia",
"    </span>",
"    &nbsp;&mdash;&nbsp;Friedreich ataxia is the most common hereditary ataxia in Caucasians. It is transmitted as an autosomal recessive trait and is caused by loss of function mutations in the frataxin gene. The major clinical manifestations are neurologic dysfunction (eg, progressive ataxia of all four limbs may be seen by age five or earlier), diabetes mellitus, and cardiac disease. Electrocardiographic and echocardiographic abnormalities are those of morphologically mild asymmetric septal hypertrophy with progressive impairment of systolic function. The main clinical manifestations are arrhythmic complications related to the cardiomyopathy which are a frequent cause of death. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?15/4/15432?source=see_link\">",
"     \"Friedreich ataxia\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h2\">",
"     Barth's syndrome",
"    </span>",
"    &nbsp;&mdash;&nbsp;Barth's syndrome is an X-linked disorder characterized by skeletal myopathy, dilated cardiomyopathy, short stature, and neutropenia. Affected individuals often die at a young age from heart failure and its complications.",
"   </p>",
"   <p>",
"    Genetic mapping studies defined a locus that overlapped with the Emery-Dreifuss muscular dystrophy locus. Barth's syndrome is caused by mutations in a novel gene (G4.5) that codes for proteins called tafazzins [",
"    <a class=\"abstract\" href=\"UTD.htm?1/20/1351/abstract/7,8\">",
"     7,8",
"    </a>",
"    ]. Alternative splicing of this gene may account for the variations in tissue and disease expression. This genetic mutation is also responsible for isolated left ventricular noncompaction [",
"    <a class=\"abstract\" href=\"UTD.htm?1/20/1351/abstract/8\">",
"     8",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?40/51/41784?source=see_link\">",
"     \"Isolated left ventricular noncompaction\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h1\">",
"     OTHER DISORDERS",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h2\">",
"     Iron overload",
"    </span>",
"    &nbsp;&mdash;&nbsp;Cardiac disease due to iron deposition within the myocardium can be seen in hereditary hemochromatosis and hereditary sideroblastic anemias. The 2005 guidelines from the American College of Physicians proposed the following cutoff levels for identifying patients with iron overload: transferrin saturation (serum iron &divide; total iron binding capacity) greater than 55 percent and serum ferritin greater than 200 or 300",
"    <span class=\"nowrap\">",
"     microg/L",
"    </span>",
"    in women and men, respectively [",
"    <a class=\"abstract\" href=\"UTD.htm?1/20/1351/abstract/9,10\">",
"     9,10",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?34/19/35129?source=see_link\">",
"     \"Pathophysiology and diagnosis of iron overload syndromes\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h3\">",
"     Hemochromatosis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Hereditary hemochromatosis is a common disorder with recessive inheritance that affects 1 in 400 individuals of northern European ancestry. It is characterized by increased iron absorption and deposition in parenchymal tissues, including the heart. This disorder is due to mutations in the HFE gene that lead to increased intestinal iron absorption. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?2/13/2266?source=see_link\">",
"     \"Genetics of hereditary hemochromatosis\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Diabetes mellitus, bronze skin changes,",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    evidence of hepatitis or cirrhosis should alert the clinician to the possible presence of hereditary hemochromatosis. However, the absence of these disorders does not exclude the diagnosis since, prior to the use of screening studies, heart disease was the presenting manifestation in up to 15 percent of patients. Iron deposition can lead to a dilated cardiomyopathy characterized by the development of heart failure and conduction disturbances such as the sick sinus syndrome. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?27/60/28617?source=see_link&amp;anchor=H14#H14\">",
"     \"Clinical manifestations of hereditary hemochromatosis\", section on 'Heart disease'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Treatment with phlebotomy has been associated with reversal of the left ventricular dysfunction, but irreversible myocardial dysfunction can occur with advanced disease. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?18/32/18952?source=see_link\">",
"     \"Treatment of hereditary hemochromatosis\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h3\">",
"     Hereditary sideroblastic anemias and thalassemias",
"    </span>",
"    &nbsp;&mdash;&nbsp;Sideroblastic anemias and thalassemias are hereditary disorders that cause anemia of varying severity depending upon the specific genetic defect. Ineffective erythropoiesis leads to increased iron absorption; in addition, regular red blood cell transfusions are necessary in the management of most of these disorders. These processes ultimately lead to iron overload and deposition in various tissues, including the heart (",
"    <a class=\"graphic graphic_picture graphicRef81850 \" href=\"UTD.htm?24/37/25177\">",
"     picture 1",
"    </a>",
"    ). Iron deposition in the myocardium can result in arrhythmias and HF, which usually occur late in the course of the disease. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?5/63/6138?source=see_link\">",
"     \"Clinical aspects, diagnosis, and treatment of the sideroblastic anemias\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?37/13/38106?source=see_link\">",
"     \"Clinical manifestations and diagnosis of the thalassemias\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Phlebotomy, which is effective in treating iron overload due to hereditary hemochromatosis, is not feasible in the sideroblastic anemias and thalassemias because of the underlying anemia. Iron chelation therapy, if initiated early, may prevent or reverse the cardiac abnormalities. Assessment of myocardial iron overload with cardiac magnetic resonance T2* imaging to guide chelation therapy has dramatically improved prognosis in thalassemia [",
"    <a class=\"abstract\" href=\"UTD.htm?1/20/1351/abstract/11,12\">",
"     11,12",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?37/60/38856?source=see_link&amp;anchor=H16#H16\">",
"     \"Iron overload syndromes other than hereditary hemochromatosis\", section on 'Chelation therapy'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h2\">",
"     Desmin cardiomyopathy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Desmin is a polypeptide that normally aggregates to form filaments of a diameter intermediate between myosin and actin in both skeletal and cardiac muscle [",
"    <a class=\"abstract\" href=\"UTD.htm?1/20/1351/abstract/13,14\">",
"     13,14",
"    </a>",
"    ]. Granulofilamentous and cytoplasmic inclusions result from abnormal forms of desmin [",
"    <a class=\"abstract\" href=\"UTD.htm?1/20/1351/abstract/14\">",
"     14",
"    </a>",
"    ]. Desminopathy is a skeletal and cardiac myopathy caused by mutations in desmin or alpha B crystallin, a chaperone for desmin.",
"   </p>",
"   <p>",
"    Desminopathy is usually inherited in an autosomal dominant pattern although some kindred demonstrate autosomal recessive transmission. In contrast to other forms of cardiomyopathy, it requires ultrastructural study for diagnosis. The failure of desmin to aggregate into intermediate filaments and the presence of granulofilamentous material leads to impairment in relaxation and contraction and clinical presentation resembling restrictive cardiomyopathy [",
"    <a class=\"abstract\" href=\"UTD.htm?1/20/1351/abstract/15\">",
"     15",
"    </a>",
"    ]. Atrioventricular block and mild or subclinical myopathy may be present. Other desmin mutations may produce an idiopathic dilated cardiomyopathy without skeletal muscle involvement [",
"    <a class=\"abstract\" href=\"UTD.htm?1/20/1351/abstract/16\">",
"     16",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?38/41/39576?source=see_link&amp;anchor=H20#H20\">",
"     \"Genetics of dilated cardiomyopathy\", section on 'Desminopathy'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5041122\">",
"    <span class=\"h2\">",
"     Naxos disease",
"    </span>",
"    &nbsp;&mdash;&nbsp;Clinical genetic studies suggest that at least 30 percent of ARVC cases are familial. Autosomal dominant inheritance is more common. A less common autosomal recessive form is called Naxos disease and is accompanied by nonepidermolytic palmoplantar keratosis which causes hyperkeratosis of the palms and soles, and wooly hair. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?22/62/23528?source=see_link&amp;anchor=H7#H7\">",
"     \"Genetics and pathogenesis of arrhythmogenic right ventricular cardiomyopathy\", section on 'Autosomal recessive disease and Naxos disease'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h2\">",
"     Carney complex",
"    </span>",
"    &nbsp;&mdash;&nbsp;Atrial myxomas are rarely inherited as part of the Carney complex, which is characterized by cardiac and mucocutaneous myxomas, lentiginosis, and endocrine dysfunction including bilateral adrenal micronodular hyperplasia that can lead to Cushing's syndrome. The cardiac tumors are often multicentric, rarely metastasize and are amenable to surgical resection. There at least three different genetic loci with two identified genes. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?17/32/17930?source=see_link\">",
"     \"Cardiac tumors\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?0/45/730?source=see_link\">",
"     \"Cushing's syndrome due to ACTH-independent macronodular adrenal hyperplasia\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"PATIENT_INFORMATION\">",
"    <span class=\"h1\">",
"     INFORMATION FOR PATIENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials, &ldquo;The Basics&rdquo; and &ldquo;Beyond the Basics.&rdquo; The Basics patient education pieces are written in plain language, at the 5",
"    <sup>",
"     th",
"    </sup>",
"    to 6",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10",
"    <sup>",
"     th",
"    </sup>",
"    to 12",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.",
"   </p>",
"   <p>",
"    Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on &ldquo;patient info&rdquo; and the keyword(s) of interest.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Basics topic (see",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?3/57/3986?source=see_link\">",
"       \"Patient information: Friedreich ataxia (The Basics)\"",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5040964\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      A variety of cardiomyopathies are due to familial disease (",
"      <a class=\"graphic graphic_table graphicRef64479 \" href=\"UTD.htm?17/63/18429\">",
"       table 1",
"      </a>",
"      ). Most are primarily associated with cardiac involvement and can lead to hypertrophic, dilated, arrhythmogenic, or restrictive cardiomyopathy. Other inherited syndromes produce systemic manifestations (eg, skeletal muscle disease) as well as cardiac disease. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?28/44/29386?source=see_link\">",
"       \"Genetics of hypertrophic cardiomyopathy\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?38/41/39576?source=see_link\">",
"       \"Genetics of dilated cardiomyopathy\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?22/62/23528?source=see_link\">",
"       \"Genetics and pathogenesis of arrhythmogenic right ventricular cardiomyopathy\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?30/3/30777?source=see_link\">",
"       \"Definition and classification of the cardiomyopathies\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Cardiomyopathy occurs in a variety of inherited neuromuscular disorders. The underlying neuromuscular disease is usually but not always apparent at the onset of cardiac disease. (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Neuromuscular disorders'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Other inherited disorders with systemic manifestations as well as cardiomyopathy include disorders that cause iron overload (hemochromatosis and hereditary sideroblastic anemias and thalassemias), desmin cardiomyopathy, and cardiocutaneous syndromes, including Naxos disease.",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/20/1351/abstract/1\">",
"      Sanyal SK, Johnson WW, Thapar MK, Pitner SE. An ultrastructural basis for electrocardiographic alterations associated with Duchenne's progressive muscular dystrophy. Circulation 1978; 57:1122.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/20/1351/abstract/2\">",
"      Sanyal SK, Johnson WW, Dische MR, et al. Dystrophic degeneration of papillary muscle and ventricular myocardium. A basis for mitral valve prolapse in Duchenne's muscular dystrophy. Circulation 1980; 62:430.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/20/1351/abstract/3\">",
"      Perloff JK. Cardiac rhythm and conduction in Duchenne's muscular dystrophy: a prospective study of 20 patients. J Am Coll Cardiol 1984; 3:1263.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/20/1351/abstract/4\">",
"      Worton R. Muscular dystrophies: diseases of the dystrophin-glycoprotein complex. Science 1995; 270:755.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/20/1351/abstract/5\">",
"      Ervasti JM, Ohlendieck K, Kahl SD, et al. Deficiency of a glycoprotein component of the dystrophin complex in dystrophic muscle. Nature 1990; 345:315.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/20/1351/abstract/6\">",
"      Melacini P, Fanin M, Danieli GA, et al. Myocardial involvement is very frequent among patients affected with subclinical Becker's muscular dystrophy. Circulation 1996; 94:3168.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/20/1351/abstract/7\">",
"      Bione S, D'Adamo P, Maestrini E, et al. A novel X-linked gene, G4.5. is responsible for Barth syndrome. Nat Genet 1996; 12:385.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/20/1351/abstract/8\">",
"      Ichida F, Tsubata S, Bowles KR, et al. Novel gene mutations in patients with left ventricular noncompaction or Barth syndrome. Circulation 2001; 103:1256.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/20/1351/abstract/9\">",
"      Schmitt B, Golub RM, Green R. Screening primary care patients for hereditary hemochromatosis with transferrin saturation and serum ferritin level: systematic review for the American College of Physicians. Ann Intern Med 2005; 143:522.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/20/1351/abstract/10\">",
"      Qaseem A, Aronson M, Fitterman N, et al. Screening for hereditary hemochromatosis: a clinical practice guideline from the American College of Physicians. Ann Intern Med 2005; 143:517.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/20/1351/abstract/11\">",
"      Modell B, Khan M, Darlison M. Survival in beta-thalassaemia major in the UK: data from the UK Thalassaemia Register. Lancet 2000; 355:2051.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/20/1351/abstract/12\">",
"      Modell B, Khan M, Darlison M, et al. Improved survival of thalassaemia major in the UK and relation to T2* cardiovascular magnetic resonance. J Cardiovasc Magn Reson 2008; 10:42.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/20/1351/abstract/13\">",
"      Fuchs E, Weber K. Intermediate filaments: structure, dynamics, function, and disease. Annu Rev Biochem 1994; 63:345.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/20/1351/abstract/14\">",
"      Goebel HH. Desmin-related neuromuscular disorders. Muscle Nerve 1995; 18:1306.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/20/1351/abstract/15\">",
"      Arbustini E, Morbini P, Grasso M, et al. Restrictive cardiomyopathy, atrioventricular block and mild to subclinical myopathy in patients with desmin-immunoreactive material deposits. J Am Coll Cardiol 1998; 31:645.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/20/1351/abstract/16\">",
"      Li D, Tapscoft T, Gonzalez O, et al. Desmin mutation responsible for idiopathic dilated cardiomyopathy. Circulation 1999; 100:461.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 4912 Version 4.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.3 - C21.34",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Morehouse School of Medicine",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1004-200.215.4.194-785DB895A1-S473950.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f1_20_1351=[""].join("\n");
var outline_f1_20_1351=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H5040964\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      NEUROMUSCULAR DISORDERS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      Dystrophin disorders",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      - Duchenne muscular dystrophy",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      - Becker muscular dystrophy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      Emery-Dreifuss muscular dystrophy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      Facioscapulohumeral muscular dystrophy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      Myotonic dystrophy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      Friedreich ataxia",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      Barth's syndrome",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      OTHER DISORDERS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      Iron overload",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      - Hemochromatosis",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      - Hereditary sideroblastic anemias and thalassemias",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      Desmin cardiomyopathy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5041122\">",
"      Naxos disease",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      Carney complex",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#PATIENT_INFORMATION\">",
"      INFORMATION FOR PATIENTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H5040964\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"CARD/4912\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"CARD/4912|PIC\">",
"      <a href=\"#\" title=\"PICTURES\">",
"       PICTURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?24/37/25177\" title=\"picture 1\">",
"      Myocardial siderosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"CARD/4912|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?17/63/18429\" title=\"table 1\">",
"      ESC 2008 CM familial",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"CARD/4912|Waveform\">",
"      <a href=\"#\" title=\"WAVEFORMS\">",
"       WAVEFORMS",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_waveform\" href=\"UTD.htm?42/56/43914\" title=\"waveform 1\">",
"      ECG in Duchenne dystrophy",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?16/45/17111?source=related_link\">",
"      Cardiac manifestations of Fabry disease and screening in patients with left ventricular hypertrophy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?17/32/17930?source=related_link\">",
"      Cardiac tumors",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?5/63/6138?source=related_link\">",
"      Clinical aspects, diagnosis, and treatment of the sideroblastic anemias",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?1/16/1290?source=related_link\">",
"      Clinical features and diagnosis of Duchenne and Becker muscular dystrophy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?23/10/23722?source=related_link\">",
"      Clinical manifestations and diagnosis of amyloid cardiomyopathy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?37/13/38106?source=related_link\">",
"      Clinical manifestations and diagnosis of the thalassemias",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?27/60/28617?source=related_link\">",
"      Clinical manifestations of hereditary hemochromatosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?0/45/730?source=related_link\">",
"      Cushing's syndrome due to ACTH-independent macronodular adrenal hyperplasia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?30/3/30777?source=related_link\">",
"      Definition and classification of the cardiomyopathies",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?20/58/21415?source=related_link\">",
"      Emery-Dreifuss muscular dystrophy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?25/34/26153?source=related_link\">",
"      Facioscapulohumeral muscular dystrophy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?15/4/15432?source=related_link\">",
"      Friedreich ataxia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?22/62/23528?source=related_link\">",
"      Genetics and pathogenesis of arrhythmogenic right ventricular cardiomyopathy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?38/41/39576?source=related_link\">",
"      Genetics of dilated cardiomyopathy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?2/13/2266?source=related_link\">",
"      Genetics of hereditary hemochromatosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?28/44/29386?source=related_link\">",
"      Genetics of hypertrophic cardiomyopathy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?37/60/38856?source=related_link\">",
"      Iron overload syndromes other than hereditary hemochromatosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?40/51/41784?source=related_link\">",
"      Isolated left ventricular noncompaction",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?19/26/19882?source=related_link\">",
"      Myotonic dystrophy: Etiology, clinical features, and diagnosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?34/19/35129?source=related_link\">",
"      Pathophysiology and diagnosis of iron overload syndromes",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?3/57/3986?source=related_link\">",
"      Patient information: Friedreich ataxia (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?18/32/18952?source=related_link\">",
"      Treatment of hereditary hemochromatosis",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f1_20_1352="Differential diagnosis of acute central nervous system demyelination in children";
var content_f1_20_1352=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Differential diagnosis of acute central nervous system demyelination in children",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?1/20/1352/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?1/20/1352/contributors\">",
"     Timothy E Lotze, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?1/20/1352/contributors\">",
"     Section Editors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?1/20/1352/contributors\">",
"     Marc C Patterson, MD, FRACP",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?1/20/1352/contributors\">",
"     Francisco Gonzalez-Scarano, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?1/20/1352/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?1/20/1352/contributors\">",
"     John F Dashe, MD, PhD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?1/20/1352/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Jan 28, 2013.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Differential diagnostic considerations for acute central nervous system demyelination in children include acute disseminated encephalomyelitis (ADEM), multiple sclerosis (MS), optic neuritis, transverse myelitis, neuromyelitis optica (Devic disease), and various infectious, metabolic, and rheumatologic conditions (",
"    <a class=\"graphic graphic_table graphicRef70259 \" href=\"UTD.htm?19/55/20347\">",
"     table 1",
"    </a>",
"    ). Most of these conditions are thought to be caused by immune system dysregulation triggered by an infectious agent in a genetically susceptible host.",
"   </p>",
"   <p>",
"    With the possible exception of the NMO-IgG autoantibody found in neuromyelitis optica, there are no disease-specific biomarkers for these conditions, making it difficult to distinguish among them at the time of the initial presentation. However, certain clinical features, laboratory results, and imaging findings can usually lead to the correct diagnosis. Multiple sclerosis is to a large extent still a diagnosis of exclusion, and therefore requires intense investigation for other conditions that might present in a similar manner.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     ACUTE DISSEMINATED ENCEPHALOMYELITIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Acute disseminated encephalomyelitis (ADEM) is characterized by acute or subacute onset of multifocal neurologic deficits with encephalopathy, often following a viral illness or vaccination. Additional typical signs associated with ADEM are headache, fever, or meningismus. Magnetic resonance imaging (MRI) demonstrates widespread asymmetric white and gray matter abnormalities (",
"    <a class=\"graphic graphic_table graphicRef74896 \" href=\"UTD.htm?24/17/24860\">",
"     table 2",
"    </a>",
"    ). (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?24/52/25416?source=see_link\">",
"     \"Acute disseminated encephalomyelitis in children: Pathogenesis, clinical features, and diagnosis\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?20/22/20838?source=see_link\">",
"     \"Acute disseminated encephalomyelitis in children: Treatment and prognosis\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    In its classic form, ADEM is a monophasic disease. However, relapsing forms of ADEM have been described and can be characterized as either recurrent ADEM or multiphasic ADEM, depending upon the clinical features. Relapsing variants of ADEM occur more than three months after the initial event and more than one month after discontinuation of steroids. Relapses occurring earlier than this are considered to be part of the same initial demyelinating episode [",
"    <a class=\"abstract\" href=\"UTD.htm?1/20/1352/abstract/1\">",
"     1",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Recurrent ADEM describes patients with a relapse of similar symptoms and MRI findings",
"     </li>",
"     <li>",
"      Multiphasic ADEM refers to patients presenting with new neurologic symptoms and MRI lesions",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    As in patients with monophasic ADEM, most patients with recurrent ADEM or multiphasic ADEM have a complete recovery. These conditions are self-limited in the number of recurrences, which typically follow in close succession.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h2\">",
"     Acute hemorrhagic leukoencephalitis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Acute hemorrhagic leukoencephalitis is a rare entity that represents a more severe and fulminant form of ADEM and is associated with diffuse central nervous system hemorrhage. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?24/52/25416?source=see_link&amp;anchor=H12#H12\">",
"     \"Acute disseminated encephalomyelitis in children: Pathogenesis, clinical features, and diagnosis\", section on 'Acute hemorrhagic leukoencephalitis'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h1\">",
"     MULTIPLE SCLEROSIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Multiple sclerosis (MS) is a chronic disease characterized by recurrent episodes of demyelination in the central nervous system separated in space and time. Acute inflammation and demyelination in a critical area of the brain, optic nerves, or spinal cord will produce a corresponding clinical deficit.",
"   </p>",
"   <p>",
"    Pediatric MS is briefly reviewed here, and discussed in detail separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?12/32/12809?source=see_link\">",
"     \"Pathogenesis, clinical features, and diagnosis of pediatric multiple sclerosis\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?20/32/21000?source=see_link\">",
"     \"Treatment and prognosis of pediatric multiple sclerosis\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Pediatric multiple sclerosis (MS) is defined as the onset of MS before the age of 18, which occurs in at least 5 percent of patients who have MS. Nevertheless, pediatric MS is a rare disease, with an estimated frequency of approximately 2.5 per 100,000 children.",
"   </p>",
"   <p>",
"    Children with MS generally have a similar clinical presentation to adults, although some evidence suggests that children may be more likely than adults to present with isolated optic neuritis; an isolated brainstem syndrome; or encephalitic symptoms such as headache, vomiting, seizure, or altered consciousness.",
"   </p>",
"   <p>",
"    More than 95 percent of children with MS initially have relapsing-remitting multiple sclerosis (RRMS), characterized by intermittent attacks of increased disability followed by either partial or complete recovery. Primary progressive multiple sclerosis (PPMS), characterized by continuous disability over time in the absence of specific attacks, is much less common than RRMS. Some patients with RRMS eventually convert to secondary progressive multiple sclerosis (SPMS), which is characterized by an initial RRMS disease course followed by progression with or without occasional relapses, minor remissions, and plateaus.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h1\">",
"     CLINICALLY ISOLATED SYNDROME",
"    </span>",
"    &nbsp;&mdash;&nbsp;A clinically isolated syndrome (CIS) is a first acute episode of clinical symptoms referable to one or more central nervous system sites with a presumed inflammatory demyelinating etiology in a child with no previous history of a central demyelinating event [",
"    <a class=\"abstract\" href=\"UTD.htm?1/20/1352/abstract/1\">",
"     1",
"    </a>",
"    ]. Typical examples of a CIS include the following:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Optic neuritis",
"     </li>",
"     <li>",
"      Transverse myelitis",
"     </li>",
"     <li>",
"      Neurologic symptoms and signs due to brainstem, cerebellar, or hemispheric dysfunction",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The clinical event may be either monofocal or multifocal in terms of symptoms [",
"    <a class=\"abstract\" href=\"UTD.htm?1/20/1352/abstract/1\">",
"     1",
"    </a>",
"    ]. Unlike ADEM, encephalopathy is not a typical feature, although it may occur in a CIS with brainstem involvement.",
"   </p>",
"   <p>",
"    An episode of CIS can create a diagnostic and therapeutic dilemma. Most children will not have recurrence after a single demyelinating event of the CNS. However, the risk is high enough to be concerning, though not yet defined precisely. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?12/32/12809?source=see_link&amp;anchor=H8#H8\">",
"     \"Pathogenesis, clinical features, and diagnosis of pediatric multiple sclerosis\", section on 'Clinically isolated syndromes'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h1\">",
"     DISTINGUISHING ADEM AND MULTIPLE SCLEROSIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The most important alternative diagnosis to multiple sclerosis (MS) is acute disseminated encephalomyelitis (ADEM), a more common and a temporally limited disorder than pediatric MS.",
"   </p>",
"   <p>",
"    At initial presentation, the two disorders cannot be distinguished with absolute certainty (",
"    <a class=\"graphic graphic_algorithm graphicRef73311 \" href=\"UTD.htm?18/19/18750\">",
"     algorithm 1",
"    </a>",
"    ). In children, subsequent attacks of MS may not occur for months or years. Furthermore, a small subset of children with ADEM may eventually develop MS, but it is difficult to accurately predict which patients will do so. Therefore, prolonged follow-up is required to establish a diagnosis.",
"   </p>",
"   <p>",
"    Certain clinical features may be helpful in supporting the diagnosis of ADEM or MS [",
"    <a class=\"abstract\" href=\"UTD.htm?1/20/1352/abstract/2-6\">",
"     2-6",
"    </a>",
"    ]. However, there is substantial overlap.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      ADEM typically follows a prodromal viral illness, while MS does not",
"     </li>",
"     <li>",
"      ADEM patients often have fever and stiff neck, which is unusual in MS",
"     </li>",
"     <li>",
"      ADEM usually produces widespread central nervous system disturbance with impaired consciousness",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      encephalopathy, while MS typically is monosymptomatic (eg, optic neuritis or a subacute myelopathy) and has a relapsing-remitting course",
"     </li>",
"     <li>",
"      Myelopathy is usually complete and accompanied by areflexia in ADEM and partial in MS",
"     </li>",
"     <li>",
"      Ataxia is a common presenting feature of ADEM, but rare in MS",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Brain MRI features may also be helpful in distinguishing ADEM from MS, although complete differentiation is not possible on the basis of a single study [",
"    <a class=\"abstract\" href=\"UTD.htm?1/20/1352/abstract/2,6,7\">",
"     2,6,7",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      ADEM usually has more MRI lesions than MS, with larger bilateral but asymmetric white matter abnormalities",
"     </li>",
"     <li>",
"      Lesions tend to be poorly defined in ADEM and have better defined margins in MS",
"     </li>",
"     <li>",
"      The presence of brain lesions of about the same age on MRI is most consistent with ADEM, while the presence of brain lesions of different ages",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      the presence of black holes (hypointense T1 lesions) suggests MS",
"     </li>",
"     <li>",
"      Thalamic lesions are common in ADEM and rare in MS",
"     </li>",
"     <li>",
"      Periventricular lesions are less common in ADEM than MS",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    In a retrospective study that compared MRI scans obtained at first attack from 28 children later diagnosed with MS and 20 children with monophasic ADEM, any two of the following proposed criteria (Callen) were more suggestive of a first attack of MS rather than monophasic ADEM [",
"    <a class=\"abstract\" href=\"UTD.htm?1/20/1352/abstract/8\">",
"     8",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      &ge;2 periventricular lesions",
"     </li>",
"     <li>",
"      Presence of black holes",
"     </li>",
"     <li>",
"      Absence of diffuse bilateral lesion distribution pattern",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Prospective validation in larger cohorts is needed to confirm the clinical utility of the Callen criteria. In a retrospective study of 49 children with a first demyelinating event of central nervous system, the Callen criteria performed well for distinguishing MS from ADEM, with a sensitivity and specificity of 75 and 95 percent, respectively [",
"    <a class=\"abstract\" href=\"UTD.htm?1/20/1352/abstract/9\">",
"     9",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h1\">",
"     OPTIC NEURITIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Optic neuritis is inflammation of the optic nerve that can be caused by any inflammatory condition or may be idiopathic. It is believed that the demyelination in optic neuritis is immune-mediated, but the specific mechanism and target antigen(s) are unknown.",
"   </p>",
"   <p>",
"    Optic neuritis is briefly reviewed here, and is discussed in detail separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?9/15/9464?source=see_link\">",
"     \"Optic neuritis: Pathophysiology, clinical features, and diagnosis\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?29/15/29944?source=see_link\">",
"     \"Optic neuritis: Prognosis and treatment\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Optic neuritis usually presents as an isolated symptom, and thus as a clinically isolated syndrome (CIS). Optic neuritis may also occur as a feature that accompanies other demyelinating disorders, including acute disseminated encephalomyelitis (ADEM), multiple sclerosis, or neuromyelitis optica.",
"   </p>",
"   <p>",
"    Optic neuritis is usually monocular in older children and adults but retrospective evidence suggests it is bilateral in approximately one-half of children younger than 12 to 15 years old. At the onset, the presentation can be asymmetrical. Patients may report headache or painful eye movements prior to the vision loss. Symptoms usually progress over several hours to a few days, with partial or complete vision loss, a relative afferent pupillary defect (Marcus Gunn pupil), and visual field defects. In addition to decreased visual acuity, an enlarged central scotoma may be detected by visual field testing.",
"   </p>",
"   <p>",
"    The funduscopic examination is variable. The optic nerve appears swollen in 75 percent of children in the acute phase. However, optic disc swelling can be mild or absent, especially if the inflammation is retrobulbar.",
"   </p>",
"   <p>",
"    MRI of the brain and orbits with gadolinium contrast provides confirmation of the diagnosis of acute demyelinating optic neuritis and important prognostic information regarding the risk of developing multiple sclerosis. Visual-evoked potentials are prolonged in affected patients. Prolongation may persist even years after the illness, despite a normal ophthalmologic examination and normal vision.",
"   </p>",
"   <p>",
"    Patients typically have normal or near-normal recovery of vision. However, subtle color impairment and stereoscopic abnormalities may persist. When vision is more severely affected at onset, a good prognosis is less certain. In addition, optic neuritis is a risk factor for the subsequent development of multiple sclerosis. Lesions outside of the optic nerves on the baseline MRI correlate with a higher risk for developing multiple sclerosis.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h1\">",
"     TRANSVERSE MYELITIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Transverse myelitis is defined as spinal cord dysfunction that develops over hours or days in patients in whom there is no evidence of a compressive lesion. Typically, it is due to an inflammatory lesion of the spinal cord. Transverse myelitis is reviewed briefly here, and discussed in greater detail separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?31/42/32426?source=see_link&amp;anchor=H3#H3\">",
"     \"Disorders affecting the spinal cord\", section on 'Transverse myelitis'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Most cases of transverse myelitis affecting children are idiopathic and presumably result from an autoimmune process [",
"    <a class=\"abstract\" href=\"UTD.htm?1/20/1352/abstract/10\">",
"     10",
"    </a>",
"    ], with up to one-half of 47 cases in one retrospective series preceded by a febrile illness, and approximately one-quarter by vaccination [",
"    <a class=\"abstract\" href=\"UTD.htm?1/20/1352/abstract/11\">",
"     11",
"    </a>",
"    ]. Transverse myelitis can present as a clinically isolated syndrome or may be a manifestation of an acquired demyelinating disease such as acute disseminated encephalomyelitis (ADEM), multiple sclerosis (MS), or neuromyelitis optica (Devic disease) [",
"    <a class=\"abstract\" href=\"UTD.htm?1/20/1352/abstract/12\">",
"     12",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Symptoms are characterized by motor and sensory deficits attributable to involvement of one or both sides of the spinal cord. They include weakness, paresthesias, and sphincter dysfunction. These typically present over a few days, with paresthesias preceding the weakness and urinary retention. A hyperacute presentation sometimes occurs with rapid onset of paraplegia, sensory abnormalities, and urinary retention. This form is often associated with significant back pain. A discrete sensory level may or may not be detected with either presentation.",
"   </p>",
"   <p>",
"    MRI of the spine should be performed to rule out spinal cord compression, especially when presentation is rapidly progressive. The MRI typically shows gadolinium-enhancing signal abnormality, extending over one or more spinal cord segments. There is usually swelling of the affected segments, particularly on T2 sequences.",
"   </p>",
"   <p>",
"    Most children with idiopathic transverse myelitis have at least a partial recovery, which usually begins within one to three months. Unfortunately, the prognosis for complete recovery is not as favorable as for ADEM or optic neuritis. Some degree of persistent disability is common, occurring in 40 percent or more [",
"    <a class=\"abstract\" href=\"UTD.htm?1/20/1352/abstract/10\">",
"     10",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h1\">",
"     NEUROMYELITIS OPTICA",
"    </span>",
"    &nbsp;&mdash;&nbsp;Classic neuromyelitis optica (NMO; also known as Devic disease) is a combination of bilateral optic neuropathy and traverse myelitis [",
"    <a class=\"abstract\" href=\"UTD.htm?1/20/1352/abstract/13-15\">",
"     13-15",
"    </a>",
"    ]. The optic neuritis and transverse myelitis can occur concurrently, or one may follow the other. While NMO may be closely related to MS, the disorders can be differentiated by application of strict diagnostic criteria [",
"    <a class=\"abstract\" href=\"UTD.htm?1/20/1352/abstract/15,16\">",
"     15,16",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H11\">",
"     'Diagnostic criteria for NMO'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    Although conclusions are limited by small numbers of patients, the available data suggest that a substantial minority of children with NMO have brain involvement at presentation associated with clinical features of encephalopathy, seizures,",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    lesions on brain MRI resembling those typically seen with multiple sclerosis or acute disseminated encephalomyelitis [",
"    <a class=\"abstract\" href=\"UTD.htm?1/20/1352/abstract/17-21\">",
"     17-21",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The clinical presentation of NMO can be primary progressive with fulminate disability at the time of presentation, or it may follow a relapsing-remitting course. Thus, any child with a severe progressive disease course should be investigated for NMO.",
"   </p>",
"   <p>",
"    Patients with NMO have a poorer prognosis for recovery of vision than those with multiple sclerosis. In addition, the myelopathy associated with NMO tends to be more severe, with less likelihood of recovery, than that seen in multiple sclerosis. The neuropathologic features of NMO at autopsy are those of a more intense necrotic lesion of the cord rather than the incomplete demyelination seen in multiple sclerosis [",
"    <a class=\"abstract\" href=\"UTD.htm?1/20/1352/abstract/22\">",
"     22",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h2\">",
"     NMO-IgG autoantibody",
"    </span>",
"    &nbsp;&mdash;&nbsp;A serum IgG autoantibody (NMO-IgG) that selectively binds to the aquaporin 4 water channel may be a specific marker for NMO and further aid in the distinction of this disorder from MS [",
"    <a class=\"abstract\" href=\"UTD.htm?1/20/1352/abstract/23,24\">",
"     23,24",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Accumulating data suggest that NMO is part of a spectrum of central nervous system inflammatory disorders associated with NMO-IgG autoantibodies and aquaporin-4 autoimmunity [",
"    <a class=\"abstract\" href=\"UTD.htm?1/20/1352/abstract/17,25\">",
"     17,25",
"    </a>",
"    ]. The spectrum extends beyond the optic nerves and spinal cord and includes some patients with monophasic or recurrent longitudinally extensive myelitis, recurrent isolated optic neuritis, and Asian optic-spinal multiple sclerosis. In addition, some patients who are seropositive for NMO-IgG have concomitant autoimmune diseases such as systemic lupus erythematosus or Sj&ouml;gren's syndrome.",
"   </p>",
"   <p>",
"    As an example, in a retrospective study with clinical information available for 58 children (4 to 18 years old) who were seropositive for NMO-IgG and followed for a median of 12 months, the following observations were made [",
"    <a class=\"abstract\" href=\"UTD.htm?1/20/1352/abstract/17\">",
"     17",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Attacks of optic neuritis, transverse myelitis, or both were noted in 98 percent",
"     </li>",
"     <li>",
"      Attacks of symptoms involving the brain or brainstem occurred in 45 percent, and included episodic encephalopathy, ophthalmoparesis, ataxia, seizures, intractable vomiting, or hiccups",
"     </li>",
"     <li>",
"      Overall, attacks were recurrent in 93 percent, with residual disability in 90 percent",
"     </li>",
"     <li>",
"      Brain lesions on MRI were present in 68 percent and predominantly involved periventricular regions, including the brainstem, supra- and infratentorial white matter, cerebellum, thalamus, and hypothalamus",
"     </li>",
"     <li>",
"      In 38 children with sufficient clinical data, coexisting autoimmune disorders were documented in 42 percent, and included systemic lupus erythematosus, Sj&ouml;gren syndrome, juvenile idiopathic arthritis, Graves disease, and autoimmune hepatitis",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    In the author's clinical experience, patients with NMO have presented with hemispheric, brainstem, and diencephalon disease, and symptoms have included encephalopathy, ataxia, aphasia, endocrinopathies, headaches, and vomiting.",
"   </p>",
"   <p>",
"    In children, the sensitivity of NMO-IgG for NMO is uncertain. In one study, serum NMO-IgG was positive in 8 of 17 children (47 percent) with NMO [",
"    <a class=\"abstract\" href=\"UTD.htm?1/20/1352/abstract/18\">",
"     18",
"    </a>",
"    ]. Seropositivity for NMO-IgG was more common among those with relapsing NMO (7 of 9 children) than those with monophasic NMO (1 of 8), but small numbers prevent definitive conclusions.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h2\">",
"     Diagnostic criteria for NMO",
"    </span>",
"    &nbsp;&mdash;&nbsp;Although the original diagnostic criteria for NMO did not permit CNS involvement beyond the optic nerves and spinal cord [",
"    <a class=\"abstract\" href=\"UTD.htm?1/20/1352/abstract/15\">",
"     15",
"    </a>",
"    ], revised criteria allow for the presence of brain lesions in patients who otherwise meet criteria for NMO [",
"    <a class=\"abstract\" href=\"UTD.htm?1/20/1352/abstract/1,16\">",
"     1,16",
"    </a>",
"    ]. Proposed diagnostic criteria for NMO in children require the following features [",
"    <a class=\"abstract\" href=\"UTD.htm?1/20/1352/abstract/1\">",
"     1",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Optic neuritis",
"     </li>",
"     <li>",
"      Myelitis",
"     </li>",
"     <li>",
"      One of the following:",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      MRI evidence of a contiguous spinal cord lesion three or more segments in length",
"     </li>",
"     <li>",
"      Seropositivity for NMO-IgG",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    In patients who meet these criteria, additional CNS involvement beyond the optic nerves and spinal cord is compatible with NMO [",
"    <a class=\"abstract\" href=\"UTD.htm?1/20/1352/abstract/1,16\">",
"     1,16",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h1\">",
"     COLLAGEN VASCULAR DISEASE",
"    </span>",
"    &nbsp;&mdash;&nbsp;Collagen vascular disease, including systemic lupus erythematosus and neurosarcoidosis, can present at a young age with principal central nervous system involvement. Other evidence for systemic inflammation, such as abnormal antinuclear antibody profile, double-stranded DNA antibodies, elevated angiotensin converting enzyme, and antiphospholipid antibodies, help to distinguish these entities. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?10/35/10810?source=see_link\">",
"     \"Systemic lupus erythematosus in children\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h1\">",
"     CENTRAL NERVOUS SYSTEM ANGIITIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Central nervous system angiitis, also known as primary angiitis of the central nervous system, is a rare disorder in children that can have a similar presentation to demyelinating disease [",
"    <a class=\"abstract\" href=\"UTD.htm?1/20/1352/abstract/26\">",
"     26",
"    </a>",
"    ], including multifocal T2-hyperintensities on the MRI. Diffusion weighted MRI sequences may demonstrate restricted diffusion in areas of acute ischemic injury.",
"   </p>",
"   <p>",
"    Patients may present with clinical features similar to ADEM, such as multifocal neurologic impairments, headaches, focal seizures, and behavior changes. Cerebral angiography may demonstrate vascular beading and intraluminal narrowing. Meningeal biopsy is sometimes required to confirm the diagnosis. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?39/42/40616?source=see_link&amp;anchor=H18#H18\">",
"     \"Classification and incidence of childhood vasculitis\", section on 'Primary angiitis of the CNS'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19372688\">",
"    <span class=\"h1\">",
"     OTHER DISORDERS",
"    </span>",
"    &nbsp;&mdash;&nbsp;A number of noninflammatory disorders can affect the white matter and mimic acute inflammatory demyelination on imaging studies. These include malignancies, mitochondrial disease, and certain leukodystrophies [",
"    <a class=\"abstract\" href=\"UTD.htm?1/20/1352/abstract/27\">",
"     27",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h2\">",
"     Malignancy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Large areas of tumefactive demyelination can give rise to concern for possible central nervous system lymphoma or high-grade glioma [",
"    <a class=\"abstract\" href=\"UTD.htm?1/20/1352/abstract/28-30\">",
"     28-30",
"    </a>",
"    ]. In the absence of other imaging suggestive of demyelination, further investigation with cerebrospinal fluid cytology may demonstrate atypical cells. Brain biopsy may be needed in such circumstances to clarify the diagnosis.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h2\">",
"     Mitochondrial disease",
"    </span>",
"    &nbsp;&mdash;&nbsp;Mitochondrial disease may present acutely in the setting of intercurrent infection. Typical features on brain MRI include increased (bright) T2 signal in the basal ganglia or predominate, symmetric involvement of the parieto-occipital region. Other features of mitochondrial disorders include elevation of serum and cerebrospinal fluid lactate levels. Symmetry of imaging abnormalities should prompt strong consideration for an underlying metabolic disease. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?7/12/7370?source=see_link&amp;anchor=H7#H7\">",
"     \"Mitochondrial myopathies: Clinical features and diagnosis\", section on 'Predominantly multisystem disease with myopathy'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h2\">",
"     Leukodystrophies",
"    </span>",
"    &nbsp;&mdash;&nbsp;The leukodystrophies are rare disorders that may occasionally be confused with multiple sclerosis or acute disseminated encephalomyelitis. White matter disease, typically symmetric, is the hallmark of these conditions (",
"    <a class=\"graphic graphic_algorithm graphicRef65871 \" href=\"UTD.htm?23/14/23785\">",
"     algorithm 2",
"    </a>",
"    ), which include the following:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Metachromatic leukodystrophy (see",
"      <a class=\"medical medical_review\" href=\"UTD.htm?41/27/42421?source=see_link\">",
"       \"Metachromatic leukodystrophy\"",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      X-linked adrenoleukodystrophy (see",
"      <a class=\"medical medical_review\" href=\"UTD.htm?32/56/33673?source=see_link\">",
"       \"Adrenoleukodystrophy\"",
"      </a>",
"      ).",
"     </li>",
"     <li>",
"      Alexander disease (see",
"      <a class=\"medical medical_review\" href=\"UTD.htm?39/58/40872?source=see_link\">",
"       \"Alexander disease\"",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Krabbe disease (see",
"      <a class=\"medical medical_review\" href=\"UTD.htm?3/60/4038?source=see_link\">",
"       \"Krabbe disease\"",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19372047\">",
"    <span class=\"h1\">",
"     SUMMARY",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Differential diagnostic considerations for acute central nervous system demyelination in children include acute disseminated encephalomyelitis, multiple sclerosis, optic neuritis, transverse myelitis, neuromyelitis optica, and various infectious, metabolic, and rheumatologic conditions (",
"      <a class=\"graphic graphic_table graphicRef70259 \" href=\"UTD.htm?19/55/20347\">",
"       table 1",
"      </a>",
"      ).",
"     </li>",
"     <li>",
"      Acute disseminated encephalomyelitis is characterized by acute or subacute onset of multifocal neurologic deficits with encephalopathy, often following a viral illness or vaccination. Additional typical signs associated with acute disseminated encephalomyelitis are headache, fever, or meningismus. Brain MRI demonstrates widespread asymmetric white and gray matter abnormalities (",
"      <a class=\"graphic graphic_table graphicRef74896 \" href=\"UTD.htm?24/17/24860\">",
"       table 2",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Acute disseminated encephalomyelitis'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Multiple sclerosis is a chronic disease characterized by recurrent episodes of demyelination in the central nervous system separated in space and time. Acute inflammation and demyelination in a critical area of the brain, optic nerves, or spinal cord will produce a corresponding clinical deficit. The most important alternative diagnosis to multiple sclerosis is acute disseminated encephalomyelitis, which is a more common and a temporally limited disorder than pediatric multiple sclerosis. At initial presentation, it can be difficult to distinguish the two disorders with absolute certainty. (See",
"      <a class=\"local\" href=\"#H4\">",
"       'Multiple sclerosis'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H6\">",
"       'Distinguishing ADEM and multiple sclerosis'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      A clinically isolated syndrome is a first acute episode of clinical symptoms referable to one or more central nervous system sites with a presumed inflammatory demyelinating etiology in a child with no previous history of a central demyelinating event. Typical examples of a clinically isolated syndrome include optic neuritis, transverse myelitis, and neurologic symptoms and signs due to brainstem, cerebellar, or hemispheric dysfunction. (See",
"      <a class=\"local\" href=\"#H5\">",
"       'Clinically isolated syndrome'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Optic neuritis is inflammation of the optic nerve that can be caused by any inflammatory condition or may be idiopathic. Optic neuritis is usually monocular in older children and adults but is bilateral in a significant percentage of children younger than 12 to 15 years old. (See",
"      <a class=\"local\" href=\"#H7\">",
"       'Optic neuritis'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Transverse myelitis is defined as spinal cord dysfunction that develops over hours or days in the absence of a compressive spinal cord lesion. Typically, it is due to an inflammatory lesion of the spinal cord. (See",
"      <a class=\"local\" href=\"#H8\">",
"       'Transverse myelitis'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Classic neuromyelitis optica, also known as Devic's disease, is a combination of bilateral optic neuropathy and traverse myelitis. The optic neuritis and transverse myelitis can occur concurrently, or one may follow the other. (See",
"      <a class=\"local\" href=\"#H9\">",
"       'Neuromyelitis optica'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Collagen vascular disease, including systemic lupus erythematosus and neurosarcoidosis, can present at a young age with principal central nervous system involvement. (See",
"      <a class=\"local\" href=\"#H12\">",
"       'Collagen vascular disease'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Central nervous system angiitis, also known as primary angiitis of the central nervous system, is a rare disorder in children that can have a similar presentation to demyelinating disease. (See",
"      <a class=\"local\" href=\"#H14\">",
"       'Central nervous system angiitis'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      A number of noninflammatory disorders can affect the white matter and mimic acute inflammatory demyelination on imaging studies. These include malignancies, mitochondrial disease, and certain leukodystrophies (",
"      <a class=\"graphic graphic_algorithm graphicRef65871 \" href=\"UTD.htm?23/14/23785\">",
"       algorithm 2",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H15\">",
"       'Malignancy'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H16\">",
"       'Mitochondrial disease'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H17\">",
"       'Leukodystrophies'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/20/1352/abstract/1\">",
"      Krupp LB, Banwell B, Tenembaum S, International Pediatric MS Study Group. Consensus definitions proposed for pediatric multiple sclerosis and related disorders. Neurology 2007; 68:S7.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/20/1352/abstract/2\">",
"      Stonehouse M, Gupte G, Wassmer E, Whitehouse WP. Acute disseminated encephalomyelitis: recognition in the hands of general paediatricians. Arch Dis Child 2003; 88:122.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/20/1352/abstract/3\">",
"      Oishi M, Mochizuki Y. Multiple sclerosis presenting as acute disseminated encephalomyelitis. J Neurol Sci 1998; 160:100.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/20/1352/abstract/4\">",
"      Menor F. [Demyelinating diseases in childhood: diagnostic contribution of magnetic resonance]. Rev Neurol 1997; 25:966.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/20/1352/abstract/5\">",
"      Kesselring J, Miller DH, Robb SA, et al. Acute disseminated encephalomyelitis. MRI findings and the distinction from multiple sclerosis. Brain 1990; 113 ( Pt 2):291.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/20/1352/abstract/6\">",
"      Alper G, Heyman R, Wang L. Multiple sclerosis and acute disseminated encephalomyelitis diagnosed in children after long-term follow-up: comparison of presenting features. Dev Med Child Neurol 2009; 51:480.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/20/1352/abstract/7\">",
"      Dale RC, de Sousa C, Chong WK, et al. Acute disseminated encephalomyelitis, multiphasic disseminated encephalomyelitis and multiple sclerosis in children. Brain 2000; 123 Pt 12:2407.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/20/1352/abstract/8\">",
"      Callen DJ, Shroff MM, Branson HM, et al. Role of MRI in the differentiation of ADEM from MS in children. Neurology 2009; 72:968.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/20/1352/abstract/9\">",
"      Ketelslegers IA, Neuteboom RF, Boon M, et al. A comparison of MRI criteria for diagnosing pediatric ADEM and MS. Neurology 2010; 74:1412.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/20/1352/abstract/10\">",
"      Wolf VL, Lupo PJ, Lotze TE. Pediatric acute transverse myelitis overview and differential diagnosis. J Child Neurol 2012; 27:1426.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/20/1352/abstract/11\">",
"      Pidcock FS, Krishnan C, Crawford TO, et al. Acute transverse myelitis in childhood: center-based analysis of 47 cases. Neurology 2007; 68:1474.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/20/1352/abstract/12\">",
"      Frohman EM, Wingerchuk DM. Clinical practice. Transverse myelitis. N Engl J Med 2010; 363:564.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/20/1352/abstract/13\">",
"      O'Riordan JI, Gallagher HL, Thompson AJ, et al. Clinical, CSF, and MRI findings in Devic's neuromyelitis optica. J Neurol Neurosurg Psychiatry 1996; 60:382.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/20/1352/abstract/14\">",
"      O'Riordan JI. Central nervous system white matter diseases other than multiple sclerosis. Curr Opin Neurol 1997; 10:211.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/20/1352/abstract/15\">",
"      Wingerchuk DM, Hogancamp WF, O'Brien PC, Weinshenker BG. The clinical course of neuromyelitis optica (Devic's syndrome). Neurology 1999; 53:1107.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/20/1352/abstract/16\">",
"      Wingerchuk DM, Lennon VA, Pittock SJ, et al. Revised diagnostic criteria for neuromyelitis optica. Neurology 2006; 66:1485.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/20/1352/abstract/17\">",
"      McKeon A, Lennon VA, Lotze T, et al. CNS aquaporin-4 autoimmunity in children. Neurology 2008; 71:93.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/20/1352/abstract/18\">",
"      Banwell B, Tenembaum S, Lennon VA, et al. Neuromyelitis optica-IgG in childhood inflammatory demyelinating CNS disorders. Neurology 2008; 70:344.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/20/1352/abstract/19\">",
"      Lotze TE, Northrop JL, Hutton GJ, et al. Spectrum of pediatric neuromyelitis optica. Pediatrics 2008; 122:e1039.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/20/1352/abstract/20\">",
"      Collongues N, Marignier R, Z&eacute;phir H, et al. Long-term follow-up of neuromyelitis optica with a pediatric onset. Neurology 2010; 75:1084.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/20/1352/abstract/21\">",
"      Tillema JM, McKeon A. The spectrum of neuromyelitis optica (NMO) in childhood. J Child Neurol 2012; 27:1437.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/20/1352/abstract/22\">",
"      Mandler RN, Davis LE, Jeffery DR, Kornfeld M. Devic's neuromyelitis optica: a clinicopathological study of 8 patients. Ann Neurol 1993; 34:162.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/20/1352/abstract/23\">",
"      Lennon VA, Wingerchuk DM, Kryzer TJ, et al. A serum autoantibody marker of neuromyelitis optica: distinction from multiple sclerosis. Lancet 2004; 364:2106.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/20/1352/abstract/24\">",
"      Jarius S, Franciotta D, Bergamaschi R, et al. NMO-IgG in the diagnosis of neuromyelitis optica. Neurology 2007; 68:1076.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/20/1352/abstract/25\">",
"      Wingerchuk DM, Lennon VA, Lucchinetti CF, et al. The spectrum of neuromyelitis optica. Lancet Neurol 2007; 6:805.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/20/1352/abstract/26\">",
"      O'Mahony J, Bar-Or A, Arnold DL, et al. Masquerades of acquired demyelination in children: experiences of a national demyelinating disease program. J Child Neurol 2013; 28:184.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/20/1352/abstract/27\">",
"      Hahn JS, Pohl D, Rensel M, et al. Differential diagnosis and evaluation in pediatric multiple sclerosis. Neurology 2007; 68:S13.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/20/1352/abstract/28\">",
"      Dagher AP, Smirniotopoulos J. Tumefactive demyelinating lesions. Neuroradiology 1996; 38:560.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/20/1352/abstract/29\">",
"      Bassuk AG, Keating GF, Stumpf DA, et al. Systemic lymphoma mimicking acute disseminated encephalomyelitis. Pediatr Neurol 2004; 30:129.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/20/1352/abstract/30\">",
"      Senatus PB, McClelland S 3rd, Tanji K, et al. The transformation of pediatric gliomatosis cerebri to cerebellar glioblastoma multiforme presenting as supra- and infratentorial acute disseminated encephalomyelitis. Case report. J Neurosurg 2005; 102:72.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 6177 Version 10.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0604-27.109.116.13-E03BC582ED-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f1_20_1352=[""].join("\n");
var outline_f1_20_1352=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H19372047\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      ACUTE DISSEMINATED ENCEPHALOMYELITIS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      Acute hemorrhagic leukoencephalitis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      MULTIPLE SCLEROSIS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      CLINICALLY ISOLATED SYNDROME",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      DISTINGUISHING ADEM AND MULTIPLE SCLEROSIS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      OPTIC NEURITIS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      TRANSVERSE MYELITIS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      NEUROMYELITIS OPTICA",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      NMO-IgG autoantibody",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      Diagnostic criteria for NMO",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      COLLAGEN VASCULAR DISEASE",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      CENTRAL NERVOUS SYSTEM ANGIITIS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H19372688\">",
"      OTHER DISORDERS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      Malignancy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      Mitochondrial disease",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      Leukodystrophies",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H19372047\">",
"      SUMMARY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"PEDS/6177\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"PEDS/6177|ALG\">",
"      <a href=\"#\" title=\"ALGORITHMS\">",
"       ALGORITHMS",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_algorithm\" href=\"UTD.htm?18/19/18750\" title=\"algorithm 1\">",
"      Diagnosis of demyelinating clinical event",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_algorithm\" href=\"UTD.htm?23/14/23785\" title=\"algorithm 2\">",
"      MRI algorithm white matter disorders",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"PEDS/6177|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?19/55/20347\" title=\"table 1\">",
"      Diff dx pediatric MS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?24/17/24860\" title=\"table 2\">",
"      Diagnostic criteria ADEM",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?24/52/25416?source=related_link\">",
"      Acute disseminated encephalomyelitis in children: Pathogenesis, clinical features, and diagnosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?20/22/20838?source=related_link\">",
"      Acute disseminated encephalomyelitis in children: Treatment and prognosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?32/56/33673?source=related_link\">",
"      Adrenoleukodystrophy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?39/58/40872?source=related_link\">",
"      Alexander disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?39/42/40616?source=related_link\">",
"      Classification and incidence of childhood vasculitis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?31/42/32426?source=related_link\">",
"      Disorders affecting the spinal cord",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?3/60/4038?source=related_link\">",
"      Krabbe disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?41/27/42421?source=related_link\">",
"      Metachromatic leukodystrophy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?7/12/7370?source=related_link\">",
"      Mitochondrial myopathies: Clinical features and diagnosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?9/15/9464?source=related_link\">",
"      Optic neuritis: Pathophysiology, clinical features, and diagnosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?29/15/29944?source=related_link\">",
"      Optic neuritis: Prognosis and treatment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?12/32/12809?source=related_link\">",
"      Pathogenesis, clinical features, and diagnosis of pediatric multiple sclerosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?10/35/10810?source=related_link\">",
"      Systemic lupus erythematosus in children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?20/32/21000?source=related_link\">",
"      Treatment and prognosis of pediatric multiple sclerosis",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f1_20_1353="Initial hormone therapy for metastatic prostate cancer";
var content_f1_20_1353=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/wk_utd-rgb.myextg\" width=\"220px\">",
"   </img>",
"  </div>",
"  <div id=\"printHeaderText\">",
"   Official reprint from  UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"   <a href=\"file://www.uptodate.com\">",
"    www.uptodate.com",
"   </a>",
"   <br>",
"    &copy;2013 UpToDate",
"    <sup>",
"     &reg;",
"    </sup>",
"   </br>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"4\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Initial hormone therapy for metastatic prostate cancer",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?1/20/1353/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?1/20/1353/contributors\">",
"     Richard J Lee, MD, PhD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?1/20/1353/contributors\">",
"     Matthew R Smith, MD, PhD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?1/20/1353/contributors\">",
"     Section Editors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?1/20/1353/contributors\">",
"     Nicholas Vogelzang, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?1/20/1353/contributors\">",
"     W Robert Lee, MD, MS, MEd",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?1/20/1353/contributors\">",
"     Jerome P Richie, MD, FACS",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?1/20/1353/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?1/20/1353/contributors\">",
"     Michael E Ross, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?1/20/1353/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Apr 9, 2013.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;The critical role of androgens in stimulating prostate cancer growth was established in 1941 by Charles Huggins [",
"    <a class=\"abstract\" href=\"UTD.htm?1/20/1353/abstract/1,2\">",
"     1,2",
"    </a>",
"    ]. These findings led to the development of androgen deprivation therapy (ADT) as the primary treatment for patients with advanced prostate cancer.",
"   </p>",
"   <p>",
"    Although ADT is palliative, it can normalize serum levels of prostate specific antigen (PSA) in over 90 percent of patients and can produce objective tumor responses in 80 to 90 percent. This antitumor activity can improve quality of life (QOL) by reducing bone pain as well as the rates of complications (eg, pathologic fracture, spinal cord compression, ureteral obstruction).",
"   </p>",
"   <p>",
"    The duration of response to ADT for patients with metastatic disease is highly variable, and most prostate cancer patients eventually experience disease progression despite treatment. Patients who have progressed while on ADT are said to have castration-resistant disease, although such tumors may remain responsive to additional therapies directed against androgenic stimulation of the prostate cancer.",
"   </p>",
"   <p>",
"    The initial hormone therapy for men with metastatic prostate cancer will be reviewed here. An overview of the treatment of disseminated prostate cancer is presented separately, as are special considerations for patients whose only manifestation of disseminated disease is a rising serum PSA. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?10/12/10442?source=see_link\">",
"     \"Overview of the treatment of disseminated prostate cancer\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?29/48/30470?source=see_link\">",
"     \"Rising serum PSA after treatment for localized prostate cancer: Systemic therapy\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h1\">",
"     TREATMENT OPTIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The primary approach to the systemic treatment of metastatic prostate cancer is the lowering of serum testosterone levels to castrate levels. This can be accomplished either by surgical orchiectomy (castration) or medical orchiectomy (using either a gonadotropin releasing hormone (GnRH) agonist or a GnRH antagonist). In some cases, antiandrogens have been combined with a GnRH agonist to block the effects of androgen produced by the adrenal gland and produce a combined androgen blockade. (See",
"    <a class=\"local\" href=\"#H6\">",
"     'Surgical orchiectomy'",
"    </a>",
"    below and",
"    <a class=\"local\" href=\"#H7\">",
"     'Medical orchiectomy'",
"    </a>",
"    below and",
"    <a class=\"local\" href=\"#H261287030\">",
"     'Combined androgen blockade'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    Historically, estrogens were also used to suppress serum testosterone levels. Estrogens inhibit the release of GnRH from the hypothalamus, thus suppressing pituitary luteinizing hormone release and thereby reducing testicular production of testosterone. Diethylstilbestrol (DES) was extensively studied as an alternative to surgical orchiectomy for the initial management of metastatic prostate cancer prior to the development of GnRH agonists. However, two large randomized trials conducted by the Veterans Administration Cooperative Urological Research Group (VACURG) found that DES at a dose of 5",
"    <span class=\"nowrap\">",
"     mg/day",
"    </span>",
"    significantly increased the risk of dying from heart disease or stroke, and that DES did not provide any advantage compared with surgical orchiectomy in terms of overall survival [",
"    <a class=\"abstract\" href=\"UTD.htm?1/20/1353/abstract/3,4\">",
"     3,4",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Guidelines from the American Society of Clinical Oncology (ASCO) and the National Comprehensive Cancer Network (NCCN) recommend androgen deprivation therapy (ADT) using either medical orchiectomy or surgical orchiectomy as the initial hormonal therapy for men with advanced prostate cancer [",
"    <a class=\"abstract\" href=\"UTD.htm?1/20/1353/abstract/5,6\">",
"     5,6",
"    </a>",
"    ]. The decision between medical and surgical treatment is based upon a variety of factors including patient preference, cost, and treatment availability",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h1\">",
"     SURGICAL ORCHIECTOMY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Bilateral orchiectomy is a relatively simple, cost-effective procedure [",
"    <a class=\"abstract\" href=\"UTD.htm?1/20/1353/abstract/7\">",
"     7",
"    </a>",
"    ]. Following surgery, serum testosterone levels rapidly decrease to castrate levels [",
"    <a class=\"abstract\" href=\"UTD.htm?1/20/1353/abstract/8\">",
"     8",
"    </a>",
"    ], and this is usually associated with improvements in bone pain and other disease-related symptoms [",
"    <a class=\"abstract\" href=\"UTD.htm?1/20/1353/abstract/2\">",
"     2",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Although orchiectomy is used much less frequently than medical castration in North America and Europe, it remains a useful alternative when an immediate decrease in testosterone is necessary (eg, impending spinal cord compression) or when costs or adherence to medical therapy are an issue. In many countries, bilateral orchiectomy remains the standard of care for initial hormone therapy of metastatic prostate cancer.",
"   </p>",
"   <p>",
"    The psychological impact of surgical castration is also an important factor for men choosing between surgery and medical treatment. In a study of 159 men with metastatic prostate cancer who were provided with standard information regarding the costs, benefits, and risks of orchiectomy and monthly GnRH agonist therapy, only 22 percent chose orchiectomy [",
"    <a class=\"abstract\" href=\"UTD.htm?1/20/1353/abstract/9\">",
"     9",
"    </a>",
"    ]. However, the benefits of lower overall cost, avoidance of injections for continued medical castration, and potentially fewer clinic visits may make orchiectomy more appealing in the current era of escalating health care costs.",
"   </p>",
"   <p>",
"    The psychological effects of orchiectomy may be ameliorated with placement of testicular prostheses or with modification of the total orchiectomy to a subcapsular orchiectomy, in which the tunica albuginea and epididymis remain intact, providing a cosmetic effect in the scrotum [",
"    <a class=\"abstract\" href=\"UTD.htm?1/20/1353/abstract/10,11\">",
"     10,11",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h1\">",
"     MEDICAL ORCHIECTOMY",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H261285669\">",
"    <span class=\"h2\">",
"     Gonadotropin releasing hormone agonists",
"    </span>",
"    &nbsp;&mdash;&nbsp;Medical castration using a gonadotropin releasing hormone (GnRH) agonist was first reported in 1982 [",
"    <a class=\"abstract\" href=\"UTD.htm?1/20/1353/abstract/12\">",
"     12",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h3\">",
"     Mechanism of action",
"    </span>",
"    &nbsp;&mdash;&nbsp;Synthetic GnRH analogs have greater receptor affinity, reduced susceptibility to enzymatic degradation, and are approximately 100-fold more potent than the natural GnRH molecule [",
"    <a class=\"abstract\" href=\"UTD.htm?1/20/1353/abstract/13\">",
"     13",
"    </a>",
"    ]. GnRH agonists bind to the GnRH receptors on pituitary gonadotropin-producing cells, causing an initial release of both luteinizing hormone (LH) and follicle stimulating hormone (FSH), which causes a subsequent increase in testosterone production from testicular Leydig cells (",
"    <a class=\"graphic graphic_figure graphicRef50484 \" href=\"UTD.htm?37/31/38384\">",
"     figure 1",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    This transient rise in LH when GnRH therapy is initiated can cause a surge in serum testosterone, which may stimulate prostate cancer growth. This \"flare\" may cause an increase in bone pain, bladder obstruction, or other symptoms due to prostate cancer [",
"    <a class=\"abstract\" href=\"UTD.htm?1/20/1353/abstract/14\">",
"     14",
"    </a>",
"    ]. Thus, initial treatment with GnRH alone is contraindicated in men with severe urinary tract obstruction or painful bone metastases. The flare phenomenon can be effectively prevented with antiandrogen therapy, which blocks the effect of the increased serum testosterone [",
"    <a class=\"abstract\" href=\"UTD.htm?1/20/1353/abstract/7\">",
"     7",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H347804711\">",
"     'Antiandrogens'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    After about one week of therapy, GnRH receptors are down-regulated on the gonadotropin-producing cells, with a decline in the pituitary production of LH and FSH [",
"    <a class=\"abstract\" href=\"UTD.htm?1/20/1353/abstract/15\">",
"     15",
"    </a>",
"    ]. The fall in serum LH leads to a decrease in serum testosterone to castrate levels within three to four weeks after the start of treatment [",
"    <a class=\"abstract\" href=\"UTD.htm?1/20/1353/abstract/16\">",
"     16",
"    </a>",
"    ]. Continued treatment maintains serum testosterone at castrate levels.",
"   </p>",
"   <p>",
"    The decrease in testosterone production is generally reversible upon cessation of GnRH agonist therapy. However, testosterone production does not always return to baseline levels and may be related to the duration of GnRH agonist therapy, patient age, and other factors [",
"    <a class=\"abstract\" href=\"UTD.htm?1/20/1353/abstract/17,18\">",
"     17,18",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h3\">",
"     Formulations",
"    </span>",
"    &nbsp;&mdash;&nbsp;Gonadotropin releasing hormone (GnRH) agonists approved for parenteral administration include",
"    <a class=\"drug drug_general\" href=\"UTD.htm?4/41/4760?source=see_link\">",
"     leuprolide",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?9/22/9574?source=see_link\">",
"     goserelin",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?9/11/9398?source=see_link\">",
"     triptorelin",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?17/10/17573?source=see_link\">",
"     buserelin",
"    </a>",
"    , and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?18/60/19397?source=see_link\">",
"     histrelin",
"    </a>",
"    . Buserelin is available in both a parenteral and nasal formulation.",
"   </p>",
"   <p>",
"    Depot formulations are widely used. These initially were available to suppress testosterone levels for about one month; even longer acting formulations are now available and commonly used. The longest lasting is a",
"    <a class=\"drug drug_general\" href=\"UTD.htm?4/41/4760?source=see_link\">",
"     leuprolide",
"    </a>",
"    formulation delivered by a small osmotic pump encased in a titanium cylinder. This is implanted subcutaneously in the upper arm where it can deliver the drug for up to one year. Castrate levels of testosterone are achieved and sustained for the entire year of implantation [",
"    <a class=\"abstract\" href=\"UTD.htm?1/20/1353/abstract/19,20\">",
"     19,20",
"    </a>",
"    ]. Annual removal and replacement is a short, outpatient procedure.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H347807333\">",
"    <span class=\"h3\">",
"     Serum testosterone level",
"    </span>",
"    &nbsp;&mdash;&nbsp;The objective of ADT is to lower the serum testosterone level at least to the same extent as that achieved with surgical orchiectomy [",
"    <a class=\"abstract\" href=\"UTD.htm?1/20/1353/abstract/21\">",
"     21",
"    </a>",
"    ]. Historically, this has correlated with a level of &lt;50",
"    <span class=\"nowrap\">",
"     ng/dL,",
"    </span>",
"    although contemporary laboratory testing indicates that testosterone levels decline to &lt;20",
"    <span class=\"nowrap\">",
"     ng/dL",
"    </span>",
"    after orchiectomy [",
"    <a class=\"abstract\" href=\"UTD.htm?1/20/1353/abstract/8\">",
"     8",
"    </a>",
"    ]. However, there are no clinical trials that clearly correlate serum testosterone level with clinical response and outcome. Our practice is consistent with the current guidelines from the National Comprehensive Cancer Network (NCCN), which use a serum testosterone level of &lt;50",
"    <span class=\"nowrap\">",
"     ng/dL",
"    </span>",
"    and state that additional hormonal maneuvers can be considered if this level cannot be achieved with initial treatment [",
"    <a class=\"abstract\" href=\"UTD.htm?1/20/1353/abstract/22\">",
"     22",
"    </a>",
"    ]. Rechecking the serum testosterone level is especially important if the serum PSA does not drop below 4 after six months.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h3\">",
"     GnRH agonists versus orchiectomy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Unlike orchiectomy, medical castration with GnRH agonists offers the potential for reversing hypogonadal symptoms upon cessation of therapy. In addition, GnRH agonists avoid the psychological issues associated with surgical castration.",
"   </p>",
"   <p>",
"    A meta-analysis of ten trials involving 1908 patients comparing a GnRH agonist with orchiectomy found equivalence in overall survival, progression-related outcomes, and time to treatment failure [",
"    <a class=\"abstract\" href=\"UTD.htm?1/20/1353/abstract/23\">",
"     23",
"    </a>",
"    ]. At two years, survival with a GnRH agonist was not statistically worse (hazard ratio for death 1.13, 95% CI 0.92-1.39, compared to orchiectomy). In this meta-analysis, there were no significant differences in efficacy between",
"    <a class=\"drug drug_general\" href=\"UTD.htm?4/41/4760?source=see_link\">",
"     leuprolide",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?9/22/9574?source=see_link\">",
"     goserelin",
"    </a>",
"    , and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?17/10/17573?source=see_link\">",
"     buserelin",
"    </a>",
"    .",
"   </p>",
"   <p>",
"    GnRH agonists are frequently used with antiandrogens to produce combined androgen blockade either during the initial period of treatment to prevent a disease flare; they also may be used in conjunction with antiandrogens for long-term therapy. (See",
"    <a class=\"local\" href=\"#H261287030\">",
"     'Combined androgen blockade'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h2\">",
"     GnRH antagonists",
"    </span>",
"    &nbsp;&mdash;&nbsp;Pure GnRH antagonists (eg,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?14/42/15013?source=see_link\">",
"     degarelix",
"    </a>",
"    ) were developed to suppress testosterone while avoiding the flare phenomenon observed with GnRH agonists. GnRH antagonists bind to the GnRH receptors on pituitary gonadotropin-producing cells, but do not stimulate an initial release of luteinizing hormone or follicle stimulating hormone (FSH).",
"   </p>",
"   <p>",
"    The efficacy of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?14/42/15013?source=see_link\">",
"     degarelix",
"    </a>",
"    was established in a phase III trial in which 610 men with prostate cancer were randomly assigned to degarelix (240 mg for one month, followed by monthly maintenance with doses of either 80 mg [n = 207] or 160 mg [n = 201]) or to",
"    <a class=\"drug drug_general\" href=\"UTD.htm?4/41/4760?source=see_link\">",
"     leuprolide",
"    </a>",
"    (7.5 mg per month) [",
"    <a class=\"abstract\" href=\"UTD.htm?1/20/1353/abstract/24\">",
"     24",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?14/42/15013?source=see_link\">",
"       Degarelix",
"      </a>",
"      suppressed testosterone levels within three days in 96 percent of patients, an outcome not achieved in patients treated with",
"      <a class=\"drug drug_general\" href=\"UTD.htm?4/41/4760?source=see_link\">",
"       leuprolide",
"      </a>",
"      . Suppression of serum testosterone levels was maintained for the duration of the twelve month trial.",
"     </li>",
"     <li>",
"      An update from the 2011 Genitourinary Cancers Symposium indicated that the incidence of PSA failure during the study on the",
"      <a class=\"drug drug_general\" href=\"UTD.htm?14/42/15013?source=see_link\">",
"       degarelix",
"      </a>",
"      <span class=\"nowrap\">",
"       240/80",
"      </span>",
"      schedule was significantly lower than on the",
"      <a class=\"drug drug_general\" href=\"UTD.htm?4/41/4760?source=see_link\">",
"       leuprolide",
"      </a>",
"      arm (8.9 versus 14.1 percent, p=0.05) [",
"      <a class=\"abstract\" href=\"UTD.htm?1/20/1353/abstract/25\">",
"       25",
"      </a>",
"      ]. However, the incidence of PSA failure during the study on the degarelix",
"      <span class=\"nowrap\">",
"       240/160",
"      </span>",
"      schedule was 14.2 percent.",
"     </li>",
"     <li>",
"      Secondary analyses from the phase III trial reported a greater suppression of serum alkaline phosphatase with",
"      <a class=\"drug drug_general\" href=\"UTD.htm?14/42/15013?source=see_link\">",
"       degarelix",
"      </a>",
"      compared with",
"      <a class=\"drug drug_general\" href=\"UTD.htm?4/41/4760?source=see_link\">",
"       leuprolide",
"      </a>",
"      . However, the mean baseline serum alkaline phosphatase was lower in the leuprolide arm in all three of the subgroups that were examined, with small numbers of patients per subgroup. Furthermore, whether greater control of serum alkaline phosphatase translates into better control of skeletal metastasis is not known [",
"      <a class=\"abstract\" href=\"UTD.htm?1/20/1353/abstract/26,27\">",
"       26,27",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Local injection site reactions were more frequent with",
"      <a class=\"drug drug_general\" href=\"UTD.htm?14/42/15013?source=see_link\">",
"       degarelix",
"      </a>",
"      than with",
"      <a class=\"drug drug_general\" href=\"UTD.htm?4/41/4760?source=see_link\">",
"       leuprolide",
"      </a>",
"      (40 versus &lt;1 percent), although no systemic allergic reactions were reported. A secondary analysis of cardiovascular complications in the phase III trial found a similar cardiovascular safety profile for both agents [",
"      <a class=\"abstract\" href=\"UTD.htm?1/20/1353/abstract/28\">",
"       28",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Additional clinical trials are in progress to determine the long-term clinical outcomes and optimal application of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?14/42/15013?source=see_link\">",
"     degarelix",
"    </a>",
"    in men with metastatic prostate cancer. The need for monthly degarelix injections and long-term experience with GnRH agonists makes the latter the preferred approach in many practices.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H261287030\">",
"    <span class=\"h2\">",
"     Combined androgen blockade",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H347804711\">",
"    <span class=\"h3\">",
"     Antiandrogens",
"    </span>",
"    &nbsp;&mdash;&nbsp;Antiandrogens (eg,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?4/23/4470?source=see_link\">",
"     flutamide",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?30/2/30758?source=see_link\">",
"     bicalutamide",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/27/33204?source=see_link\">",
"     nilutamide",
"    </a>",
"    ) bind to androgen receptors and competitively inhibit their interaction with testosterone and dihydrotestosterone. Antiandrogens alone do not block the hypothalamic pituitary axis; testosterone levels are normal or increased. Available antiandrogens and their use as second line endocrine therapies are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?37/39/38520?source=see_link&amp;anchor=H9#H9\">",
"     \"Secondary endocrine therapies for castration resistant prostate cancer\", section on 'Antiandrogens'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Antiandrogens are not indicated for monotherapy in previously untreated patients with advanced prostate cancer. A meta-analysis of eight trials that compared antiandrogens with medical or surgical castration found a trend toward shorter overall survival with antiandrogen monotherapy compared with castration that approached, but did not reach, statistical significance (HR 1.22, 95% CI 0.99-1.40) [",
"    <a class=\"abstract\" href=\"UTD.htm?1/20/1353/abstract/23\">",
"     23",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    However, antiandrogens have a role in conjunction with either medical or surgical castration to produce a combined androgen blockade, which may be useful either to block the side effects associated with the flare phenomenon at the initiation of ADT or for long term treatment to increase the efficacy of ADT.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H347804322\">",
"    <span class=\"h3\">",
"     Initiation of ADT",
"    </span>",
"    &nbsp;&mdash;&nbsp;We use antiandrogens in the management of men with disseminated prostate cancer during the initiation of treatment with a GnRH agonist, in order to prevent a disease flare due to the transient increase in testosterone levels [",
"    <a class=\"abstract\" href=\"UTD.htm?1/20/1353/abstract/7\">",
"     7",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H8\">",
"     'Mechanism of action'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    A placebo-controlled trial demonstrated that antiandrogens decrease bone pain at the initiation of GnRH agonists for patients with metastatic prostate cancer [",
"    <a class=\"abstract\" href=\"UTD.htm?1/20/1353/abstract/29\">",
"     29",
"    </a>",
"    ]. In practice, antiandrogen therapy is often started seven days prior to GnRH agonist initiation for men at high risk of flare symptoms, or concurrently for asymptomatic patients. Antiandrogen therapy is then continued for two to four weeks.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H347804425\">",
"    <span class=\"h3\">",
"     Long-term combined androgen blockade",
"    </span>",
"    &nbsp;&mdash;&nbsp;Long-term administration of antiandrogens has been combined with medical or surgical castration to block the effects of adrenal testosterone in a combined androgen blockade. However, both toxicity and costs are higher and limit the potential benefits of this approach. Our approach is to use monotherapy with a GnRH agonist rather than combined androgen blockade. Both NCCN and ASCO guidelines consider combined androgen blockade an appropriate option but do not make a specific recommendation [",
"    <a class=\"abstract\" href=\"UTD.htm?1/20/1353/abstract/5,6\">",
"     5,6",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Numerous randomized trials have compared combined androgen blockade with monotherapy; these are illustrated by two of the largest of these trials:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Intergroup trial INT 0036 randomly assigned 603 men with metastatic disease to",
"      <a class=\"drug drug_general\" href=\"UTD.htm?4/41/4760?source=see_link\">",
"       leuprolide",
"      </a>",
"      plus",
"      <a class=\"drug drug_general\" href=\"UTD.htm?4/23/4470?source=see_link\">",
"       flutamide",
"      </a>",
"      or leuprolide alone [",
"      <a class=\"abstract\" href=\"UTD.htm?1/20/1353/abstract/30\">",
"       30",
"      </a>",
"      ]. Men treated with the combination had significantly longer progression-free and median survival compared to leuprolide alone (16.5 versus 13.9 months and 35.6 versus 28.3 months).",
"     </li>",
"     <li>",
"      Intergroup trial INT 0105 randomly assigned 1387 men with metastatic disease to orchiectomy and either",
"      <a class=\"drug drug_general\" href=\"UTD.htm?4/23/4470?source=see_link\">",
"       flutamide",
"      </a>",
"      or placebo [",
"      <a class=\"abstract\" href=\"UTD.htm?1/20/1353/abstract/31\">",
"       31",
"      </a>",
"      ]. Although more patients treated with the combined approach achieved a serum PSA &lt;4",
"      <span class=\"nowrap\">",
"       ng/mL",
"      </span>",
"      (74 versus 62 percent with placebo), the differences in median and progression-free survival were not statistically significant (34 versus 30 months, and 20 versus 19 months, respectively). Withdrawal from the study due to toxicity was significantly more common in those assigned to flutamide (33 versus 10 patients with placebo).",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The reasons for the differences in outcome between these two trials are not certain. In INT 0105, ADT utilized orchiectomy [",
"    <a class=\"abstract\" href=\"UTD.htm?1/20/1353/abstract/31\">",
"     31",
"    </a>",
"    ], while in INT 0036, ADT relied upon daily injections of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?4/41/4760?source=see_link\">",
"     leuprolide",
"    </a>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?1/20/1353/abstract/30\">",
"     30",
"    </a>",
"    ]. Lack of adherence to the leuprolide regimen may have led to incomplete androgen deprivation, and therefore a larger benefit when an antiandrogen was added to the treatment in the combined androgen blockade arm [",
"    <a class=\"abstract\" href=\"UTD.htm?1/20/1353/abstract/31\">",
"     31",
"    </a>",
"    ]. Castrate levels of testosterone were not systematically confirmed in INT 0036.",
"   </p>",
"   <p>",
"    Several meta-analyses suggest a benefit in five-year survival but not at earlier time points for combined androgen blockade [",
"    <a class=\"abstract\" href=\"UTD.htm?1/20/1353/abstract/32-35\">",
"     32-35",
"    </a>",
"    ]. The largest of these, which was conducted by the Prostate Cancer Trialists' Collaborative Group, analyzed individual patient data from 27 randomized trials that included 8275 men (88 percent with metastatic disease) [",
"    <a class=\"abstract\" href=\"UTD.htm?1/20/1353/abstract/32\">",
"     32",
"    </a>",
"    ]. Combined androgen blockade was associated with a trend toward decreased five-year mortality (70.4 versus 72.4 percent, hazard ratio [HR] 0.96; 95% CI 0.91-1.01). When the seven studies using the steroidal antiandrogen",
"    <a class=\"drug drug_general\" href=\"UTD.htm?14/2/14374?source=see_link\">",
"     cyproterone acetate",
"    </a>",
"    were excluded, the reduction in mortality with combined androgen blockade was statistically significant (72.4 versus 75.3 percent; HR 0.92). These data do not resolve the question of whether combined androgen blockade is preferable to medical or surgical orchiectomy alone, since toxicity and costs are higher and potential benefits limited with combined androgen blockade.",
"   </p>",
"   <p>",
"    There are no data to support the use of more potent androgen receptor antagonists such as",
"    <a class=\"drug drug_general\" href=\"UTD.htm?15/46/16103?source=see_link\">",
"     enzalutamide",
"    </a>",
"    in combination with a GnRH agonist, but such approaches are under investigation.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H261287591\">",
"    <span class=\"h2\">",
"     Intermittent androgen deprivation",
"    </span>",
"    &nbsp;&mdash;&nbsp;Intermittent androgen deprivation (IAD) attempts to minimize the adverse effects of medical castration by withdrawing treatment in patients who have responded to ADT and then reinstituting ADT when there is evidence of recurrent or progressive disease.",
"   </p>",
"   <p>",
"    The biological rationale is twofold. First, prolonged ADT theoretically may facilitate progression from androgen dependence to androgen independence. In addition, many of the acute and chronic side effects of ADT are due to castrate levels of testosterone. Periods of time when men are off-therapy may be associated with decreases in these side effects, thereby improving quality of life.",
"   </p>",
"   <p>",
"    IAD typically involves treatment for either a fixed interval of time or until a maximal response is achieved based upon serum PSA levels. ADT is then withdrawn, and patients are followed for evidence of recurrence. As testosterone production resumes, the side effects of ADT are mitigated, but the risk of disease progression also increases. The patient is followed with PSA measurements, and ADT is reinitiated based on a predefined threshold level of serum PSA (which varies with different practices, but is often between 10 and 20",
"    <span class=\"nowrap\">",
"     ng/mL),",
"    </span>",
"    or with evidence of new metastatic disease.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H261289169\">",
"    <span class=\"h3\">",
"     Metastatic disease",
"    </span>",
"    &nbsp;&mdash;&nbsp;Preliminary results from two relatively large, multicenter trials suggested that IAD was a reasonable option for patients with advanced or metastatic disease [",
"    <a class=\"abstract\" href=\"UTD.htm?1/20/1353/abstract/36,37\">",
"     36,37",
"    </a>",
"    ]. However, the interpretation of these two trials is limited by the fact that both used time to progression as the primary endpoint, rather than overall survival. Furthermore, only 30 to 40 percent of patients in these trials had metastatic disease.",
"   </p>",
"   <p>",
"    The Intergroup trial INT 0162 (S9346, NCT00002651) compared the impact of IAD with continuous ADT for its impact on overall survival and quality of life in patients with metastatic, hormone sensitive prostate cancer and a serum PSA &ge;5",
"    <span class=\"nowrap\">",
"     ng/mL",
"    </span>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?1/20/1353/abstract/38\">",
"     38",
"    </a>",
"    ]. Patients were treated with a combination of a GnRH analog and antiandrogen for seven months. Patients who achieved a PSA &le;4",
"    <span class=\"nowrap\">",
"     ng/mL",
"    </span>",
"    were then randomly assigned to either continuous ADT or IAD. Patients assigned to IAD remained off therapy until they met a prespecified criterion (serum PSA either &ge;20",
"    <span class=\"nowrap\">",
"     ng/mL",
"    </span>",
"    or back to original baseline), at which point ADT was resumed. Patients who responded to resumption of ADT could be managed with additional cycles off therapy.",
"   </p>",
"   <p>",
"    Of the 3040 patients who were enrolled, 1749 patients were randomized and 1535 patients were available for analysis at a median follow-up of 9.8 years:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      INT 0162 was designed as a noninferiority trial based upon overall survival. Survival with IAD was to be considered noninferior if the 95% confidence interval for the hazard ratio excluded 1.20 (ie, a 20 percent difference roughly equal to one year).",
"     </li>",
"     <li>",
"      Overall survival measured from the time of randomization was longer with continuous ADT than with IAD (median 5.8 versus 5.1 years, HR 1.10, 95%CI 0.99-1.23). Based upon these results, IAD could not be considered noninferior compared with continuous ADT. In unplanned subset analyses, results were consistent across all subgroups except for those with extensive metastatic disease, where IAD did meet the criteria for noninferiority.",
"     </li>",
"     <li>",
"      Quality of life parameters (erectile function, libido, vitality, physical functioning, mental health) were assessed at baseline, and 3, 9, and 15 months after randomization. There were statistically significant improvements in erectile function and mental health at three months with IAD but not at later time points.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Based upon the results of the INT 0162 trial, continuous ADT remains the standard of care for patients with metastatic disease.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H261289176\">",
"    <span class=\"h3\">",
"     Rising PSA",
"    </span>",
"    &nbsp;&mdash;&nbsp;The North American JPR.7 trial studied 1386 men with a rising serum PSA but without detectable metastases following definitive radiation therapy. Preliminary results were reported at the 2011 Genitourinary Cancers Symposium [",
"    <a class=\"abstract\" href=\"UTD.htm?1/20/1353/abstract/39\">",
"     39",
"    </a>",
"    ]. The JPR.7 trial met the predetermined criteria for noninferiority for IAD compared with continuous ADT in terms of overall survival.",
"   </p>",
"   <p>",
"    The JPR.7 trial and the role of continuous ADT versus IAD are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?29/48/30470?source=see_link&amp;anchor=H7#H7\">",
"     \"Rising serum PSA after treatment for localized prostate cancer: Systemic therapy\", section on 'Intermittent androgen deprivation'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H25\">",
"    <span class=\"h2\">",
"     Timing of ADT",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H26\">",
"    <span class=\"h3\">",
"     Asymptomatic metastases",
"    </span>",
"    &nbsp;&mdash;&nbsp;Treatment for metastatic prostate cancer is not curative and treatment-related side effects can adversely affect quality of life. Therefore, a major question remains for asymptomatic patients whether to start therapy as soon as metastatic disease is diagnosed or whether to delay treatment until significant symptoms are present.",
"   </p>",
"   <p>",
"    The optimal timing for therapeutic intervention has been addressed in a number of randomized trials. However, the interpretation of these trials is limited by their heterogeneous patient populations, which often included large numbers of patients with locally advanced disease but without evidence of disseminated metastases. Furthermore, some of the patients in these trials did not receive deferred treatment as originally planned.",
"   </p>",
"   <p>",
"    A 2007 meta-analysis combined the results from 3065 patients in four randomized trials [",
"    <a class=\"abstract\" href=\"UTD.htm?1/20/1353/abstract/5\">",
"     5",
"    </a>",
"    ]. In this analysis, early ADT was associated with a statistically significant decrease in prostate cancer-related deaths (relative risk [RR] 0.84; 95% CI 0.77-0.92, although there was no significant benefit in overall survival (RR 0.98; 95% CI 0.95-1.01).",
"   </p>",
"   <p>",
"    The completed trials did not incorporate prognostic factors that are associated with disease progression, such as PSA doubling time, Gleason score, and PSA response to ADT. Additional studies will be required to determine if there are subsets of patients with asymptomatic metastases in whom therapy initiation can be deferred.",
"   </p>",
"   <p>",
"    We suggest that early treatment be used to reduce the morbidity from potential complications of untreated disease (eg, ureteral obstruction, pathologic fractures, spinal cord compression, urethral obstruction, extraskeletal metastases). Appropriate attention should be given to the potential for significant treatment-related side effects. The most recent ASCO guidelines could not make a strong recommendation about whether or not early intervention was indicated [",
"    <a class=\"abstract\" href=\"UTD.htm?1/20/1353/abstract/5\">",
"     5",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H261287816\">",
"    <span class=\"h3\">",
"     Rising serum PSA",
"    </span>",
"    &nbsp;&mdash;&nbsp;The factors affecting the optimal timing of treatment for men whose only manifestation of disseminated prostate cancer is an elevated serum PSA are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?29/48/30470?source=see_link&amp;anchor=H4#H4\">",
"     \"Rising serum PSA after treatment for localized prostate cancer: Systemic therapy\", section on 'Timing of ADT'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H456228842\">",
"    <span class=\"h1\">",
"     ADT PLUS CHEMOTHERAPY",
"    </span>",
"    &nbsp;&mdash;&nbsp;There is no indication for the use of chemotherapy in combination with ADT in men with hormone sensitive metastatic prostate cancer [",
"    <a class=\"abstract\" href=\"UTD.htm?1/20/1353/abstract/40\">",
"     40",
"    </a>",
"    ], even though",
"    <a class=\"drug drug_general\" href=\"UTD.htm?40/59/41913?source=see_link\">",
"     docetaxel",
"    </a>",
"    can prolong overall survival in men with castrate resistant disease. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?10/12/10442?source=see_link&amp;anchor=H456228329#H456228329\">",
"     \"Overview of the treatment of disseminated prostate cancer\", section on 'ADT plus chemotherapy'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2165880530\">",
"    <span class=\"h1\">",
"     PREVENTION OF OSTEOPOROSIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Androgen deprivation therapy (ADT), with either medical or surgical orchiectomy, increases bone turnover, decreases bone mineral density, and increases the risk of clinical bone fractures in men with prostate cancer [",
"    <a class=\"abstract\" href=\"UTD.htm?1/20/1353/abstract/41-43\">",
"     41-43",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    We recommend dietary calcium intake (food and supplements) of 1000 to 1200 mg daily and supplemental vitamin D 800 to 1000 international units daily for all men receiving ADT. We also recommend weight bearing exercise, decreased alcohol consumption, and smoking cessation [",
"    <a class=\"abstract\" href=\"UTD.htm?1/20/1353/abstract/44-47\">",
"     44-47",
"    </a>",
"    ]. Estimates of fracture risk using the FRAX algorithm",
"    <span class=\"nowrap\">",
"     (file://www.shef.ac.uk/FRAX/)",
"    </span>",
"    with or without bone density measurements may provide guidance in consideration of medical therapies to prevent fracture (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?21/30/21993?source=see_link&amp;anchor=H261290808#H261290808\">",
"     \"Side effects of androgen deprivation therapy\", section on 'Lifestyle modification'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The roles of concurrent therapy with an osteoclast inhibitor (",
"    <a class=\"drug drug_general\" href=\"UTD.htm?20/53/21335?source=see_link\">",
"     denosumab",
"    </a>",
"    , bisphosphonates) in men with and without bone metastases are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?36/8/36999?source=see_link&amp;anchor=H19250956#H19250956\">",
"     \"Management of bone metastases in advanced prostate cancer\", section on 'Osteoclast inhibition'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?21/30/21993?source=see_link&amp;anchor=H9#H9\">",
"     \"Side effects of androgen deprivation therapy\", section on 'Prevention'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6968275\">",
"    <span class=\"h1\">",
"     SIDE EFFECTS OF ANDROGEN DEPRIVATION THERAPY",
"    </span>",
"    &nbsp;&mdash;&nbsp;The side effects of androgen deprivation therapy, including prevention and management, are discussed in detail separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?21/30/21993?source=see_link\">",
"     \"Side effects of androgen deprivation therapy\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4110520\">",
"    <span class=\"h1\">",
"     SURVEILLANCE DURING TREATMENT",
"    </span>",
"    &nbsp;&mdash;&nbsp;Surveillance strategies during treatment for disseminated prostate cancer are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?9/52/10055?source=see_link&amp;anchor=H11088148#H11088148\">",
"     \"Follow-up surveillance during and after treatment for prostate cancer\", section on 'Metastatic prostate cancer'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"PATIENT_INFORMATION\">",
"    <span class=\"h1\">",
"     INFORMATION FOR PATIENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials, &ldquo;The Basics&rdquo; and &ldquo;Beyond the Basics.&rdquo; The Basics patient education pieces are written in plain language, at the 5",
"    <sup>",
"     th",
"    </sup>",
"    to 6",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10",
"    <sup>",
"     th",
"    </sup>",
"    to 12",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.",
"   </p>",
"   <p>",
"    Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on &ldquo;patient info&rdquo; and the keyword(s) of interest.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Beyond the Basics topic (see",
"      <a class=\"medical medical_patient\" href=\"UTD.htm?41/41/42643?source=see_link\">",
"       \"Patient information: Treatment for advanced prostate cancer (Beyond the Basics)\"",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H30\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Androgens are known to stimulate the growth of both normal and cancerous prostate cells. Clinical interventions based upon these observations established androgen deprivation therapy (ADT) as the preferred initial treatment approach for men in whom systemic therapy is indicated.",
"     </li>",
"     <li>",
"      The standard approach to the initial treatment of men with symptomatic metastatic prostate cancer to lower the serum testosterone level to castrate levels. This can be accomplished either by surgical orchiectomy (castration) or medical orchiectomy (using either a gonadotropin releasing hormone (GnRH) agonist or a GnRH antagonist). Newer modalities that have been demonstrated to prolong survival in men with metastatic disease have only been evaluated in men who have progressed after ADT (ie, castrate resistant disease) and are not indicated in this setting (",
"      <a class=\"graphic graphic_table graphicRef85716 \" href=\"UTD.htm?17/56/18317\">",
"       table 1",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H6\">",
"       'Surgical orchiectomy'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H7\">",
"       'Medical orchiectomy'",
"      </a>",
"      above and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?10/12/10442?source=see_link\">",
"       \"Overview of the treatment of disseminated prostate cancer\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      For patients managed with medical orchiectomy, we suggest using an antiandrogen for two to four weeks during GnRH agonist initiation to prevent a disease flare due to the transient increase in testosterone levels (",
"      <a class=\"grade\" href=\"._grade_5?title=Grade 2B\">",
"       Grade 2B",
"      </a>",
"      ). &nbsp;(See",
"      <a class=\"local\" href=\"#H347804711\">",
"       'Antiandrogens'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H8\">",
"       'Mechanism of action'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      After the initial treatment induction, we suggest monotherapy using a GnRH agonist rather than combined androgen blockade with a GnRH agonist plus an antiandrogen (",
"      <a class=\"grade\" href=\"._grade_5?title=Grade 2B\">",
"       Grade 2B",
"      </a>",
"      ). Long-term combined androgen blockade may have a modest survival benefit compared to GnRH agonist monotherapy, but combined androgen blockade has more side effects and greater cost. (See",
"      <a class=\"local\" href=\"#H261287030\">",
"       'Combined androgen blockade'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      We recommend continuous therapy rather than intermittent androgen deprivation (",
"      <a class=\"grade\" href=\"._grade_2?title=Grade 1B\">",
"       Grade 1B",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H261287591\">",
"       'Intermittent androgen deprivation'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Because of the increased bone turnover and decreased bone mineral density, we recommend dietary calcium intake (food and supplements) of 1000 to 1200 mg daily and supplemental vitamin D 800 to 1000 international units daily, as well as lifestyle modifications (weight bearing exercise, decreased alcohol consumption, smoking discontinuation) for all men beginning ADT and for those who undergo surgical orchiectomy. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?21/30/21993?source=see_link&amp;anchor=H9#H9\">",
"       \"Side effects of androgen deprivation therapy\", section on 'Prevention'",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      For men with asymptomatic metastatic disease, we suggest early rather than delayed treatment (",
"      <a class=\"grade\" href=\"._grade_5?title=Grade 2B\">",
"       Grade 2B",
"      </a>",
"      ). Although early treatment may not improve overall survival, this approach is associated with improved progression-free survival. (See",
"      <a class=\"local\" href=\"#H26\">",
"       'Asymptomatic metastases'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      For men whose only evidence of disseminated disease is an elevated or rising serum PSA, issues regarding the optimal timing of initiating treatment and the use of continuous vs intermittent ADT are discussed separately. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?29/48/30470?source=see_link\">",
"       \"Rising serum PSA after treatment for localized prostate cancer: Systemic therapy\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/20/1353/abstract/1\">",
"      Huggins, C, Hodges, CV. Studies on prostatic cancer: I. The effects of castration, of estrogen, and of androgen injection on serum phosphatases in metastatic carcinoma of the prostate. Cancer Res 1941; 1:293.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/20/1353/abstract/2\">",
"      Huggins, C, Stevens, J, Hodges, CV. Studies on prostatic cancer: II. The effects of castration on advanced carcinoma of the prostate gland. Arch Surg 1941; 43:209.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/20/1353/abstract/3\">",
"      Byar DP. Proceedings: The Veterans Administration Cooperative Urological Research Group's studies of cancer of the prostate. Cancer 1973; 32:1126.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/20/1353/abstract/4\">",
"      Byar DP, Corle DK. Hormone therapy for prostate cancer: results of the Veterans Administration Cooperative Urological Research Group studies. NCI Monogr 1988; :165.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/20/1353/abstract/5\">",
"      Loblaw DA, Virgo KS, Nam R, et al. Initial hormonal management of androgen-sensitive metastatic, recurrent, or progressive prostate cancer: 2006 update of an American Society of Clinical Oncology practice guideline. J Clin Oncol 2007; 25:1596.",
"     </a>",
"    </li>",
"    <li>",
"     file://www.nccn.org/professionals/physician_gls/f_guidelines.asp (Accessed on July 06, 2012).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/20/1353/abstract/7\">",
"      Loblaw DA, Mendelson DS, Talcott JA, et al. American Society of Clinical Oncology recommendations for the initial hormonal management of androgen-sensitive metastatic, recurrent, or progressive prostate cancer. J Clin Oncol 2004; 22:2927.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/20/1353/abstract/8\">",
"      Oefelein MG, Feng A, Scolieri MJ, et al. Reassessment of the definition of castrate levels of testosterone: implications for clinical decision making. Urology 2000; 56:1021.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/20/1353/abstract/9\">",
"      Cassileth BR, Soloway MS, Vogelzang NJ, et al. Patients' choice of treatment in stage D prostate cancer. Urology 1989; 33:57.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/20/1353/abstract/10\">",
"      Chapman JP. Comparison of testosterone and LH values in subcapsular vs total orchiectomy patients. Urology 1987; 30:27.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/20/1353/abstract/11\">",
"      Zhang XZ, Donovan MP, Williams BT, Mohler JL. Comparison of subcapsular and total orchiectomy for treatment of metastatic prostate cancer. Urology 1996; 47:402.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/20/1353/abstract/12\">",
"      Tolis G, Ackman D, Stellos A, et al. Tumor growth inhibition in patients with prostatic carcinoma treated with luteinizing hormone-releasing hormone agonists. Proc Natl Acad Sci U S A 1982; 79:1658.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/20/1353/abstract/13\">",
"      Schally AV, Coy DH, Arimura A. LH-RH agonists and antagonists. Int J Gynaecol Obstet 1980; 18:318.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/20/1353/abstract/14\">",
"      Waxman J, Man A, Hendry WF, et al. Importance of early tumour exacerbation in patients treated with long acting analogues of gonadotrophin releasing hormone for advanced prostatic cancer. Br Med J (Clin Res Ed) 1985; 291:1387.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/20/1353/abstract/15\">",
"      Conn PM, Crowley WF Jr. Gonadotropin-releasing hormone and its analogues. N Engl J Med 1991; 324:93.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/20/1353/abstract/16\">",
"      Limonta P, Montagnani Marelli M, Moretti RM. LHRH analogues as anticancer agents: pituitary and extrapituitary sites of action. Expert Opin Investig Drugs 2001; 10:709.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/20/1353/abstract/17\">",
"      Shahidi M, Norman AR, Gadd J, et al. Recovery of serum testosterone, LH and FSH levels following neoadjuvant hormone cytoreduction and radical radiotherapy in localized prostate cancer. Clin Oncol (R Coll Radiol) 2001; 13:291.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/20/1353/abstract/18\">",
"      Hall MC, Fritzsch RJ, Sagalowsky AI, et al. Prospective determination of the hormonal response after cessation of luteinizing hormone-releasing hormone agonist treatment in patients with prostate cancer. Urology 1999; 53:898.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/20/1353/abstract/19\">",
"      Fowler JE, Flanagan M, Gleason DM, et al. Evaluation of an implant that delivers leuprolide for 1 year for the palliative treatment of prostate cancer. Urology 2000; 55:639.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/20/1353/abstract/20\">",
"      Fowler JE Jr, Gottesman JE, Reid CF, et al. Safety and efficacy of an implantable leuprolide delivery system in patients with advanced prostate cancer. J Urol 2000; 164:730.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/20/1353/abstract/21\">",
"      Djavan B, Eastham J, Gomella L, et al. Testosterone in prostate cancer: the Bethesda consensus. BJU Int 2012; 110:344.",
"     </a>",
"    </li>",
"    <li>",
"     file://www.nccn.org/professionals/physician_gls/f_guidelines.asp (Accessed on July 18, 2012).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/20/1353/abstract/23\">",
"      Seidenfeld J, Samson DJ, Hasselblad V, et al. Single-therapy androgen suppression in men with advanced prostate cancer: a systematic review and meta-analysis. Ann Intern Med 2000; 132:566.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/20/1353/abstract/24\">",
"      Klotz L, Boccon-Gibod L, Shore ND, et al. The efficacy and safety of degarelix: a 12-month, comparative, randomized, open-label, parallel-group phase III study in patients with prostate cancer. BJU Int 2008; 102:1531.",
"     </a>",
"    </li>",
"    <li>",
"     Shore ND, Moul JW, Crawford E et al. Prostate-specific antigen progression-free survival: A comparison of degarelix versus leuprolide in patients with prostate cancer (abstract #12). J Clin Oncol 2011.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/20/1353/abstract/26\">",
"      Schr&ouml;der FH, Tombal B, Miller K, et al. Changes in alkaline phosphatase levels in patients with prostate cancer receiving degarelix or leuprolide: results from a 12-month, comparative, phase III study. BJU Int 2010; 106:182.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/20/1353/abstract/27\">",
"      Tombal B, Miller K, Boccon-Gibod L, et al. Additional analysis of the secondary end point of biochemical recurrence rate in a phase 3 trial (CS21) comparing degarelix 80 mg versus leuprolide in prostate cancer patients segmented by baseline characteristics. Eur Urol 2010; 57:836.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/20/1353/abstract/28\">",
"      Smith MR, Klotz L, Persson BE, et al. Cardiovascular safety of degarelix: results from a 12-month, comparative, randomized, open label, parallel group phase III trial in patients with prostate cancer. J Urol 2010; 184:2313.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/20/1353/abstract/29\">",
"      Kuhn JM, Billebaud T, Navratil H, et al. Prevention of the transient adverse effects of a gonadotropin-releasing hormone analogue (buserelin) in metastatic prostatic carcinoma by administration of an antiandrogen (nilutamide). N Engl J Med 1989; 321:413.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/20/1353/abstract/30\">",
"      Crawford ED, Eisenberger MA, McLeod DG, et al. A controlled trial of leuprolide with and without flutamide in prostatic carcinoma. N Engl J Med 1989; 321:419.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/20/1353/abstract/31\">",
"      Eisenberger MA, Blumenstein BA, Crawford ED, et al. Bilateral orchiectomy with or without flutamide for metastatic prostate cancer. N Engl J Med 1998; 339:1036.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/20/1353/abstract/32\">",
"      Maximum androgen blockade in advanced prostate cancer: an overview of the randomised trials. Prostate Cancer Trialists' Collaborative Group. Lancet 2000; 355:1491.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/20/1353/abstract/33\">",
"      Schmitt B, Bennett C, Seidenfeld J, et al. Maximal androgen blockade for advanced prostate cancer. Cochrane Database Syst Rev 2000; :CD001526.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/20/1353/abstract/34\">",
"      Samson DJ, Seidenfeld J, Schmitt B, et al. Systematic review and meta-analysis of monotherapy compared with combined androgen blockade for patients with advanced prostate carcinoma. Cancer 2002; 95:361.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/20/1353/abstract/35\">",
"      Klotz L, Schellhammer P, Carroll K. A re-assessment of the role of combined androgen blockade for advanced prostate cancer. BJU Int 2004; 93:1177.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/20/1353/abstract/36\">",
"      Calais da Silva FE, Bono AV, Whelan P, et al. Intermittent androgen deprivation for locally advanced and metastatic prostate cancer: results from a randomised phase 3 study of the South European Uroncological Group. Eur Urol 2009; 55:1269.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/20/1353/abstract/37\">",
"      Miller K, Steiner U, Lingnau A, et al. Randomised prospective study of intermittent versus continuous androgen suppression in advanced prostate cancer (abstract #5015). J Clin Oncol 2007.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/20/1353/abstract/38\">",
"      Hussain M, Tangen CM, Berry DL, et al. Intermittent versus continuous androgen deprivation in prostate cancer. N Engl J Med 2013; 368:1314.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/20/1353/abstract/39\">",
"      Klotz L, O'Callaghan CJ, Ding K. A phase III randomized trial comparing intermittent versus continuous androgen suppression for patients with PSA progression after radical therapy: NCIC CTG PR.7/SWOG  JPR.7/CTSU JPR.7/UK Intercontinental Trial CRUKE/01/013 (abstract #3). J Clin Oncol 2011.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/20/1353/abstract/40\">",
"      Gravis G, Fizazi K, Joly F, et al. Androgen-deprivation therapy alone or with docetaxel in non-castrate metastatic prostate cancer (GETUG-AFU 15): a randomised, open-label, phase 3 trial. Lancet Oncol 2013; 14:149.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/20/1353/abstract/41\">",
"      Smith MR, Lee WC, Brandman J, et al. Gonadotropin-releasing hormone agonists and fracture risk: a claims-based cohort study of men with nonmetastatic prostate cancer. J Clin Oncol 2005; 23:7897.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/20/1353/abstract/42\">",
"      Shahinian VB, Kuo YF, Freeman JL, Goodwin JS. Risk of fracture after androgen deprivation for prostate cancer. N Engl J Med 2005; 352:154.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/20/1353/abstract/43\">",
"      Smith MR, Boyce SP, Moyneur E, et al. Risk of clinical fractures after gonadotropin-releasing hormone agonist therapy for prostate cancer. J Urol 2006; 175:136.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/20/1353/abstract/44\">",
"      Segal RJ, Reid RD, Courneya KS, et al. Resistance exercise in men receiving androgen deprivation therapy for prostate cancer. J Clin Oncol 2003; 21:1653.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/20/1353/abstract/45\">",
"      Ross RW, Small EJ. Osteoporosis in men treated with androgen deprivation therapy for prostate cancer. J Urol 2002; 167:1952.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/20/1353/abstract/46\">",
"      Bae DC, Stein BS. The diagnosis and treatment of osteoporosis in men on androgen deprivation therapy for advanced carcinoma of the prostate. J Urol 2004; 172:2137.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/20/1353/abstract/47\">",
"      Saad F, Olsson C, Schulman CC. Skeletal morbidity in men with prostate cancer: quality-of-life considerations throughout the continuum of care. Eur Urol 2004; 46:731.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 6951 Version 16.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.3 - C21.34",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Morehouse School of Medicine",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0502-189.2.19.178-485ACEB782-S473950.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f1_20_1353=[""].join("\n");
var outline_f1_20_1353=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H30\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      TREATMENT OPTIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      SURGICAL ORCHIECTOMY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      MEDICAL ORCHIECTOMY",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H261285669\">",
"      Gonadotropin releasing hormone agonists",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      - Mechanism of action",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      - Formulations",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H347807333\">",
"      - Serum testosterone level",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      - GnRH agonists versus orchiectomy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      GnRH antagonists",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H261287030\">",
"      Combined androgen blockade",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H347804711\">",
"      - Antiandrogens",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H347804322\">",
"      - Initiation of ADT",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H347804425\">",
"      - Long-term combined androgen blockade",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H261287591\">",
"      Intermittent androgen deprivation",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H261289169\">",
"      - Metastatic disease",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H261289176\">",
"      - Rising PSA",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H25\">",
"      Timing of ADT",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H26\">",
"      - Asymptomatic metastases",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H261287816\">",
"      - Rising serum PSA",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H456228842\">",
"      ADT PLUS CHEMOTHERAPY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2165880530\">",
"      PREVENTION OF OSTEOPOROSIS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H6968275\">",
"      SIDE EFFECTS OF ANDROGEN DEPRIVATION THERAPY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H4110520\">",
"      SURVEILLANCE DURING TREATMENT",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#PATIENT_INFORMATION\">",
"      INFORMATION FOR PATIENTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H30\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"ONC/6951\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"ONC/6951|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?37/31/38384\" title=\"figure 1\">",
"      Hypothal pituitary testic axis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"ONC/6951|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?17/56/18317\" title=\"table 1\">",
"      Therapies for castrate resistant prostate cancer",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?9/52/10055?source=related_link\">",
"      Follow-up surveillance during and after treatment for prostate cancer",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?36/8/36999?source=related_link\">",
"      Management of bone metastases in advanced prostate cancer",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?10/12/10442?source=related_link\">",
"      Overview of the treatment of disseminated prostate cancer",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?41/41/42643?source=related_link\">",
"      Patient information: Treatment for advanced prostate cancer (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?29/48/30470?source=related_link\">",
"      Rising serum PSA after treatment for localized prostate cancer: Systemic therapy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?37/39/38520?source=related_link\">",
"      Secondary endocrine therapies for castration resistant prostate cancer",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?21/30/21993?source=related_link\">",
"      Side effects of androgen deprivation therapy",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f1_20_1354="Epicondylitis (tennis and golf elbow)";
var content_f1_20_1354=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"4\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Epicondylitis (tennis and golf elbow)",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?1/20/1354/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?1/20/1354/contributors\">",
"     Neeru Jayanthi, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?1/20/1354/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?1/20/1354/contributors\">",
"     Karl B Fields, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?1/20/1354/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?1/20/1354/contributors\">",
"     Jonathan Grayzel, MD, FAAEM",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?1/20/1354/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Mar 19, 2013.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;The lateral epicondyle of the elbow is the bony origin for wrist extensors; the medial epicondyle is the bony origin for wrist flexors. Pain at the myotendinous junction of these muscle groups is referred to as lateral and medial epicondylitis, respectively. Lateral epicondylitis is often called tennis elbow and medial epicondylitis, golfer's elbow. Although tennis and golf can cause these injuries, so can a number of other occupational and recreational activities.",
"   </p>",
"   <p>",
"    Subacute and chronic symptoms of pain and disability at the lateral and medial epicondyles typically represent a tendinosis of the respective myotendinous group, and are referred to as elbow tendinosis. Other terms used to describe the constellation of symptoms at these locations include elbow tendinopathy, elbow tendonitis, and epicondylalgia. We refer to these conditions as medial and lateral epicondylitis throughout this topic review.",
"   </p>",
"   <p>",
"    This topic review will discuss the development, presentation, and management of epicondylitis. Other problems associated with elbow pain and a general discussion of treatments for tendinopathy is provided separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?14/40/14983?source=see_link\">",
"     \"Evaluation of elbow pain in adults\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?37/40/38532?source=see_link\">",
"     \"Radial head subluxation (nursemaid's elbow)\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?22/25/22937?source=see_link\">",
"     \"Elbow injuries in the young athlete\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?19/39/20089?source=see_link\">",
"     \"Overview of the management of overuse (chronic) tendinopathy\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     EPIDEMIOLOGY AND RISK FACTORS",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5808241\">",
"    <span class=\"h2\">",
"     General population and occupational risk factors",
"    </span>",
"    &nbsp;&mdash;&nbsp;According to an observational study of 5871 working age Finns, the prevalence of lateral epicondylitis is 1.3 percent and of medial epicondylitis, 0.4 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?1/20/1354/abstract/1\">",
"     1",
"    </a>",
"    ]. The incidence may approach 1 to 3 percent in the general population, while the incidence in general practice is approximately 0.4 to 0.7 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?1/20/1354/abstract/2\">",
"     2",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Smoking, obesity, age 45 to 54, repetitive movement for at least two hours daily, and forceful activity (managing physical loads over 20 kg) appear to be risk factors in the general population for the development of epicondylitis [",
"    <a class=\"abstract\" href=\"UTD.htm?1/20/1354/abstract/1\">",
"     1",
"    </a>",
"    ]. Factors that correlate with a poorer prognosis include high physical strain at work, dominant side involvement, concomitant neck pain (with or without signs of nerve root involvement), duration of symptoms greater than three months, and severe pain at presentation [",
"    <a class=\"abstract\" href=\"UTD.htm?1/20/1354/abstract/3,4\">",
"     3,4",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5808248\">",
"    <span class=\"h2\">",
"     Tennis epidemiology and risk factors",
"    </span>",
"    &nbsp;&mdash;&nbsp;The elbow was the most commonly injured joint in a survey of 529 recreational USTA (United States Tennis Association) players, comprising approximately 20 percent of all injuries [",
"    <a class=\"abstract\" href=\"UTD.htm?1/20/1354/abstract/5\">",
"     5",
"    </a>",
"    ]. In this study, the prevalence of elbow injuries was 10.6 injuries per 100 players (average age 46.9 years), with an incidence of 0.6 injuries per 1000 hours played.",
"   </p>",
"   <p>",
"    Risk increases with age. There is a 50 percent lifetime incidence of elbow injury among club players 30 years or older, with higher rates in players over 40 [",
"    <a class=\"abstract\" href=\"UTD.htm?1/20/1354/abstract/6,7\">",
"     6,7",
"    </a>",
"    ]. The risk of injury is two to four times greater among those who play more than two hours daily [",
"    <a class=\"abstract\" href=\"UTD.htm?1/20/1354/abstract/7\">",
"     7",
"    </a>",
"    ], but there is no increased risk among those who play up to six hours weekly [",
"    <a class=\"abstract\" href=\"UTD.htm?1/20/1354/abstract/5\">",
"     5",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Only one case of lateral epicondylitis was reported among over 700 players (including seniors) over three years at the French Open [",
"    <a class=\"abstract\" href=\"UTD.htm?1/20/1354/abstract/8\">",
"     8",
"    </a>",
"    ]. This supports the notion that tennis elbow occurs infrequently among advanced players, and is more common among recreational players, likely as a result of differences in technique. (See",
"    <a class=\"local\" href=\"#H5\">",
"     'Mechanisms of injury'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    According to an EMG study, variations in tennis racket grip size up to 0.25 inches (6.35 mm) smaller or larger than that measured by Nirschl criteria do not alter the forearm muscle firing patterns of one-handed backhands, and therefore may not represent a significant risk for tennis elbow [",
"    <a class=\"abstract\" href=\"UTD.htm?1/20/1354/abstract/9\">",
"     9",
"    </a>",
"    ]. The Nirschl criteria suggest that appropriate grip size is determined by the distance from the middle of the proximal palmar crease of the hand to the distal tip of the ring finger in inches.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h1\">",
"     CLINICAL ANATOMY",
"    </span>",
"    &nbsp;&mdash;&nbsp;The distal humerus has a medial humeral epicondyle and a lateral humeral epicondyle. The lateral humeral epicondyle serves as the bony common origin of the wrist extensors; the medial humeral epicondyle serves as the bony common origin of the wrist flexors. The epicondyles are extraarticular structures.",
"   </p>",
"   <p>",
"    Injury to the extensor carpi radialis brevis muscle (ECRB) (felt at tip of lateral epicondyle) and occasionally, the extensor digitorum communis muscle (EDC) (felt just posterior and distal to tip of lateral epicondyle) constitutes lateral epicondylitis. Injury to the pronator teres and flexor carpi radialis muscles, which originate at the medial epicondyle, causes medial epicondylitis.",
"   </p>",
"   <p>",
"    The elbow is the articulation between the ulna and radius and the humerus. The elbow joint is best palpated as the soft spot in the middle of a triangle formed by the lateral epicondyle, olecranon, and radial head (",
"    <a class=\"graphic graphic_picture graphicRef81857 \" href=\"UTD.htm?10/22/10596\">",
"     picture 1",
"    </a>",
"    ). Forearm pronation makes it easier to palpate the radial head.",
"   </p>",
"   <p>",
"    It is important to differentiate an effusion in this region, which represents intraarticular pathology or swelling posteriorly from olecranon bursitis, from the symptoms of lateral epicondylitis. (See",
"    <a class=\"local\" href=\"#H7\">",
"     'Clinical presentation and examination'",
"    </a>",
"    below and",
"    <a class=\"local\" href=\"#H8\">",
"     'Differential diagnosis'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    Medial elbow stability is provided primarily by the anterior bundle of the medial collateral ligament. The ulnar nerve is exposed in the ulnar groove, which lies posterior and lateral to the medial epicondyle. The ulnar nerve can be compressed just distally in the cubital tunnel.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h1\">",
"     PATHOPHYSIOLOGY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Epicondylitis represents a chronic tendinosis, rather than an acute inflammatory process, involving disorganized tissue and neovessels. Researchers describe the process as angiofibroblastic tendinosis; few inflammatory cells are found in these lesions [",
"    <a class=\"abstract\" href=\"UTD.htm?1/20/1354/abstract/10\">",
"     10",
"    </a>",
"    ]. Studies using grayscale ultrasonography and color Doppler followed by anesthetic injection suggest that vasculoneural growth in the common extensor origin is the likely source of pain in lateral epicondylitis [",
"    <a class=\"abstract\" href=\"UTD.htm?1/20/1354/abstract/11\">",
"     11",
"    </a>",
"    ]. The extensor carpi radialis brevis muscle (ECRB) is most often involved. Targeting this degenerative tendinosis and neovascularization is the focus of emerging treatments. (See",
"    <a class=\"local\" href=\"#H15\">",
"     'Secondary management'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h1\">",
"     MECHANISMS OF INJURY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Repetitive or explosive athletic movements involving eccentric motion, in which the muscle-tendon unit is lengthened while contracting, may increase susceptibility to injury [",
"    <a class=\"abstract\" href=\"UTD.htm?1/20/1354/abstract/7,12-15\">",
"     7,12-15",
"    </a>",
"    ]. This should not be confused with isolated, controlled eccentric exercises done as part of a rehabilitation program. (See",
"    <a class=\"local\" href=\"#H14\">",
"     'Physical therapy and eccentric exercise'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    Performing strenuous or exaggerated movements with degenerative or disorganized tissue further increases the risk of injury.",
"   </p>",
"   <p>",
"    Occupational injuries associated with epicondylitis can involve repetitive motions in which the wrist frequently deviates from a neutral position (ie, not held straight) [",
"    <a class=\"abstract\" href=\"UTD.htm?1/20/1354/abstract/16\">",
"     16",
"    </a>",
"    ]. A dose dependent relationship exists between the regular handling of loads over 20 kg and development of epicondylitis. A significant relationship between work tasks that involve vibrating tools (eg, jackhammer) and epicondylitis has yet to be demonstrated [",
"    <a class=\"abstract\" href=\"UTD.htm?1/20/1354/abstract/1\">",
"     1",
"    </a>",
"    ]. Activity modification to limit repetitive motion, forceful tasks, and possibly vibration may reduce the risk of injury. (See",
"    <a class=\"local\" href=\"#H9\">",
"     'Initial management'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h1\">",
"     RISK REDUCTION IN TENNIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;A number of factors, including poor stroke mechanics and inappropriate racquet type, predispose tennis players to developing epicondylitis.",
"   </p>",
"   <p>",
"    Proper stroke mechanics are important to minimize the risk of epicondylitis and prevent recurrence after treatment. In one observational study, instruction on stroke modification and routine conservative therapy led to a resolution of symptoms in 90 percent of tennis players with symptom duration less than six months [",
"    <a class=\"abstract\" href=\"UTD.htm?1/20/1354/abstract/17\">",
"     17",
"    </a>",
"    ]. Correction of mechanics may require formal assessment by a tennis coach, physical therapist, or other appropriate professional.",
"   </p>",
"   <p>",
"    The tennis serve provides a good example for understanding the importance of proper mechanics. Over half of the force generated for tennis serves should come from the hips and pelvis; excessive use of the wrist to generate force predisposes to injury [",
"    <a class=\"abstract\" href=\"UTD.htm?1/20/1354/abstract/18\">",
"     18",
"    </a>",
"    ]. Subsequent upper body force generation during serves should be much less, with the shoulder contributing approximately 21 percent, the elbow 15 percent, and the wrist 10 percent. Fluid sequential transmission of force (ie, proper kinetic chain integration) from the lower to the upper body and a knee bend greater than 10 degrees mitigate shoulder and elbow torque, reducing the risk of injury [",
"    <a class=\"abstract\" href=\"UTD.htm?1/20/1354/abstract/19\">",
"     19",
"    </a>",
"    ]. Isolation of the body's upper quarter in the performance of any overhand athletic maneuver (eg, tennis serve, baseball throw) reflects a breakdown in the smooth transfer of force from the lower to the upper body (ie, disruption in the kinetic chain).",
"   </p>",
"   <p>",
"    A number of biomechanical faults increase the risk of epicondylitis among tennis players and should be corrected [",
"    <a class=\"abstract\" href=\"UTD.htm?1/20/1354/abstract/17,19\">",
"     17,19",
"    </a>",
"    ]. Examples include the following:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Continuous contraction of wrist extensors, insufficient follow through, and leading with the elbow are three common faults with the beginner's backhand (",
"      <a class=\"graphic graphic_picture graphicRef69399 \" href=\"UTD.htm?31/30/32225\">",
"       picture 2",
"      </a>",
"      ). All three increase the load placed on forearm extensors.",
"     </li>",
"     <li>",
"      Excessive forearm pronation with forehand strokes or in combination with wrist snap during serves creates a sudden eccentric load on forearm extensors [",
"      <a class=\"abstract\" href=\"UTD.htm?1/20/1354/abstract/17\">",
"       17",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Preparation for an advanced forehand tennis stroke often consists of a combination of extreme supination with ulnar deviation of the wrist, followed by a low to high trajectory, terminating with rapid and forceful wrist pronation to generate topspin (",
"      <a class=\"graphic graphic_picture graphicRef82708 \" href=\"UTD.htm?35/59/36784\">",
"       picture 3",
"      </a>",
"      ). Such extreme supination, particularly with an exaggerated grip, may theoretically increase the risk for medial epicondylitis.",
"     </li>",
"     <li>",
"      Excessive wrist extension either before impact or during follow-through of a backhand stroke increases the load on forearm extensors.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Use of a one-handed backhand may increase the risk of developing tennis elbow compared with a two-handed backhand, although evidence is scant [",
"    <a class=\"abstract\" href=\"UTD.htm?1/20/1354/abstract/20\">",
"     20",
"    </a>",
"    ]. Wrist extensor activity with one and two handed backhands is fundamentally the same; however, the extra hand may limit end ranges of motion thereby reducing abnormal elbow and forearm movement and controlling terminal wrist extension [",
"    <a class=\"abstract\" href=\"UTD.htm?1/20/1354/abstract/21\">",
"     21",
"    </a>",
"    ]. Greater wrist extension and pronation create eccentric stress during impact and early follow through, which may account for the increased risk of the one-handed backhand [",
"    <a class=\"abstract\" href=\"UTD.htm?1/20/1354/abstract/22,23\">",
"     22,23",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    No published trials demonstrate a causal relationship between racquet characteristics and the development of lateral epicondylitis. Nevertheless, many sports physicians and tennis pros believe that factors such as light weight, heavy head, and inappropriately small grip size increase the forces transferred to the forearm, thereby increasing the risk of lateral epicondylitis. Use of a racquet grip size up to 0.25 inches (6.35 mm) smaller or larger than that determined by the Nirschl criteria is appropriate (",
"    <a class=\"graphic graphic_figure graphicRef66638 \" href=\"UTD.htm?15/42/16032\">",
"     figure 1",
"    </a>",
"    ). Information about racquet selection is available at a number of websites, including",
"    <a class=\"external\" href=\"file://www.racquetresearch.com/\">",
"     www.racquetresearch.com",
"    </a>",
"    .",
"   </p>",
"   <p>",
"    Racquet shock absorbers to mitigate transmission of impact forces have not been shown to be effective in reducing vibrations [",
"    <a class=\"abstract\" href=\"UTD.htm?1/20/1354/abstract/24\">",
"     24",
"    </a>",
"    ]. Other strategies that have theoretical but unsupported utility include lowering string tension and releasing grip tightness after impact to reduce transmission of forces to the wrist and elbow.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h1\">",
"     CLINICAL PRESENTATION AND EXAMINATION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients with epicondylitis typically complain of extraarticular medial or lateral elbow pain. The pain's severity can range from having a minimal effect on sports or work activities to severely impairing basic daily tasks and sleep. Symptoms are usually exacerbated by repetitive movements of the wrist and elbow. Nirschl characterizes seven stages of tendinopathy (",
"    <a class=\"graphic graphic_table graphicRef56664 \" href=\"UTD.htm?18/12/18635\">",
"     table 1",
"    </a>",
"    )&nbsp;[",
"    <a class=\"abstract\" href=\"UTD.htm?1/20/1354/abstract/10\">",
"     10",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Lateral epicondylitis is diagnosed clinically by the following findings:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Localized tenderness over the lateral epicondyle and proximal wrist extensor muscle mass (",
"      <a class=\"graphic graphic_picture graphicRef64356 \" href=\"UTD.htm?17/46/18145\">",
"       picture 4",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Pain with resisted wrist extension with the elbow in full extension (",
"      <a class=\"graphic graphic_picture graphicRef63260 \" href=\"UTD.htm?20/45/21202\">",
"       picture 5",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Pain with passive terminal wrist flexion with the elbow in full extension (",
"      <a class=\"graphic graphic_picture graphicRef77389 \" href=\"UTD.htm?25/15/25843\">",
"       picture 6",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Medial epicondylitis is diagnosed clinically by the following findings:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Localized tenderness over the medial epicondyle (",
"      <a class=\"graphic graphic_picture graphicRef55147 \" href=\"UTD.htm?40/20/41280\">",
"       picture 7",
"      </a>",
"      ) and proximal wrist flexor muscle mass (the ulnar",
"      <span class=\"nowrap\">",
"       nerve/ulnar",
"      </span>",
"      groove and medial collateral ligament should not be tender)",
"     </li>",
"     <li>",
"      Pain with resisted wrist flexion with the elbow in full extension (",
"      <a class=\"graphic graphic_picture graphicRef75033 \" href=\"UTD.htm?4/33/4627\">",
"       picture 8",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Pain with passive terminal wrist extension with the elbow in full extension (",
"      <a class=\"graphic graphic_picture graphicRef63786 \" href=\"UTD.htm?12/61/13264\">",
"       picture 9",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Pain from either condition can be further elicited with resisted wrist pronation or supination and grip strength testing, particularly when the elbow is in full extension. Absence of increased pain does not preclude the diagnosis.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h1\">",
"     DIFFERENTIAL DIAGNOSIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;A number of conditions can cause focal medial or lateral elbow pain (",
"    <a class=\"graphic graphic_table graphicRef73460 \" href=\"UTD.htm?5/27/5563\">",
"     table 2",
"    </a>",
"    and",
"    <a class=\"graphic graphic_table graphicRef52503 \" href=\"UTD.htm?2/35/2619\">",
"     table 3",
"    </a>",
"    ). A focused history and examination, including a few special maneuvers when suggested by the history, can be used to differentiate among potential alternative diagnoses. General evaluation of the patient with elbow pain is discussed elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?14/40/14983?source=see_link\">",
"     \"Evaluation of elbow pain in adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Intraarticular effusions or painful elbow motion may represent intraarticular pathology. Pain with forceful, active terminal extension may represent posterior osteoarthritis or valgus extension overload, which is seen in overhand athletes. Osteochondritis dissecans of the olecranon fossa can also cause pain with forceful terminal extension in overhead athletes.",
"   </p>",
"   <p>",
"    A history of blunt trauma (eg, fall) suggests the possibility of a fracture. Elbow radiographs should be obtained in such instances.",
"   </p>",
"   <p>",
"    Neurologic conditions can cause unilateral elbow pain. Compression of the posterior interosseous nerve in the radial tunnel (ie, radial tunnel syndrome) often causes tenderness a few centimeters distal to the lateral epicondyle. Compression of the median nerve in the cubital tunnel (ie, cubital tunnel syndrome) often causes tenderness just distal to the medial ulnar groove. Pain or paresthesias from ulnar neuritis can be elicited by tapping over the ulnar nerve at the ulnar groove (ulnar nerve Tinel's sign), or by placing the elbow in full flexion (elbow flexion test). Pain with Spurling's maneuver may represent cervical radiculopathy, which can mimic elbow pain. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?8/44/8906?source=see_link\">",
"     \"Overview of upper extremity peripheral nerve syndromes\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?35/19/36152?source=see_link\">",
"     \"Clinical features and diagnosis of cervical radiculopathy\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The Milking maneuver (",
"    <a class=\"graphic graphic_picture graphicRef68632 \" href=\"UTD.htm?14/13/14548\">",
"     picture 10",
"    </a>",
"    ) places valgus stress on the medial collateral ligament (MCL) of the elbow in a throwing position. Pain elicited by the test may suggest MCL insufficiency in overhand athletes, although the characteristics of this test are not well studied [",
"    <a class=\"abstract\" href=\"UTD.htm?1/20/1354/abstract/25\">",
"     25",
"    </a>",
"    ]. Diffuse muscle tenderness in atypical patterns in patients with chronic symptoms may represent myofascial pain complexes. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?41/30/42472?source=see_link\">",
"     \"Overview of soft tissue rheumatic disorders\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h1\">",
"     INITIAL MANAGEMENT",
"    </span>",
"    &nbsp;&mdash;&nbsp;A systematic review of 54 prospective randomized trials for management of lateral epicondylitis revealed a wide range of treatment options, but little sound evidence supporting a particular approach [",
"    <a class=\"abstract\" href=\"UTD.htm?1/20/1354/abstract/26\">",
"     26",
"    </a>",
"    ]. Most trials had significant limitations, including inadequate study design, small sample size, and limited statistical analysis. The management approach discussed below is based upon these limited studies and our clinical experience.",
"   </p>",
"   <p>",
"    Once a clinical diagnosis of epicondylitis is made, our initial treatment consists of activity modification, counter force bracing, NSAIDs if not contraindicated, and physical therapy (",
"    <a class=\"graphic graphic_algorithm graphicRef57758 \" href=\"UTD.htm?2/12/2242\">",
"     algorithm 1",
"    </a>",
"    ). These initial steps are discussed immediately below; persistent or worsening pain despite appropriate management often prompts imaging and additional therapies. (See",
"    <a class=\"local\" href=\"#H17\">",
"     'Antiinflammatory treatments'",
"    </a>",
"    below and",
"    <a class=\"local\" href=\"#H15\">",
"     'Secondary management'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h2\">",
"     Observation",
"    </span>",
"    &nbsp;&mdash;&nbsp;If left untreated, symptoms associated with epicondylitis persist between six months and two years [",
"    <a class=\"abstract\" href=\"UTD.htm?1/20/1354/abstract/2\">",
"     2",
"    </a>",
"    ]. For patients who can function adequately without intervention or who prefer conservative management, a \"wait and see\" approach may be reasonable. These patients must understand that rest alone may not lead to a resolution of symptoms and a recovery period of months to years may be necessary.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h2\">",
"     Modification of activity and biomechanics",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients should try to avoid activities that exacerbate symptoms. For athletes, correction of faulty mechanics must be part of their activity modification. (See",
"    <a class=\"local\" href=\"#H6\">",
"     'Risk reduction in tennis'",
"    </a>",
"    above.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h2\">",
"     Bracing",
"    </span>",
"    &nbsp;&mdash;&nbsp;As part of our initial management of lateral epicondylitis, we apply a counter force brace (",
"    <a class=\"graphic graphic_picture graphicRef87063 \" href=\"UTD.htm?30/35/31281\">",
"     picture 11",
"    </a>",
"    ). Counter force braces may provide benefit during the first six weeks following injury [",
"    <a class=\"abstract\" href=\"UTD.htm?1/20/1354/abstract/2\">",
"     2",
"    </a>",
"    ] and are easy to use and inexpensive. These braces are placed on the forearm approximately ten centimeters distal to the elbow joint [",
"    <a class=\"abstract\" href=\"UTD.htm?1/20/1354/abstract/27\">",
"     27",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In a systematic review of the use of braces in epicondylitis, limited data prevented the authors from drawing firm conclusions [",
"    <a class=\"abstract\" href=\"UTD.htm?1/20/1354/abstract/28\">",
"     28",
"    </a>",
"    ]. Nevertheless, counter force bracing may reduce tendon and muscle strain at the origin of the forearm extensor muscles, thereby relieving pain and improving function.",
"   </p>",
"   <p>",
"    A controlled, observational, manufacturer-sponsored study of extensor carpi radialis brevis and extensor digitorum communis activity using electromyelograms (EMG) found that the application of a counterforce brace with an air-filled bladder significantly reduced muscle activity proximal to the brace [",
"    <a class=\"abstract\" href=\"UTD.htm?1/20/1354/abstract/29\">",
"     29",
"    </a>",
"    ]. No such reduction was found in patients treated with a standard counterforce brace or no brace.",
"   </p>",
"   <p>",
"    No significant differences in outcome were found at 26 and 52 weeks in one clinical trial in which patients were randomly assigned to initial treatment using a counterforce brace alone, physical therapy alone, or a combination of bracing and therapy [",
"    <a class=\"abstract\" href=\"UTD.htm?1/20/1354/abstract/2\">",
"     2",
"    </a>",
"    ]. Over the first six weeks, physical therapy led to better pain and disability scores than bracing alone. No placebo group was included.",
"   </p>",
"   <p>",
"    New types of braces are being developed, but evidence of their effectiveness is scant. A small, manufacturer-supported trial of a dynamic extensor brace found improved function and reduced pain for up to 24 weeks among patients randomly assigned to treatment with the brace and standard care compared with those receiving standard care alone [",
"    <a class=\"abstract\" href=\"UTD.htm?1/20/1354/abstract/30\">",
"     30",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h2\">",
"     Splints",
"    </span>",
"    &nbsp;&mdash;&nbsp;Some clinicians use volar splints to reduce activity of the wrist extensors and flexors during particularly painful episodes of epicondylitis. We do not recommend splinting except in the most severe cases. Splinting was not found to be more effective than counterforce bracing in a small randomized trial [",
"    <a class=\"abstract\" href=\"UTD.htm?1/20/1354/abstract/31\">",
"     31",
"    </a>",
"    ]. Furthermore, a multicenter, retrospective cohort study involving 4614 workers diagnosed with epicondylitis found that patients treated with splints had higher rates of limited duty, more medical visits, higher charges, and longer durations of treatment than those managed without splints [",
"    <a class=\"abstract\" href=\"UTD.htm?1/20/1354/abstract/32\">",
"     32",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h2\">",
"     Physical therapy and eccentric exercise",
"    </span>",
"    &nbsp;&mdash;&nbsp;We have found well-designed physical therapy programs to be effective initial treatment for many patients with epicondylitis. Effective programs may include progressive eccentric and isometric strengthening, incorporating flexibility training and other modalities as needed [",
"    <a class=\"abstract\" href=\"UTD.htm?1/20/1354/abstract/2,15,33-35\">",
"     2,15,33-35",
"    </a>",
"    ]. Nevertheless, a systematic review of 23 randomized control trials involving physical therapy for lateral epicondylitis found insufficient evidence to demonstrate benefit [",
"    <a class=\"abstract\" href=\"UTD.htm?1/20/1354/abstract/34\">",
"     34",
"    </a>",
"    ]. We believe inconsistencies in methodologic quality and the wide range of approaches to physical therapy in the studies reviewed account for this conclusion.",
"   </p>",
"   <p>",
"    A number of studies in conditions such as Achilles' tendinopathy suggest that daily eccentric isokinetic strengthening exercises provide effective treatment for chronic tendinopathy. Extrapolating from such studies, some researchers advocate this rehabilitative approach for epicondylitis and we believe such exercises should be included in physical therapy. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?31/49/32537?source=see_link\">",
"     \"Achilles tendinopathy and tendon rupture\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?19/39/20089?source=see_link&amp;anchor=H6#H6\">",
"     \"Overview of the management of overuse (chronic) tendinopathy\", section on 'Eccentric and heavy load exercise'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Eccentric exercise is the application of a load (ie, muscular contraction) during the lengthening of a muscle (",
"    <a class=\"graphic graphic_picture graphicRef60246 \" href=\"UTD.htm?21/35/22067\">",
"     picture 12",
"    </a>",
"    and",
"    <a class=\"graphic graphic_picture graphicRef67934 \" href=\"UTD.htm?38/35/39486\">",
"     picture 13",
"    </a>",
"    ). Application of this technique for epicondylitis involves holding a weight or a taut resistance band with the wrist extended and then flexing the wrist while maintaining tension in the wrist extensors (ie, eccentrically contracting the wrist extensors).",
"   </p>",
"   <p>",
"    In one controlled trial, researchers randomly assigned patients with chronic lateral epicondylitis to either standard physical therapy or standard therapy, plus an isokinetic eccentric strengthening program for the forearm supinators and wrist extensors [",
"    <a class=\"abstract\" href=\"UTD.htm?1/20/1354/abstract/15\">",
"     15",
"    </a>",
"    ]. Patients in the eccentric training group demonstrated marked reductions in pain within one month, less disability, and greater improvement in tendon appearance on ultrasound compared with patients treated with standard physical therapy. Upon completion of the program, patients in the eccentric training group had no strength deficit of their wrist extensors and forearm supinators compared with the unaffected side.",
"   </p>",
"   <p>",
"    Standard physical rehabilitation of upper extremity sports injuries includes core strengthening and sports-specific movement exercises (",
"    <a class=\"graphic graphic_picture graphicRef82491 \" href=\"UTD.htm?27/37/28241\">",
"     picture 14",
"    </a>",
"    ). Although few supporting trials exist, we advocate this approach.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h1\">",
"     SECONDARY MANAGEMENT",
"    </span>",
"    &nbsp;&mdash;&nbsp;In patients who do not improve with standard initial interventions, we often obtain imaging studies before resorting to other treatments, such as steroid injection or alternative therapies. An alternative diagnosis revealed by imaging is managed appropriately; persistent epicondylitis can be treated with continued conservative treatment including physical therapy, antiinflammatory agents, nontraditional modalities, or surgical referral (",
"    <a class=\"graphic graphic_algorithm graphicRef69505 \" href=\"UTD.htm?33/60/34754\">",
"     algorithm 2",
"    </a>",
"    ). Surgical referral is generally reserved for patients with severe symptoms who do not improve despite careful compliance with a well-designed physical therapy program for greater than six months.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h1\">",
"     RADIOGRAPHIC FINDINGS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Radiography is often unnecessary for the diagnosis and treatment of epicondylitis and associated tendinosis. For recalcitrant cases, however, we generally obtain a standard 3-view elbow x-ray series, which should include an axial view if posterior elbow pain is present. The axial view is used to evaluate posterior osteophytes and calcifications within the tendons [",
"    <a class=\"abstract\" href=\"UTD.htm?1/20/1354/abstract/36\">",
"     36",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    MRI may play a role in determining whether surgery is needed for treatment of chronic, recalcitrant symptoms of six months or longer duration. The presence of intermediate or high T2 signal intensity within the common flexor tendon or the presence of peritendinous soft tissue edema were the most specific findings of medial epicondylitis when compared with asymptomatic elbows in a small observational trial [",
"    <a class=\"abstract\" href=\"UTD.htm?1/20/1354/abstract/37\">",
"     37",
"    </a>",
"    ]. High signal on T2 images of the extensor carpi radialis brevis helped guide surgical treatment in a small study involving 11 cases of refractory lateral epicondylitis [",
"    <a class=\"abstract\" href=\"UTD.htm?1/20/1354/abstract/38\">",
"     38",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Musculoskeletal ultrasound (MUS) can be used in chronic, recalcitrant epicondylitis to localize lesions prior to surgery or the use of injections or alternative treatments. In experienced hands, MUS can identify abnormal tendon appearance (eg, tendon thickening, partial tear at tendon origin, calcifications) and neovascularity when color flow Doppler is used [",
"    <a class=\"abstract\" href=\"UTD.htm?1/20/1354/abstract/39,40\">",
"     39,40",
"    </a>",
"    ]. MUS is noninvasive and often preferred by patients.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h1\">",
"     ANTIINFLAMMATORY TREATMENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Antiinflammatories have been a mainstay of the treatment of epicondylitis for many years, although supporting evidence consists of anecdotal success and a few limited studies. As the scientific understanding of tendinopathy has developed, controversy surrounding the role of antiinflammatory medications in the treatment of epicondylitis and other chronic degenerative tendinopathies has grown. Examples of antiinflammatory treatment include icing, nonsteroidal antiinflammatory medicines, iontophoresis, and corticosteroid injection. Ice in combination with an eccentric strength and flexibility program was no better than eccentric training alone for lateral epicondylitis [",
"    <a class=\"abstract\" href=\"UTD.htm?1/20/1354/abstract/41\">",
"     41",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H4\">",
"     'Pathophysiology'",
"    </a>",
"    above.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h2\">",
"     Nonsteroidal antiinflammatory drugs (NSAIDs)",
"    </span>",
"    &nbsp;&mdash;&nbsp;Although evidence is limited, a systematic review found that NSAIDs may reduce pain and improve function in the short-term (ie, six weeks) [",
"    <a class=\"abstract\" href=\"UTD.htm?1/20/1354/abstract/42\">",
"     42",
"    </a>",
"    ]. We try to limit both the amount and duration of NSAID therapy, given the potential side effects of NSAIDs and our understanding of the pathophysiology of tendinopathy. (See",
"    <a class=\"local\" href=\"#H4\">",
"     'Pathophysiology'",
"    </a>",
"    above.) Topical NSAID's (eg,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?37/29/38352?source=see_link\">",
"     diclofenac",
"    </a>",
"    gel) may have limited benefit in acute epicondylitis, but studies are preliminary [",
"    <a class=\"abstract\" href=\"UTD.htm?1/20/1354/abstract/43\">",
"     43",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h2\">",
"     Glucocorticoid injections",
"    </span>",
"    &nbsp;&mdash;&nbsp;Multiple trials and two systematic reviews have found that glucocorticoid injection for lateral epicondylitis improves many short-term (six week) outcome measures [",
"    <a class=\"abstract\" href=\"UTD.htm?1/20/1354/abstract/44,45\">",
"     44,45",
"    </a>",
"    ], but does not prevent recurrence and may lead to worse long-term outcomes [",
"    <a class=\"abstract\" href=\"UTD.htm?1/20/1354/abstract/33,46-48\">",
"     33,46-48",
"    </a>",
"    ]. For short-term relief of severe symptoms, glucocorticoid injection is a reasonable treatment option when used as part of a comprehensive management program including physical therapy (",
"    <a class=\"graphic graphic_picture graphicRef60436 \" href=\"UTD.htm?42/1/43024\">",
"     picture 15",
"    </a>",
"    ). We do not advocate multiple injections. Injections for medial epicondylitis should be used judiciously due to the proximity of the ulnar nerve.",
"   </p>",
"   <p>",
"    Trials of glucocorticoid injection in epicondylitis are limited [",
"    <a class=\"abstract\" href=\"UTD.htm?1/20/1354/abstract/45\">",
"     45",
"    </a>",
"    ]. In a typical study, 198 patients with lateral epicondylitis of at least six weeks duration without prior treatment were randomized to eight sessions of standard physical therapy, glucocorticoid injections, or observation [",
"    <a class=\"abstract\" href=\"UTD.htm?1/20/1354/abstract/33\">",
"     33",
"    </a>",
"    ]. Patients in the glucocorticoid group showed the greatest improvement in symptoms at 6 weeks, but had high rates of recurrence at 52 weeks. Moreover, the glucocorticoid group performed significantly worse on all outcome measures in long-term follow-up.",
"   </p>",
"   <p>",
"    Another study of glucocorticoid injection involved a \"peppering\" technique in which the painful tendon is injected approximately 40 to 50 times [",
"    <a class=\"abstract\" href=\"UTD.htm?1/20/1354/abstract/49\">",
"     49",
"    </a>",
"    ]. The 120 patients in this study were randomly assigned to receive injections of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?38/38/39520?source=see_link\">",
"     triamcinolone",
"    </a>",
"    , 1 mL",
"    <a class=\"drug drug_general\" href=\"UTD.htm?34/34/35360?source=see_link\">",
"     lidocaine",
"    </a>",
"    , or 2 mL of lidocaine. Most patients had excellent results at one year regardless of the medication or dose, suggesting that the technique of injection played an important role. The researchers speculate that the \"peppering\" technique promotes a beneficial inflammatory response. (See",
"    <a class=\"local\" href=\"#H15\">",
"     'Secondary management'",
"    </a>",
"    above.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20\">",
"    <span class=\"h2\">",
"     Iontophoresis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Studies of iontophoresis are small and preliminary, but the technique may provide some short-term benefit. In one randomized controlled trial, patients treated with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?33/4/33856?source=see_link\">",
"     dexamethasone",
"    </a>",
"    by iontophoresis noted significant improvement of symptoms at two days compared with placebo, but this benefit was lost at one month [",
"    <a class=\"abstract\" href=\"UTD.htm?1/20/1354/abstract/50\">",
"     50",
"    </a>",
"    ]. Phonophoresis and Iontophoresis with topical",
"    <a class=\"drug drug_general\" href=\"UTD.htm?42/43/43705?source=see_link\">",
"     naproxen",
"    </a>",
"    showed similar benefits in pain and function scores in patients with epicondylitis [",
"    <a class=\"abstract\" href=\"UTD.htm?1/20/1354/abstract/51\">",
"     51",
"    </a>",
"    ]. No studies have compared topical NSAIDs with topical steroids in epicondylitis.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21\">",
"    <span class=\"h1\">",
"     OTHER TREATMENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;A number of potential treatments for epicondylitis are under study and reflect the changing understanding of the pathophysiology of tendinopathy. The mechanism for many of these treatments is not clearly understood. Tissue growth factors may play a role in some therapies. Other treatments are described as \"proinflammatory.\" Theoretically, proinflammatory treatments address disorganized tendon patterns, neovessels, and degenerative changes by stimulating an inflammatory response (",
"    <a class=\"graphic graphic_table graphicRef78876 \" href=\"UTD.htm?4/14/4331\">",
"     table 4",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    The mechanical and medicinal interventions described below are the subject of ongoing research. Small, preliminary clinical trials suggest they provide benefit in some patients.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H22\">",
"    <span class=\"h2\">",
"     Platelet-rich plasma injections",
"    </span>",
"    &nbsp;&mdash;&nbsp;This method involves the percutaneous injection of platelet-rich plasma (PRP), which may contain growth factors that stimulate tissue repair. A small number of randomized trials involving PRP have been performed with inconsistent results:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In a randomized, double-blinded trial of 60 patients with chronic lateral epicondylitis (symptoms for minimum of three months), no significant difference in the reduction of pain or disability at three months was found in patients treated with PRP compared to those treated with glucocorticoid or placebo (saline) [",
"      <a class=\"abstract\" href=\"UTD.htm?1/20/1354/abstract/52\">",
"       52",
"      </a>",
"      ]. In addition, PRP injection did not have a notable effect upon the ultrasound appearance of the involved tendons. The intended one year follow up was not possible due to the large number of patients in all groups who dropped out of the study.",
"     </li>",
"     <li>",
"      In a randomized, double-blinded trial of 100 patients with chronic lateral epicondylitis, those who received a PRP injection had significant and sustained improvement in function compared to those treated with a glucocorticoid injection [",
"      <a class=\"abstract\" href=\"UTD.htm?1/20/1354/abstract/53,54\">",
"       53,54",
"      </a>",
"      ]. Both groups received physical therapy involving an eccentric strengthening program and function was measured using a validated assessment tool. These studies did not include a placebo arm and were funded in part by a manufacturer of the centrifuge used to obtain PRP.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H23\">",
"    <span class=\"h2\">",
"     Autologous blood injections",
"    </span>",
"    &nbsp;&mdash;&nbsp;In refractory cases of epicondylitis, another treatment option involves injecting a sample of the patient's blood under ultrasound guidance into the site of chronic elbow tendinosis. Small, uncontrolled, observational studies of patients with refractory medial and lateral epicondylitis who received ultrasound-guided autologous blood injection with dry-needling have reported improvements in symptoms and in the ultrasound appearance of involved tendons [",
"    <a class=\"abstract\" href=\"UTD.htm?1/20/1354/abstract/55,56\">",
"     55,56",
"    </a>",
"    ]. The relative importance of the inflammatory response stimulated by the blood and dry-needling or growth factors present in the blood remains unclear.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H24\">",
"    <span class=\"h2\">",
"     Ultrasound-guided percutaneous needle tenotomy",
"    </span>",
"    &nbsp;&mdash;&nbsp;This method involves injecting local anesthetic and then using a needle under ultrasound guidance to fenestrate tendinotic tissue, break up calcifications, and if needed abrade the surface of underlying bone. An injection of corticosteroid and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?33/60/34758?source=see_link\">",
"     bupivacaine",
"    </a>",
"    is performed following the procedure. Patients then perform passive stretching and standard physical therapy exercises at home. In an observational, uncontrolled trial of this protocol, 55 patients with chronic epicondylitis despite standard conservative treatment reported good or excellent outcomes at an average of 28 months [",
"    <a class=\"abstract\" href=\"UTD.htm?1/20/1354/abstract/57\">",
"     57",
"    </a>",
"    ]. Again, the mechanism remains unclear.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H25\">",
"    <span class=\"h2\">",
"     Extracorporeal shock wave therapy (ESWT)",
"    </span>",
"    &nbsp;&mdash;&nbsp;Acoustic waves have been used to treat chronic lateral elbow tendinosis. Overall, evidence supporting ESWT is unconvincing and we do not recommend it. The procedure is generally uncomfortable and although studies exist that suggest ESWT provides some benefit [",
"    <a class=\"abstract\" href=\"UTD.htm?1/20/1354/abstract/58\">",
"     58",
"    </a>",
"    ] several studies have failed to do so [",
"    <a class=\"abstract\" href=\"UTD.htm?1/20/1354/abstract/59,60\">",
"     59,60",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H26\">",
"    <span class=\"h2\">",
"     Acupuncture",
"    </span>",
"    &nbsp;&mdash;&nbsp;A systematic review of studies of acupuncture in the treatment of lateral elbow pain found insufficient evidence to determine whether the technique is effective [",
"    <a class=\"abstract\" href=\"UTD.htm?1/20/1354/abstract/61\">",
"     61",
"    </a>",
"    ]. Results from a few small randomized trials suggest acupuncture may provide some short term relief, but there is no evidence of sustained benefit. Further study is needed. The role of acupuncture for analgesia is discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?27/50/28457?source=see_link\">",
"     \"Acupuncture\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H27\">",
"    <span class=\"h2\">",
"     Botulinum injection",
"    </span>",
"    &nbsp;&mdash;&nbsp;Injection of botulinum toxin A at the myotendinous junction is another purported means of stimulating an inflammatory response for treatment of tendinopathy. In one randomized controlled trial of this approach, patients with chronic, refractory epicondylitis treated with botulinum toxin A experienced a reduction in their symptoms compared with those receiving placebo [",
"    <a class=\"abstract\" href=\"UTD.htm?1/20/1354/abstract/62\">",
"     62",
"    </a>",
"    ]. No difference in grip strength was detected. An anticipated side effect of the botulinum toxin A injection (transient weakness in middle finger extension) did occur in some patients at two weeks but resolved. Recurrence rates and long-term outcome were not reported.",
"   </p>",
"   <p>",
"    A similar trial of 48 patients performed injections at a location one-third the length of the forearm measured from the lateral epicondyle, along the course of the posterior interosseus nerve. Pain relief at rest was greater for the group treated with botulinum toxin compared to placebo. However, grip strength did not differ between groups and weakness of the third and fourth fingers in patients injected with botulinum toxin A persisted up to sixteen weeks [",
"    <a class=\"abstract\" href=\"UTD.htm?1/20/1354/abstract/63\">",
"     63",
"    </a>",
"    ]. &nbsp;",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H28\">",
"    <span class=\"h2\">",
"     Prolotherapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;This treatment for chronic tendinopathy involves injection of a local irritant to elicit an inflammatory response. Numerous case reports and a small number of controlled trials suggest that prolotherapy may be effective in some chronic musculoskeletal injuries [",
"    <a class=\"abstract\" href=\"UTD.htm?1/20/1354/abstract/64\">",
"     64",
"    </a>",
"    ]. In a double-blinded, controlled trial of 24 adults with chronic lateral epicondylitis, patients randomly assigned to treatment with prolotherapy experienced reduced pain and improved extensor and grip strength [",
"    <a class=\"abstract\" href=\"UTD.htm?1/20/1354/abstract/65\">",
"     65",
"    </a>",
"    ]. The role of prolotherapy in the treatment of epicondylitis warrants further investigation.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H29\">",
"    <span class=\"h2\">",
"     Topical glyceryl trinitrate application",
"    </span>",
"    &nbsp;&mdash;&nbsp;Nitric oxide may stimulate collagen synthesis by wound fibroblasts. Topical application of glyceryl trinitrate in chronic tendinopathies theoretically improves tendon healing by this mechanism. This hypothesis was tested in a controlled trial of 86 patients with chronic lateral epicondylitis treated with standard physical therapy and either a transdermal glycerol trinitrate patch or a placebo patch. The trinitrate group demonstrated significant improvements in symptoms and function throughout the six month course of the study [",
"    <a class=\"abstract\" href=\"UTD.htm?1/20/1354/abstract/66\">",
"     66",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H30\">",
"    <span class=\"h2\">",
"     Sclerosing polidocanol injections",
"    </span>",
"    &nbsp;&mdash;&nbsp;Neovascularity associated with chronic tendinopathy is thought to contribute to pain. Sclerosing",
"    <a class=\"drug drug_general\" href=\"UTD.htm?0/6/110?source=see_link\">",
"     polidocanol",
"    </a>",
"    injections under ultrasound guidance are an investigational procedure meant to target neovessels and reduce pain. An uncontrolled pilot study of 11 patients with chronic lateral epicondylitis treated with a single injection of polidocanol into the extensor tendon origin with signs of neovascularity found improvement in patients' pain scores and maximal grip strength up to eight months following injection [",
"    <a class=\"abstract\" href=\"UTD.htm?1/20/1354/abstract/67\">",
"     67",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H31\">",
"    <span class=\"h1\">",
"     INDICATIONS FOR ORTHOPEDIC REFERRAL",
"    </span>",
"    &nbsp;&mdash;&nbsp;Over 90 percent of cases of epicondylitis can be managed nonoperatively [",
"    <a class=\"abstract\" href=\"UTD.htm?1/20/1354/abstract/10\">",
"     10",
"    </a>",
"    ]. The most severe, recalcitrant cases that have failed to respond to at least six months of nonoperative management may warrant surgical evaluation.",
"   </p>",
"   <p>",
"    Indications for orthopedic referral include:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Severe pain or marked dysfunction for six months or longer",
"     </li>",
"     <li>",
"      Failure of conservative management, including properly performed physical therapy, to improve symptoms or function over six months",
"     </li>",
"     <li>",
"      Patient uninterested in pursuing nonoperative treatment options (eg, alternative treatments described above) for chronic tendinopathy",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Studies of surgical management are scant, but one retrospective single-center review of all patients treated operatively for lateral epicondylitis found no difference in outcome among patients treated using open, arthroscopic, or percutaneous surgical approaches [",
"    <a class=\"abstract\" href=\"UTD.htm?1/20/1354/abstract/68\">",
"     68",
"    </a>",
"    ]. Conservative care averaged 13.2 months in each group prior to surgery. Studies suggest that patients with residual histologic tendinopathy after arthroscopic debridement have poorer outcomes [",
"    <a class=\"abstract\" href=\"UTD.htm?1/20/1354/abstract/69\">",
"     69",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H32\">",
"    <span class=\"h1\">",
"     RETURN TO SPORT OR WORK",
"    </span>",
"    &nbsp;&mdash;&nbsp;The goal of epicondylitis treatment is a pain-free functional return to work or sport. Some patients may be able to return to work so long as aggravating activities can be avoided. Secondary gain may play a role in some patients with occupational injuries [",
"    <a class=\"abstract\" href=\"UTD.htm?1/20/1354/abstract/3,4\">",
"     3,4",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Improper tennis stroke mechanics can contribute to injury in the recreational tennis player [",
"    <a class=\"abstract\" href=\"UTD.htm?1/20/1354/abstract/17\">",
"     17",
"    </a>",
"    ]. The patient must receive instruction and demonstrate proper mechanics before returning to full participation. A slow functional progression of tennis exercises allows for a safer return to sport following rehabilitation and is generally recommended prior to resuming competition (",
"    <a class=\"graphic graphic_table graphicRef60005 \" href=\"UTD.htm?7/30/7659\">",
"     table 5",
"    </a>",
"    ). (See",
"    <a class=\"local\" href=\"#H6\">",
"     'Risk reduction in tennis'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    Some athletes can continue playing in a modified fashion while undergoing rehabilitation, provided they continue to improve. This approach is reasonable in players who experience pain only after matches. Modified play may include switching to a two-handed backhand, reducing string tension, and eliminating shots with exaggerated spin. Some players require complete rest from inciting activities during rehabilitation to ensure recovery.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"PATIENT_INFORMATION\">",
"    <span class=\"h1\">",
"     INFORMATION FOR PATIENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials, &ldquo;The Basics&rdquo; and &ldquo;Beyond the Basics.&rdquo; The Basics patient education pieces are written in plain language, at the 5",
"    <sup>",
"     th",
"    </sup>",
"    to 6",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10",
"    <sup>",
"     th",
"    </sup>",
"    to 12",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.",
"   </p>",
"   <p>",
"    Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on &ldquo;patient info&rdquo; and the keyword(s) of interest.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Basics topic (see",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?37/47/38642?source=see_link\">",
"       \"Patient information: Elbow tendinopathy (tennis and golf elbow) (The Basics)\"",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Beyond the Basics topic (see",
"      <a class=\"medical medical_patient\" href=\"UTD.htm?43/18/44321?source=see_link\">",
"       \"Patient information: Elbow tendinopathy (tennis and golf elbow) (Beyond the Basics)\"",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H34\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Increased age, repetitive movement for at least two hours daily, and forceful activity (managing physical loads over 20 kg) comprise the major risk factors for epicondylitis in the general population. Epicondylitis represents a chronic tendinosis, rather than an acute inflammatory process, involving disorganized tissue and neovessels. (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Epidemiology and risk factors'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H5\">",
"       'Mechanisms of injury'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H4\">",
"       'Pathophysiology'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      A number of factors, including poor stroke mechanics and inappropriate racquet type, predispose tennis players to developing epicondylitis (elbow tendinosis). (See",
"      <a class=\"local\" href=\"#H6\">",
"       'Risk reduction in tennis'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Patients with epicondylitis (elbow tendinosis) typically complain of extraarticular medial or lateral elbow pain. Pain is exacerbated by contraction or passive flexion of either the wrist extensor muscles (lateral epicondylitis) or flexor muscles (medial epicondylitis). (See",
"      <a class=\"local\" href=\"#H7\">",
"       'Clinical presentation and examination'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      A number of conditions can cause focal medial or lateral elbow pain (",
"      <a class=\"graphic graphic_table graphicRef73460 \" href=\"UTD.htm?5/27/5563\">",
"       table 2",
"      </a>",
"      and",
"      <a class=\"graphic graphic_table graphicRef52503 \" href=\"UTD.htm?2/35/2619\">",
"       table 3",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H8\">",
"       'Differential diagnosis'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Evidence supporting specific treatments for epicondylitis (elbow tendinosis) is scant. Once a clinical diagnosis is made, our initial treatment consists of activity modification, counter force bracing, NSAIDs if not contraindicated, and physical therapy (",
"      <a class=\"graphic graphic_algorithm graphicRef57758 \" href=\"UTD.htm?2/12/2242\">",
"       algorithm 1",
"      </a>",
"      ). Counter force bracing may reduce tendon and muscle strain at the origin of the forearm extensor muscles, thereby relieving pain and improving function. Well-designed physical therapy programs that include progressive eccentric strengthening can be effective initial treatment for many patients with epicondylitis. (See",
"      <a class=\"local\" href=\"#H9\">",
"       'Initial management'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H14\">",
"       'Physical therapy and eccentric exercise'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Glucocorticoid injection for lateral epicondylitis improves many short-term (six week) outcome measures, but does not prevent recurrence and may lead to worse long-term outcomes. (See",
"      <a class=\"local\" href=\"#H19\">",
"       'Glucocorticoid injections'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      In patients who do not improve with standard initial interventions, we often obtain imaging studies before resorting to other treatments. A number of potential therapies for tendon healing are under study and may provide benefit for some patients, but evidence is limited. (See",
"      <a class=\"local\" href=\"#H21\">",
"       'Other treatments'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Indications for orthopedic referral include severe pain or marked dysfunction for six months or longer and failure of conservative management to improve symptoms or function over six months. (See",
"      <a class=\"local\" href=\"#H31\">",
"       'Indications for orthopedic referral'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/20/1354/abstract/1\">",
"      Shiri R, Viikari-Juntura E, Varonen H, Heli&ouml;vaara M. Prevalence and determinants of lateral and medial epicondylitis: a population study. Am J Epidemiol 2006; 164:1065.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/20/1354/abstract/2\">",
"      Struijs PA, Kerkhoffs GM, Assendelft WJ, Van Dijk CN. Conservative treatment of lateral epicondylitis: brace versus physical therapy or a combination of both-a randomized clinical trial. Am J Sports Med 2004; 32:462.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/20/1354/abstract/3\">",
"      Smidt N, Lewis M, VAN DER Windt DA, et al. Lateral epicondylitis in general practice: course and prognostic indicators of outcome. J Rheumatol 2006; 33:2053.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/20/1354/abstract/4\">",
"      Haahr JP, Andersen JH. Prognostic factors in lateral epicondylitis: a randomized trial with one-year follow-up in 266 new cases treated with minimal occupational intervention or the usual approach in general practice. Rheumatology (Oxford) 2003; 42:1216.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/20/1354/abstract/5\">",
"      Jayanthi, NA, Sallay, P, Hunker, P. Skill level related injuries in Competition Tennis Players. Med Sci Tennis 2005; 10:12.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/20/1354/abstract/6\">",
"      Nirschl RP. The etiology and treatment of tennis elbow. J Sports Med 1974; 2:308.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/20/1354/abstract/7\">",
"      Gruchow HW, Pelletier D. An epidemiologic study of tennis elbow. Incidence, recurrence, and effectiveness of prevention strategies. Am J Sports Med 1979; 7:234.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/20/1354/abstract/8\">",
"      Montalvan, B, Parier, J, Gires, A, et al. Results of Three Years Medical Surveillance of the International Championships at Roland Garros: an Epidemiological Study in Sports Pathology. Medicine and Science in Tennis 2004; 9:.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/20/1354/abstract/9\">",
"      Hatch GF 3rd, Pink MM, Mohr KJ, et al. The effect of tennis racket grip size on forearm muscle firing patterns. Am J Sports Med 2006; 34:1977.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/20/1354/abstract/10\">",
"      Nirschl RP. Elbow tendinosis/tennis elbow. Clin Sports Med 1992; 11:851.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/20/1354/abstract/11\">",
"      Zeisig E, Ohberg L, Alfredson H. Extensor origin vascularity related to pain in patients with Tennis elbow. Knee Surg Sports Traumatol Arthrosc 2006; 14:659.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/20/1354/abstract/12\">",
"      Evans WJ, Meredith CN, Cannon JG, et al. Metabolic changes following eccentric exercise in trained and untrained men. J Appl Physiol 1986; 61:1864.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/20/1354/abstract/13\">",
"      Newham DJ, Jones DA, Clarkson PM. Repeated high-force eccentric exercise: effects on muscle pain and damage. J Appl Physiol 1987; 63:1381.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/20/1354/abstract/14\">",
"      Tsuang YH, Lam SL, Wu LC, et al. Isokinetic eccentric exercise can induce skeletal muscle injury within the physiologic excursion of muscle-tendon unit: a rabbit model. J Orthop Surg Res 2007; 2:13.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/20/1354/abstract/15\">",
"      Croisier JL, Foidart-Dessalle M, Tinant F, et al. An isokinetic eccentric programme for the management of chronic lateral epicondylar tendinopathy. Br J Sports Med 2007; 41:269.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/20/1354/abstract/16\">",
"      Werner RA, Franzblau A, Gell N, et al. Predictors of persistent elbow tendonitis among auto assembly workers. J Occup Rehabil 2005; 15:393.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/20/1354/abstract/17\">",
"      Ilfeld FW. Can stroke modification relieve tennis elbow? Clin Orthop Relat Res 1992; :182.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/20/1354/abstract/18\">",
"      Kibler WB. Clinical biomechanics of the elbow in tennis: implications for evaluation and diagnosis. Med Sci Sports Exerc 1994; 26:1203.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/20/1354/abstract/19\">",
"      Fleisig G, Nicholls R, Elliott B, Escamilla R. Kinematics used by world class tennis players to produce high-velocity serves. Sports Biomech 2003; 2:51.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/20/1354/abstract/20\">",
"      Giangarra CE, Conroy B, Jobe FW, et al. Electromyographic and cinematographic analysis of elbow function in tennis players using single- and double-handed backhand strokes. Am J Sports Med 1993; 21:394.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/20/1354/abstract/21\">",
"      De Smedt T, de Jong A, Van Leemput W, et al. Lateral epicondylitis in tennis: update on aetiology, biomechanics and treatment. Br J Sports Med 2007; 41:816.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/20/1354/abstract/22\">",
"      Kelley JD, Lombardo SJ, Pink M, et al. Electromyographic and cinematographic analysis of elbow function in tennis players with lateral epicondylitis. Am J Sports Med 1994; 22:359.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/20/1354/abstract/23\">",
"      Riek S, Chapman AE, Milner T. A simulation of muscle force and internal kinematics of extensor carpi radialis brevis during backhand tennis stroke: implications for injury. Clin Biomech (Bristol, Avon) 1999; 14:477.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/20/1354/abstract/24\">",
"      Li FX, Fewtrell D, Jenkins M. String vibration dampers do not reduce racket frame vibration transfer to the forearm. J Sports Sci 2004; 22:1041.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/20/1354/abstract/25\">",
"      Rettig AC, Sherrill C, Snead DS, et al. Nonoperative treatment of ulnar collateral ligament injuries in throwing athletes. Am J Sports Med 2001; 29:15.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/20/1354/abstract/26\">",
"      Cowan J, Lozano-Calder&oacute;n S, Ring D. Quality of prospective controlled randomized trials. Analysis of trials of treatment for lateral epicondylitis as an example. J Bone Joint Surg Am 2007; 89:1693.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/20/1354/abstract/27\">",
"      Walther M, Kirschner S, Koenig A, et al. Biomechanical evaluation of braces used for the treatment of epicondylitis. J Shoulder Elbow Surg 2002; 11:265.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/20/1354/abstract/28\">",
"      Bisset L, Paungmali A, Vicenzino B, Beller E. A systematic review and meta-analysis of clinical trials on physical interventions for lateral epicondylalgia. Br J Sports Med 2005; 39:411.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/20/1354/abstract/29\">",
"      Snyder-Mackler L, Epler M. Effect of standard and Aircast tennis elbow bands on integrated electromyography of forearm extensor musculature proximal to the bands. Am J Sports Med 1989; 17:278.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/20/1354/abstract/30\">",
"      Faes M, van den Akker B, de Lint JA, et al. Dynamic extensor brace for lateral epicondylitis. Clin Orthop Relat Res 2006; 442:149.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/20/1354/abstract/31\">",
"      Van De Streek MD, Van Der Schans CP, De Greef MH, Postema K. The effect of a forearm/hand splint compared with an elbow band as a treatment for lateral epicondylitis. Prosthet Orthot Int 2004; 28:183.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/20/1354/abstract/32\">",
"      Derebery VJ, Devenport JN, Giang GM, Fogarty WT. The effects of splinting on outcomes for epicondylitis. Arch Phys Med Rehabil 2005; 86:1081.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/20/1354/abstract/33\">",
"      Bisset L, Beller E, Jull G, et al. Mobilisation with movement and exercise, corticosteroid injection, or wait and see for tennis elbow: randomised trial. BMJ 2006; 333:939.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/20/1354/abstract/34\">",
"      Smidt N, Assendelft WJ, Arola H, et al. Effectiveness of physiotherapy for lateral epicondylitis: a systematic review. Ann Med 2003; 35:51.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/20/1354/abstract/35\">",
"      Park JY, Park HK, Choi JH, et al. Prospective evaluation of the effectiveness of a home-based program of isometric strengthening exercises: 12-month follow-up. Clin Orthop Surg 2010; 2:173.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/20/1354/abstract/36\">",
"      Chen AL, Youm T, Ong BC, et al. Imaging of the elbow in the overhead throwing athlete. Am J Sports Med 2003; 31:466.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/20/1354/abstract/37\">",
"      Kijowski R, De Smet AA. Magnetic resonance imaging findings in patients with medial epicondylitis. Skeletal Radiol 2005; 34:196.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/20/1354/abstract/38\">",
"      Aoki M, Wada T, Isogai S, et al. Magnetic resonance imaging findings of refractory tennis elbows and their relationship to surgical treatment. J Shoulder Elbow Surg 2005; 14:172.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/20/1354/abstract/39\">",
"      Levin D, Nazarian LN, Miller TT, et al. Lateral epicondylitis of the elbow: US findings. Radiology 2005; 237:230.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/20/1354/abstract/40\">",
"      Clarke AW, Ahmad M, Curtis M, Connell DA. Lateral elbow tendinopathy: correlation of ultrasound findings with pain and functional disability. Am J Sports Med 2010; 38:1209.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/20/1354/abstract/41\">",
"      Manias P, Stasinopoulos D. A controlled clinical pilot trial to study the effectiveness of ice as a supplement to the exercise programme for the management of lateral elbow tendinopathy. Br J Sports Med 2006; 40:81.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/20/1354/abstract/42\">",
"      Green S, Buchbinder R, Barnsley L, et al. Non-steroidal anti-inflammatory drugs (NSAIDs) for treating lateral elbow pain in adults. Cochrane Database Syst Rev 2002; :CD003686.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/20/1354/abstract/43\">",
"      Burnham R, Gregg R, Healy P, Steadward R. The effectiveness of topical diclofenac for lateral epicondylitis. Clin J Sport Med 1998; 8:78.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/20/1354/abstract/44\">",
"      Tonks JH, Pai SK, Murali SR. Steroid injection therapy is the best conservative treatment for lateral epicondylitis: a prospective randomised controlled trial. Int J Clin Pract 2007; 61:240.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/20/1354/abstract/45\">",
"      Smidt N, Assendelft WJ, van der Windt DA, et al. Corticosteroid injections for lateral epicondylitis: a systematic review. Pain 2002; 96:23.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/20/1354/abstract/46\">",
"      Stahl S, Kaufman T. The efficacy of an injection of steroids for medial epicondylitis. A prospective study of sixty elbows. J Bone Joint Surg Am 1997; 79:1648.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/20/1354/abstract/47\">",
"      Smidt N, van der Windt DA, Assendelft WJ, et al. Corticosteroid injections, physiotherapy, or a wait-and-see policy for lateral epicondylitis: a randomised controlled trial. Lancet 2002; 359:657.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/20/1354/abstract/48\">",
"      Coombes BK, Bisset L, Vicenzino B. Efficacy and safety of corticosteroid injections and other injections for management of tendinopathy: a systematic review of randomised controlled trials. Lancet 2010; 376:1751.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/20/1354/abstract/49\">",
"      Altay T, G&uuml;nal I, Ozt&uuml;rk H. Local injection treatment for lateral epicondylitis. Clin Orthop Relat Res 2002; :127.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/20/1354/abstract/50\">",
"      Nirschl RP, Rodin DM, Ochiai DH, et al. Iontophoretic administration of dexamethasone sodium phosphate for acute epicondylitis. A randomized, double-blinded, placebo-controlled study. Am J Sports Med 2003; 31:189.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/20/1354/abstract/51\">",
"      Bakurt F, Ozcan A, Algun C. Comparison of effects of phonophoresis and iontophoresis of naproxen in the treatment of lateral epicondylitis. Clin Rehabil 2003; 17:96.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/20/1354/abstract/52\">",
"      Krogh TP, Fredberg U, Stengaard-Pedersen K, et al. Treatment of lateral epicondylitis with platelet-rich plasma, glucocorticoid, or saline: a randomized, double-blind, placebo-controlled trial. Am J Sports Med 2013; 41:625.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/20/1354/abstract/53\">",
"      Peerbooms JC, Sluimer J, Bruijn DJ, Gosens T. Positive effect of an autologous platelet concentrate in lateral epicondylitis in a double-blind randomized controlled trial: platelet-rich plasma versus corticosteroid injection with a 1-year follow-up. Am J Sports Med 2010; 38:255.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/20/1354/abstract/54\">",
"      Gosens T, Peerbooms JC, van Laar W, den Oudsten BL. Ongoing positive effect of platelet-rich plasma versus corticosteroid injection in lateral epicondylitis: a double-blind randomized controlled trial with 2-year follow-up. Am J Sports Med 2011; 39:1200.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/20/1354/abstract/55\">",
"      Suresh SP, Ali KE, Jones H, Connell DA. Medial epicondylitis: is ultrasound guided autologous blood injection an effective treatment? Br J Sports Med 2006; 40:935.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/20/1354/abstract/56\">",
"      Connell DA, Ali KE, Ahmad M, et al. Ultrasound-guided autologous blood injection for tennis elbow. Skeletal Radiol 2006; 35:371.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/20/1354/abstract/57\">",
"      McShane JM, Nazarian LN, Harwood MI. Sonographically guided percutaneous needle tenotomy for treatment of common extensor tendinosis in the elbow. J Ultrasound Med 2006; 25:1281.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/20/1354/abstract/58\">",
"      Spacca G, Necozione S, Cacchio A. Radial shock wave therapy for lateral epicondylitis: a prospective randomised controlled single-blind study. Eura Medicophys 2005; 41:17.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/20/1354/abstract/59\">",
"      Ho C. Extracorporeal shock wave treatment for chronic rotator cuff tendonitis (shoulder pain). Issues Emerg Health Technol 2007; :1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/20/1354/abstract/60\">",
"      Buchbinder R, Green SE, Youd JM, et al. Systematic review of the efficacy and safety of shock wave therapy for lateral elbow pain. J Rheumatol 2006; 33:1351.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/20/1354/abstract/61\">",
"      Green S, Buchbinder R, Barnsley L, et al. Acupuncture for lateral elbow pain. Cochrane Database Syst Rev 2002; :CD003527.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/20/1354/abstract/62\">",
"      Placzek R, Drescher W, Deuretzbacher G, et al. Treatment of chronic radial epicondylitis with botulinum toxin A. A double-blind, placebo-controlled, randomized multicenter study. J Bone Joint Surg Am 2007; 89:255.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/20/1354/abstract/63\">",
"      Espandar R, Heidari P, Rasouli MR, et al. Use of anatomic measurement to guide injection of botulinum toxin for the management of chronic lateral epicondylitis: a randomized controlled trial. CMAJ 2010; 182:768.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/20/1354/abstract/64\">",
"      Rabago D, Best TM, Beamsley M, Patterson J. A systematic review of prolotherapy for chronic musculoskeletal pain. Clin J Sport Med 2005; 15:376.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/20/1354/abstract/65\">",
"      Scarpone M, Rabago DP, Zgierska A, et al. The efficacy of prolotherapy for lateral epicondylosis: a pilot study. Clin J Sport Med 2008; 18:248.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/20/1354/abstract/66\">",
"      Paoloni JA, Appleyard RC, Nelson J, Murrell GA. Topical nitric oxide application in the treatment of chronic extensor tendinosis at the elbow: a randomized, double-blinded, placebo-controlled clinical trial. Am J Sports Med 2003; 31:915.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/20/1354/abstract/67\">",
"      Zeisig E, Ohberg L, Alfredson H. Sclerosing polidocanol injections in chronic painful tennis elbow-promising results in a pilot study. Knee Surg Sports Traumatol Arthrosc 2006; 14:1218.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/20/1354/abstract/68\">",
"      Szabo SJ, Savoie FH 3rd, Field LD, et al. Tendinosis of the extensor carpi radialis brevis: an evaluation of three methods of operative treatment. J Shoulder Elbow Surg 2006; 15:721.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/20/1354/abstract/69\">",
"      Cummins CA. Lateral epicondylitis: in vivo assessment of arthroscopic debridement and correlation with patient outcomes. Am J Sports Med 2006; 34:1486.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 248 Version 9.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0505-122.72.76.133-D6C6C51ACA-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f1_20_1354=[""].join("\n");
var outline_f1_20_1354=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H34\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      EPIDEMIOLOGY AND RISK FACTORS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5808241\">",
"      General population and occupational risk factors",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5808248\">",
"      Tennis epidemiology and risk factors",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      CLINICAL ANATOMY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      PATHOPHYSIOLOGY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      MECHANISMS OF INJURY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      RISK REDUCTION IN TENNIS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      CLINICAL PRESENTATION AND EXAMINATION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      DIFFERENTIAL DIAGNOSIS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      INITIAL MANAGEMENT",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      Observation",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      Modification of activity and biomechanics",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      Bracing",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      Splints",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      Physical therapy and eccentric exercise",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      SECONDARY MANAGEMENT",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      RADIOGRAPHIC FINDINGS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      ANTIINFLAMMATORY TREATMENTS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      Nonsteroidal antiinflammatory drugs (NSAIDs)",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      Glucocorticoid injections",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H20\">",
"      Iontophoresis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H21\">",
"      OTHER TREATMENTS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H22\">",
"      Platelet-rich plasma injections",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H23\">",
"      Autologous blood injections",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H24\">",
"      Ultrasound-guided percutaneous needle tenotomy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H25\">",
"      Extracorporeal shock wave therapy (ESWT)",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H26\">",
"      Acupuncture",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H27\">",
"      Botulinum injection",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H28\">",
"      Prolotherapy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H29\">",
"      Topical glyceryl trinitrate application",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H30\">",
"      Sclerosing polidocanol injections",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H31\">",
"      INDICATIONS FOR ORTHOPEDIC REFERRAL",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H32\">",
"      RETURN TO SPORT OR WORK",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#PATIENT_INFORMATION\">",
"      INFORMATION FOR PATIENTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H34\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"EM/248\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"EM/248|ALG\">",
"      <a href=\"#\" title=\"ALGORITHMS\">",
"       ALGORITHMS",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_algorithm\" href=\"UTD.htm?2/12/2242\" title=\"algorithm 1\">",
"      Management of acute epicondylitis algorithm",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_algorithm\" href=\"UTD.htm?33/60/34754\" title=\"algorithm 2\">",
"      Management of chronic epicondylitis algorithm",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"EM/248|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?15/42/16032\" title=\"figure 1\">",
"      Tennis racquet grip size measurement",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"EM/248|PIC\">",
"      <a href=\"#\" title=\"PICTURES\">",
"       PICTURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?10/22/10596\" title=\"picture 1\">",
"      Elbow joint external landmarks",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?31/30/32225\" title=\"picture 2\">",
"      Incorrect tennis backhand",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?35/59/36784\" title=\"picture 3\">",
"      Advanced tennis forehand grip",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?17/46/18145\" title=\"picture 4\">",
"      Palpation lateral epicondyle",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?20/45/21202\" title=\"picture 5\">",
"      Examination of wrist extension",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?25/15/25843\" title=\"picture 6\">",
"      Passive wrist flexion",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?40/20/41280\" title=\"picture 7\">",
"      Palpation of elbow medial epicondyle",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?4/33/4627\" title=\"picture 8\">",
"      Wrist flexion examination",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?12/61/13264\" title=\"picture 9\">",
"      Passive extension of wrist",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?14/13/14548\" title=\"picture 10\">",
"      Milking maneuver for elbow medial collateral ligament",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?30/35/31281\" title=\"picture 11\">",
"      Counter force brace for epicondylitis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?21/35/22067\" title=\"picture 12\">",
"      Concentric exercise elbow epicondylitis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?38/35/39486\" title=\"picture 13\">",
"      Eccentric exercise for elbow epicondylitis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?27/37/28241\" title=\"picture 14\">",
"      Core stability rehabilitation for tennis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?42/1/43024\" title=\"picture 15\">",
"      Local injection for lateral epicondylitis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"EM/248|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?18/12/18635\" title=\"table 1\">",
"      Tendinopathy phases",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?5/27/5563\" title=\"table 2\">",
"      Differential diagnosis for lateral elbow pain",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?2/35/2619\" title=\"table 3\">",
"      Differential diagnosis for medial elbow pain",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?4/14/4331\" title=\"table 4\">",
"      Pro-inflammatory treatment options",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?7/30/7659\" title=\"table 5\">",
"      Functional exercise progression for return to tennis",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?31/49/32537?source=related_link\">",
"      Achilles tendinopathy and tendon rupture",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?27/50/28457?source=related_link\">",
"      Acupuncture",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?35/19/36152?source=related_link\">",
"      Clinical features and diagnosis of cervical radiculopathy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?22/25/22937?source=related_link\">",
"      Elbow injuries in the young athlete",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?14/40/14983?source=related_link\">",
"      Evaluation of elbow pain in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?41/30/42472?source=related_link\">",
"      Overview of soft tissue rheumatic disorders",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?19/39/20089?source=related_link\">",
"      Overview of the management of overuse (chronic) tendinopathy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?8/44/8906?source=related_link\">",
"      Overview of upper extremity peripheral nerve syndromes",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?43/18/44321?source=related_link\">",
"      Patient information: Elbow tendinopathy (tennis and golf elbow) (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?37/47/38642?source=related_link\">",
"      Patient information: Elbow tendinopathy (tennis and golf elbow) (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?37/40/38532?source=related_link\">",
"      Radial head subluxation (nursemaid's elbow)",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f1_20_1355="Thrombolytic therapy guidelines";
var content_f1_20_1355=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PULM%2F79949&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PULM%2F79949&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Guidelines for thrombolytic therapy in venous thromboembolism",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td>",
"        Clear documentation of PE (or DVT)*",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Potential contraindications carefully reviewed",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Delivery by peripheral intravenous infusion",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Initiate or continue other supportive therapy",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Discontinue heparin during thrombolytic infusion",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"     * High-probability ventilation-perfusion scan or positive pulmonary arteriogram.",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f1_20_1355=[""].join("\n");
var outline_f1_20_1355=null;
var title_f1_20_1356="Comparison of the arousal parasomnias";
var content_f1_20_1356=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PEDS%2F81349&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=10\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PEDS%2F81349&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=10\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    A comparison of the arousal parasomnias",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\">",
"        Clinical feature",
"       </td>",
"       <td class=\"subtitle1\">",
"        Confusional arousal",
"       </td>",
"       <td class=\"subtitle1\">",
"        Sleep terror",
"       </td>",
"       <td class=\"subtitle1\">",
"        Sleep walking",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Age of onset",
"       </td>",
"       <td>",
"        2-10 years",
"       </td>",
"       <td>",
"        2-10 years",
"       </td>",
"       <td>",
"        5-10 years",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Frequency",
"       </td>",
"       <td>",
"        3-4/week to 1-2/month",
"       </td>",
"       <td>",
"        3-4/week to 1-2/month",
"       </td>",
"       <td>",
"        3-4/week to 1-2/month",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Peak time of occurrence",
"       </td>",
"       <td>",
"        First third of night sleep",
"       </td>",
"       <td>",
"        First third of night sleep",
"       </td>",
"       <td>",
"        First third of night sleep",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Behavior during event",
"       </td>",
"       <td>",
"        Whimpering, some articulation, sitting up in bed, inconsolable",
"       </td>",
"       <td>",
"        Screaming, agitation, flushed face, sweating, inconsolable",
"       </td>",
"       <td>",
"        Walking about the room or house, may be quiet or agitated, unresponsive to verbal commands",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Electroencephalogram findings during event",
"       </td>",
"       <td>",
"        Slow wave sleep, with rhythmic theta or delta activity",
"       </td>",
"       <td>",
"        Slow wave sleep, with rhythmic theta or delta activity",
"       </td>",
"       <td>",
"        Slow wave sleep, with rhythmic theta or delta activity",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Duration",
"       </td>",
"       <td>",
"        10-30 minutes",
"       </td>",
"       <td>",
"        10-20 minutes",
"       </td>",
"       <td>",
"        10-20 minutes",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: Kotagal S. Parasomnias of childhood. Curr Opin Pediatr 2008; 20:659. Copyright &copy; 2008 Lippincott Williams &amp; Wilkins.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f1_20_1356=[""].join("\n");
var outline_f1_20_1356=null;
var title_f1_20_1357="Drugs causing lichenoid eruptions";
var content_f1_20_1357=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=DERM%2F83762&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=DERM%2F83762&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Drugs causing lichenoid eruptions (drug-induced lichen planus)",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <colgroup span=\"2\" width=\"50%\">",
"     </colgroup>",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\">",
"        Group of drug",
"       </td>",
"       <td class=\"subtitle1\">",
"        &nbsp;",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Antimicrobial substances",
"       </td>",
"       <td>",
"        Aminosalicylate sodium, ethambutol, griseofulvin, ketoconazole, streptomycin, tetracycline, trovafloxacin, isoniazid",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Antihistamines (H",
"        <sub>",
"         2",
"        </sub>",
"        -blocker)",
"       </td>",
"       <td>",
"        Ranitidine, roxatidine",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Antihypertensives/antiarrhythmics",
"       </td>",
"       <td>",
"        <strong>",
"         ACE-inhibitors",
"        </strong>",
"        (captopril, enalapril), doxazosin,",
"        <strong>",
"         beta blockers",
"        </strong>",
"        (propranolol, labetalol, sotalol),",
"        <strong>",
"         methyldopa",
"        </strong>",
"        , prazosin, nifedipine,",
"        <strong>",
"         quinidine",
"        </strong>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Antimalarial drugs",
"       </td>",
"       <td>",
"        <strong>",
"         Chloroquine",
"        </strong>",
"        ,",
"        <strong>",
"         hydroxychloroquine",
"        </strong>",
"        , quinine",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Antidepressives/antianxiety drugs/antipsychotics/anticonvulsants",
"       </td>",
"       <td>",
"        Amitriptyline, carbamazepine, chlorpromazine, levopromazine, methopromazine, imipramine, lorazepam, phenytoin",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Diuretics",
"       </td>",
"       <td>",
"        <strong>",
"         Thiazide diuretics",
"        </strong>",
"        (chlorothiazide and hydrochlorothiazide), furosemide, spironolactone",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Antidiabetics",
"       </td>",
"       <td>",
"        Sulfonylureas (chlorpropamide, glimepiride, tolazamide, tolbutamide, glyburide)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Metals",
"       </td>",
"       <td>",
"        <strong>",
"         Gold salts",
"        </strong>",
"        , arsenic, bismuth, mercury, palladium, lithium",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Nonsteroidal-antiinflammatory drugs (NSAIDs)",
"       </td>",
"       <td>",
"        Acetylsalicylic acid, benoxaprofen, diflunisal, fenclofenac, flurbiprofen, ibuprofen, indomethacin, naproxen, sulindac",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Proton pump inhibitors",
"       </td>",
"       <td>",
"        Omeprazole, lansoprazole, pantoprazole",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Lipid lowering drugs",
"       </td>",
"       <td>",
"        Pravastatin, simvastatin, gemfibrozil",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Tumor necrosis factor-alpha antagonists",
"       </td>",
"       <td>",
"        Infliximab, adalimumab, etanercept, lenercept",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Varia",
"       </td>",
"       <td>",
"        Allopurinol, bleomycin, cinnarizine, cyanamide, dapsone, hydroxyurea, hepatitis B-vaccine, imatinib, immunoglobulins, interferon alfa, l-thyroxin, levamisole, mesalamine, methycran,",
"        <strong>",
"         penicillamine",
"        </strong>",
"        , procainamide, pyrimethamine, pyrithioxine,",
"        <strong>",
"         quinacrine",
"        </strong>",
"        , sildenafil, sulfasalazine, terbinafine, trihexyphenidyl, ursodeoxycholic acid",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    The",
"    <strong>",
"     bolded",
"    </strong>",
"    drugs are the ones most frequently implicated.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     References:",
"     <br/>",
"     <ol>",
"      <li>",
"       Halevy S, Shai A. Lichenoid drug eruptions. J Am Acad Dermatol 1993; 29:249.",
"      </li>",
"      <li>",
"       Shiohara T, Kano Y. Lichen planus and lichenoid dermatoses. In: Dermatology, Bologna JL (Ed), Mosby, London 2003. p.188.",
"      </li>",
"      <li>",
"       Bork K. Lichenoid eruptions. In: Cutaneous Side Effects of Drugs, Bork K (Ed), WB Saunders, Philadelphia 1988. p.170.",
"      </li>",
"     </ol>",
"     Reproduced from: Shiohara T, Kano Y. Lichen planus and lichenoid dermatoses. In: Dermatology, 3rd Edition, Bolognia JL, Jorizzo JL, Schaffer JV (Eds), Elsevier, London 2012. Table used with the permission of Elsevier Inc. All rights reserved.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f1_20_1357=[""].join("\n");
var outline_f1_20_1357=null;
var title_f1_20_1358="Distribution of colon ischemia";
var content_f1_20_1358=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=GAST%2F65067&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=GAST%2F65067&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Distribution of colon ischemia",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 448px; height: 218px; background-image: url(data:image/gif;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"     * Other areas refer to combination of different regions.",
"    </div>",
"    <div class=\"reference\">",
"     Data from: Reinus JF, Brandt LJ, Boley SJ, Gastroenterol Clin North Am 1990; 19:319.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f1_20_1358=[""].join("\n");
var outline_f1_20_1358=null;
var title_f1_20_1359="DNA based HLA typing";
var content_f1_20_1359=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=RHEUM%2F67233&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=RHEUM%2F67233&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    DNA based method of HLA typing",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 342px; height: 558px; background-image: url(data:image/gif;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Summary of DNA-based method of HLA typing, showing the main steps of DNA denaturation per amplification, and specific sequence detection by sequence specific oligonucleotide probe.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Barbara S Nepom, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f1_20_1359=[""].join("\n");
var outline_f1_20_1359=null;
